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Abstract 
Many cell signalling pathways contribute to prostate cancer (PCa) initiation and survival, but the 
interplay between them remains poorly understood.  In this thesis, conditional transgenic 
models were employed to investigate the impact of mutating the proto-oncogenes β-catenin, 
and Kras, and the tumour suppressor gene PTEN, alone and in combination within the murine 
prostate. 
β-catenin and Pten single mutants display progression from PIN to invasive adenocarcinoma 
that appears similar to human Gleason pattern 3.  Tumours demonstrate co-activation of the 
Wnt, PI3K/Akt/mTOR, and Ras/MAPK pathways.  Kras single mutants develop PIN but do not 
progress to adenocarcinoma.  Double and triple mutants develop more aggressive tumours 
comparable to Gleason pattern 4.  Furthermore, double and triple mutants display upregulated 
Wnt, PI3K/Akt/mTOR and Ras/MAPK signalling.  Expression of p63 negatively correlates with 
tumour grade, and moreover, progression from PIN to invasive adenocarcinoma is 
characterised by the synergistic elevation of AR and Ki67, which parallels human PCa. 
Malignant transformation of a normal prostate epithelial stem cell (PrSC) gives rise to the 
cancer stem cell (CSC), which may contribute to castrate-resistant PCa.  In this study a 3D 
primary tissue culture assay was optimised to allow maintenance and expansion of prostate 
cells that display stem-like characteristics in vitro. 
PrSCs can be isolated by fluorescence activated cell sorting for the antigenic profile Lin-
Sca1+CD49f+TropHi, and consistently form spherical structures in Matrigel.  PrSCs can withstand 
multiple round of passage in vitro, and demonstrate the ability to maintain an undifferentiated 
state.  PrSC spheres possess a basal phenotype, supporting a basal location of PrSCs in prostate 
epithelium. 
In summary, these mouse models of PCa demonstrate cooperation between important cell 
signalling pathways in prostate tumourigenesis, and provide a platform for testing novel 
therapeutics.  In addition, the successful isolation and cultivation of cells with stem-like 
attributes will allow their unique biological properties to be explored further, providing a 
baseline standard with which to compare the function of CSCs.  
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Chapter 1: General Introduction 
1.1 THE PROSTATE GLAND 
The prostate gland is largely an androgen-sensitive exocrine gland of the male mammalian 
reproductive system.  The following section focusses on the function, anatomy, embryology, 
and histopathology of the prostate in both the human and mouse.  In addition, the similarities 
and disparities between human and mouse prostate will be described with the aims of 
emphasising the pros and cons of mouse models in studying prostate tumourigenesis, and the 
evidence for stem cells and cancer stem cells in both species. 
1.1.1 Prostate gland function 
The prostate gland, one of the male accessory glands, is exclusive to mammals.  Other male 
mammalian accessory glands can include the vesicular glands, seminal vesicles, ampullary 
glands, bulbourethral glands, and preputial glands.  The products of these glands serve to 
nourish and activate spermatozoa, to clear the urethral tract prior to ejaculation, to serve as the 
vehicle of transport of the spermatozoa in the female tract, and to plug the female tract after 
placement of spermatozoa to aid fertilisation.  While accessory glands are usually described as 
tubulo-alveolar, they vary in their number, organisation and in their distribution in different 
species. 
The main function of the prostate is secretory; it contributes around 30% of the ejaculate (Fair 
and Cordonnier, 1978).  Due to its surrounding muscular stroma, the prostate forces emission 
of prostatic fluid to mix with seminal fluid during ejaculation.  Prostatic secretions contain 
various important molecules which all play important roles in reproductive homeostasis.  Many 
of these important substances are listed in table 1. 
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 Constituent name 
 
Function 
 
Reference 
 
 
Proteins 
Prostate acid 
phosphatase (PAP) and 
Prostate specific antigen 
(PSA) 
Semen liquefaction Fair and Cordonnier (1978) 
Leucine aminopeptidase Antigen presentation, processing of spent 
bioactive peptides (oxytocin, vasopressin, 
enkephalins), and vesicle trafficking to 
the plasma membrane 
Matsui et al. (2006) 
Diamine oxidase Degrades polyamines spermine, 
spermidine, putrescine and affects 
motility 
Le Calve et al. (1995) 
Β-Glucuronidase Catalyses carbohydrates for sperm 
nutrition, roles in sperm acrosome 
reaction and maturation of spermatozoa 
Hall and Killian (1987), 
Kareskoski and Katila 
(2008) 
Plasminogen activator Promotes fibrinolysis and sperm motility Maier et al. (1991) 
Complement (C3 and C4) Sperm agglutination Azim et al. (1978) 
Transferrin and 
transferritin 
Immunological role; binds iron thus 
impeding bacterial survival 
Barthelemy et al. (1988) 
Growth factors Sperm motility Iyibozkurt et al. (2009) 
 
Non-
proteins 
Citrate Essential for sperm mitochondrial 
function, a buffer 
Cappello et al. (2012) 
Polyamines (spermine, 
spermidine, putrescine) 
Regulate cell growth and gene expression 
and promote sperm motility 
Rubinstein and Breitbart 
(1990 ), Lefevre et al. 
(2011) 
Zinc Stabilises chromatin in sperm Canale et al. (1986) 
Myoinositol Regulates seminal plasma osmolarity and 
volume, sperm motility, capacitation, and 
acrosome reaction 
Condorelli et al. (2012) 
Cholesterol Sperm capacitation Osheroff et al. (1999) 
 
Table 1: Some of the important constituents of mammalian prostatic secretions and their 
effects 
1.1.2 Embryology and prostate gland development 
In man, the development of the male and female genitourinary tract is identical until 7 weeks 
gestation.  A male foetus develops in the presence of a Y-chromosome which encodes the SRY 
(sex-determining region Y) protein. The SRY protein enables testicular differentiation and the 
production of androgens including testosterone.  The indifferent gonad comprises two zones: 
the medulla in males differentiates into the testis, whereas the cortex involutes, giving rise to 
vestigial remnants.  In addition to the SRY protein and androgens a third factor is required for 
male development, anti-Müllerian hormone (AMH), also known as Müllerian Inhibitory 
Substance (MIS) (Munsterberg and Lovell-Badge, 1991). AMH/MIS prevents female genital 
ductal differentiation causing the Müllerian (paramesonephric) duct to degenerate which forms 
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the prostatic utricle.  At approximately week 8 the fetal testis produces testosterone and as a 
consequence, the human prostate begins to develop at about the 10th week of gestation.  As a 
result, the initial outgrowths of the prostatic buds from the urogenital sinus (UGS) occur in 
response to the binding of 5α-dihydrotesterone to androgen receptors localised in the 
surrounding mesenchymal tissue (Shannon and Cunha, 1983, Lasnitzki et al., 1989, Takeda et 
al., 1985, Takeda and Chang, 1991).  These prostatic buds begin as solid cords of epithelial cells 
that elongate and undergo extensive branching morphogenesis during the latter stages of fetal 
growth to develop primitive lumens (Timms, 2008).  During weeks 13 to 15, serum testosterone 
elevates and remains high until week 25, which in turn induces epithelial differentiation.  At this 
point, the 3 important epithelial populations are distinct – luminal, basal and neuroendocrine 
cells (Timms, 2008).  At week 25 testosterone level diminishes and the gland remains in a 
quiescent state until puberty.  During the postnatal period and under the influence of 
androgens, the ducts form true patent lumens, and the epithelial cells lining the acini fully 
differentiate to synthesise a variety of secretory products (as listed in table 1 earlier).  During 
puberty, serum testosterone increases to induce epithelial proliferation and the formation of a 
mature, adult prostate.  Hypogonadism of ageing can occur with increasing age beyond 45-50 
years, which in turn leads to prostate gland involution and atrophy. 
Development of the murine prostate begins at around embryonal day 10 (E10) when the UGS is 
evident at dissection (Staack et al., 2003).  The UGS is an endodermal tube derived from 
hindgut, which is clearly demarcated by E13–14 (Staack et al., 2003).  At this time the Leydig 
cells within the fetal testes differentiate, synthesise and secrete testosterone (Pointis et al., 
1980).  Testosterone and its metabolites stimulate the Wolffian ducts and mesonephric tubules 
to form the epididymi, vasa deferentia, seminal vesicles, and efferent ducts.  At approximately 
E14–15, and similar to events in the human at 7-8 weeks gestation, the Sertoli cells of the 
murine fetal testes initiate production of AMH/MIS, which elicits destruction of the Müllerian 
(paramesonephric) ducts in males (Kuroda et al., 1990).  The prostatic buds emerge from the 
urogenital sinus epithelium at approximately E17 and grow and branch within the surrounding 
urogenital sinus mesenchyme, forming their characteristic pattern which reflects the eventual 
lobar structure of the gland (Cunha et al., 1987, Timms et al., 1994).  Branching morphogenesis 
continues postnatally and is almost complete by 2-3 weeks of age (Sugimura et al., 1986a). 
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1.1.3 Anatomy of the human prostate 
The human prostate lies inferior to the urinary bladder within the pelvis and both are separated 
from the rectum posteriorly by Denonvilliers’ fascia, a variable sheet of fused fibromuscular 
layers that extends upward to cover the seminal vesicles at the superior, posterior aspect of the 
prostate.  The prostate is conical in shape and its base is intimately related to the bladder neck 
superiorly while the apex is directed downward and is in contact with the superior part of the 
urogenital diaphragm.  The human prostate is surrounded by a prominent fibromuscular 
stroma, which is vastly more abundant than in the rodent, extending beyond the outer 
perimeter of the gland to form a distinct capsule separating the prostate from periprostatic fat.  
The capsule is best defined histologically in the posterior and lateral portions of the human 
prostate.  The adult prostate is separated into fused zones that are anatomically distinct, have 
characteristic histological features, and importantly, have specific predisposition to benign or 
malignant neoplastic change.  Although lobes are recognisable in the developing human 
prostate, the lobar classification is more frequently used for anatomical or surgical description 
(see table 2). 
Prostate lobe Corresponding prostate zone 
Anterior (isthmus) Mainly transitional zone 
Posterior Part of the peripheral zone 
Median (or middle) The central and transition zones 
Lateral Spans all zones 
 
Table 2: Each anatomical prostate lobe corresponds to part(s) of a pathological zone.  The 
terminology relating to prostate lobar anatomy is commonly used in gross anatomy or for 
surgical description.  Prostate lobes do not precisely correspond to individual prostate zones; 
indeed the lateral lobes (readily visible during transurethral surgery) span all zones. 
 
The human prostate is composed of the anterior fibromuscular stroma, which is devoid of 
glandular components, the periurethral transitional zone (TZ), the peripheral zone (PZ), and the 
central zone (CZ) (McNeal, 1981a, McNeal, 1981b).  The CZ surrounds the ejaculatory ducts and 
comprises the portion of the prostate from where the ejaculatory ducts enter the urethra, near 
the prostatic utricle at the verumontanum, to the base.  The TZ is located interiorly between the 
urethra and the surrounding PZ and CZ while the PZ is found on the posterolateral aspects of 
the prostate.    The distinction between these anatomical zones is shown in figure 1. 
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Figure 1: Anatomy of the normal human prostate.  (a) Illustration of a sagittal section through 
the prostate demonstrating the orientation of the base (most cranial aspect) and the apex 
(most caudal aspect).  Adapted from McNeal (1969) in Valkenburg and Williams (2011)  (b)  
Schematic representation of the prostate in axial section through the base of the prostate 
highlighting its intimate relation to the pubis (anteriorly) and rectum (posteriorly).  Adapted 
from Walz et al. (2009)  (c) An H&E section through the base of a prostate removed following an 
open radical retropubic prostatectomy for localised prostate cancer.    The striking demarcation 
delineating the transition (T) and peripheral (P) zones are due the patient’s young age; in older 
men these planes would be more indistinct.  U, urethra; ED, ejaculatory duct; A, anterior 
fibromuscular stroma.   H&E slide (c) courtesy of Dr David Griffiths, Consultant Histopathologist, 
University Hospital of Wales, Cardiff. 
 
1.1.4 Histology of the normal human prostate 
The CZ within human prostate consists of large complex glands demonstrating greatly irregular 
luminal contours, epithelial tufting, papillary formations, and with frequent Roman arches or 
cribriform patterning that lacks cytological atypia (Shappell et al., 2004).  Secretory cells in the 
CZ are irregularly arranged with large nuclei at multiple levels to adjacent cells and visible basal 
cells.  Acini in the CZ are separated by fewer bands of compact smooth muscle fibres than the 
PZ and TZ.  
Benign glands of the PZ are larger and have a tufted or undulating luminal border intermediate 
between that of the frequently-folded CZ and rounded TZ glands.  Secretory cells of the PZ are 
columnar with a regular luminal border and smaller, more uniform, flattened basal nuclei.  The 
PZ fibromuscular stroma is abundant with loosely woven, randomly arranged muscle fibres 
separated by irregular spaces and numerous collagen fibres. 
(a) (b) (c) 
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The TZ acini are distributed uniformly and are more rounded in shape with compactly arranged 
smooth muscle and collagen fibres in the stroma surrounding them.  Secretory cells of the TZ 
are columnar with regular small basal nuclei, whereas flattened basal cells with slender dark 
nuclei lie parallel to the basement membrane.   
Representative examples of normal human prostate, highlighting the zonal differences, are 
demonstrated in figure 2. 
 
Figure 2:  Histology of normal human prostate.  The above photographs were taken from the 
RRP specimen in figure 1(c) above, thus the central zone (CZ) is not shown.  Peripheral zone 
(PZ): acini have irregular tufted luminal epithelium with irregularly arranged multilevel large 
round nuclei (black arrows), whereas the regular location of basal cells can be clearly seen here 
(black arrowheads).  The PZ is intermediate in its appearance between the CZ (not shown) and 
TZ.  Transitional zone (TZ): acini are more rounded; the luminal secretory border consists of 
orderly columnar cells (braced bracket) with regular small basal nuclei, and white arrowheads 
highlight the flatter dark nuclei of basal cells.  The anterior zone (AZ) is devoid of epithelium; 
instead it is comprised of fibromuscular stroma.  H&E slides courtesy of Dr David Griffiths, 
Consultant Histopathologist, University Hospital of Wales, Cardiff. 
 
1.1.5 Histopathology of the human prostate and the zonal origin of prostate cancer 
The TZ is the exclusive site of benign prostatic hyperplasia (BPH) in the human and is associated 
with ageing.  BPH is seen in 80-90% of radical prostatectomy (RP) specimens but less than 20% 
of clinically significant PCas originate here (McNeal, 1992).  TZ tumours often have a 
characteristic histological appearance, usually composed of well differentiated tumours.  They 
are felt to arise as the result of precursor lesions called atypical adenomatous hyperplasia (or 
adenosis), that are distinct from prostatic intraepithelial neoplasia (PIN), including high-grade 
PIN (HGPIN), seen in the PZ.  In contrast to its common occurrence in the PZ, PIN/HGPIN is 
rarely seen in the TZ.   
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The PZ contains the majority of glandular tissue in the normal human prostate and is the most 
frequent site of PCa origin (McNeal et al., 1988).  Conversely, the CZ is rarely the site of origin 
for PCa, although it can be involved through direct invasion from a PZ tumour.  The fact that the 
PZ is located at the posterolateral aspects of the prostate, explains anatomically why digital 
rectal examination is mandatory in the assessment of men with suspected PCa.  DRE allows 
assessment of both prostate and tumour volumes, and can help differentiate localised from 
locally-advanced tumours to determine suitability for surgery based on the likelihood of a 
curative tumour excision.  The PZ is the exclusive site of PIN/HGPIN in the human prostate (De 
Marzo et al., 2003).  Epithelial hyperplasia analogous to that seen in TZ BPH does not occur in 
the PZ, instead epithelial proliferation occurs within the confines of pre-existing normal gland 
profiles, and is deemed low- or high-grade PIN based on nuclear morphology (Bostwick et al., 
1996). 
1.1.6 Cellular organisation of human prostate epithelium 
Three phenotypically distinct cell types are readily identifiable within a two-layered epithelium: 
luminal secretory cells, basal cells, and rare, scattered neuroendocrine cells (see figure 3).  The 
presence of a fourth population, prostate epithelial stem cells, is discussed in detail later (see 
section 1.4.1). 
The normal, adult human prostate demonstrates sophisticated cellular organisation. Terminally 
differentiated luminal cells constitute the majority of normal and malignant prostate and they 
are reliant on androgens for their survival and thus express high levels of androgen receptor 
(AR) (Bonkhoff and Remberger, 1993), CD57 (Liu et al., 1997), PSA and PAP.  Paradoxically the 
basal layer, which is independent of androgens and thus expresses low levels of AR, is largely 
undifferentiated and comprises approximately 10% of prostate epithelial cells.  The basal cells 
are closely adherent to the basement membrane and lack secretory activity.  They express CD44 
(Liu et al., 1997), Bcl-2 (Bonkhoff et al., 1998), telomerase (Paradis et al., 1999) and p63 (a p53 
homolog) (Signoretti et al., 2000).  Basal and luminal cells can be further discriminated by their 
expression of specific cytokeratins; basal cells express cytokeratins 5 (CK 5) and 14, whereas 
luminal cells express CK 8 and 18 (Sherwood et al., 1991).  Neuroendocrine cells (NE) are 
relatively few (1% in humans, <0.3% in mice) terminally differentiated, androgen-insensitive 
cells scattered throughout the basal epithelial compartment and they readily express 
synaptophysin and chromogranin A (Shappell et al., 2004).  Despite the fact that cells with NE-
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like expression are routinely found in prostate cancer (PCa), their precise function is unknown.  
However, evidence suggests that NE cells are a post-mitotic cell type derived from luminal cells 
(Bonkhoff et al., 1991, Bonkhoff et al., 1995). 
 
 
Figure 3: Schematic representation of human prostate epithelial morphology.  The terminally 
differentiated columnar luminal cells secrete protein-rich fluid into the lumen of prostate acini 
and are intimately related to relatively undifferentiated basal cells, seen here uniformly 
adjacent to the basement membrane.  Neuroendocrine cells are distinguishable from basal cells 
and represent approximately 1% of the cellular population.  Stem cells represent ≤1% of the 
total cell population (approximately 1% of basal cells).  Biomarkers to identify each population 
are shown here in bold.  Adapted from Oldridge et al. (2012). 
 
Without the supporting stromal microenvironment, the prostate epithelial compartment is 
reportedly ill-equipped to function independently.  Thus so-called “mesenchymal-epithelial 
crosstalk” (Cunha et al., 2004), is vital for epithelial cell development in utero (Hayward and 
Cunha, 2000),  for sustaining growth and cell maintenance, and epithelial cell differentiation 
(Hall et al., 2002, Berry et al., 2008). 
 
1.2 MOUSE PROSTATE ANATOMY 
In stark contrast to the human, mouse prostate is divided into separate lobes; namely the 
anterior prostate (AP), which is intimately related to the concave aspect of the seminal vesicles 
along its entire length, the ventral lobes, and the dorsal and lateral lobes, often collectively 
called the dorsolateral lobes (see figure 4).  
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Figure 4: Anatomy of the mouse genitourinary tract.  (a) Photograph of the genitourinary tract 
from a wild-type mouse, aged 100 days, dissected en bloc.  A, anterior lobe; B, bladder; L, 
lateral lobe; SV, seminal vesicles; U, urethra (cut); V, ventral lobe; dorsal lobe hidden from view 
posteriorly.  (b) Cartoon of mouse genitourinary tract with each lobe highlighted in colour, 
adapted from Valkenburg and Williams (2011). 
 
Individual lobes are invested by a thin mesothelial-lined capsule, appreciable microscopically, 
that separates one lobe from another.  Mouse prostate lobes are composed of a series of blind-
ending branching ducts or tubules, which in turn are surrounded by a thin fibromuscular tunica 
of smooth muscle cells interspersed with eosinophilic collagen.  Glandular cells are separated 
from the capsule by loose fibroadipose connective tissue where blood vessels and nerves are 
found.  The abundant dense fibromuscular stroma present in human prostate is not comparable 
to the mouse; here it is less complex and sparse (Tsujimura et al., 2002, Shappell et al., 2004).  
Due to these fundamental differences in the anatomical organisation of the prostate between 
the human and mouse, mouse models may not be adequate or suited to address the staging 
issues related to extra-prostatic extension, and thus progression to T3 disease, in human PCa 
(see section 1.3.2). 
Each lobe of the mouse prostate has a distinctive histological appearance, and these differences 
can be appreciated in figure 5.  
 
 
(b) (a) 
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Figure 5: Normal mouse prostate.  (a) Histological appearance of 10% formalin-fixed, paraffin-
embedded sections stained with haematoxylin and eosin from all four lobes of wild-type murine 
prostate aged 100 days taken at 40x magnification, scale bars represent 100µm.  (b)  Spatial 
relationship of the lobar anatomy (at 4x magnification) in the axial/transverse plane through 
the urethra, at or near the level of the SV junction (anterior lobe not shown).  A, anterior lobe; 
D, dorsal lobe; L, lateral lobe; U, urethra; V, ventral lobe. 
 
The mouse DP is lined by simple columnar and occasionally stratified, tufted epithelium. The 
degree of infolding is intermediate between the AP and the flatter luminal borders of the LP 
and VP.  The secretory cells of the DP have central to basally located small uniform nuclei 
containing inconspicuous or small nucleoli.  Gland lumens contain homogenous eosinophilic 
secretions.  The LP has flatter luminal edges, with only sparse infoldings, with the abundant 
luminal space containing more particulate eosinophilic secretions.  The epithelium is cuboidal to 
low columnar, with small uniform basally located nuclei.   
Histologically the mouse AP normally demonstrates a more papillary and cribriform growth 
pattern than the other lobes, with cuboidal to columnar epithelial cells containing typically 
central nuclei with inconspicuous to small nucleoli, and eosinophilic granular cytoplasm. The 
gland lumens contain abundant slightly eosinophilic secretions. 
The mouse VP has flatter luminal edges and only focal epithelial tufting or in-folding. The 
abundant luminal spaces contain homogenous pale serous secretions. The nuclei are small, 
uniform, typically basally located, and have inconspicuous to small nucleoli.  
(b) 
(a) 
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The mouse dorso-lateral prostate (DLP) has, for around 50 years, been reported as being most 
homologous to the human PZ, perhaps because the majority of adenocarcinomas in genetically-
engineered mice originated here (Price, 1963, Roy-Burman et al., 2004).   More recently this has 
been disputed (Shappell et al., 2004).  Each developing lobe in the embryo remains recognisable 
in the postnatal and adult mouse prostate, as the lobes described previously.  Even though the 
developing lobes are recognisable in the human embryo, they are not readily identifiable in the 
adult (Price, 1963).  There is therefore no existing supporting evidence for a direct relationship 
between the mouse prostate lobes and the specific zones in the human prostate (Shappell et 
al., 2004).  
1.2.1 Cellular organisation of mouse prostate epithelium 
The glands of each mouse prostate lobe appear to have normal cell populations homologous to 
the human prostate.  However, in contrast to human prostate, the murine prostate structure is 
much simpler and consists of a luminal-like epithelium in direct contact with the basement 
membrane, a discontinuous layer of fewer basal cells, and a minor population of NE  (see figure 
6).  The location of murine prostate stem cells is felt to be within the basal subpopulation. 
 
Figure 6: Schematic representation of murine prostate epithelial morphology.  In contrast to 
the human, mouse prostate epithelium contains a discontinuous layer of basal cells.  
Neuroendocrine cells represent approximately 0.3% of the cellular population.  Stem cells are 
estimated to represent ≤1% of the total cell population.  Biomarkers expressed by each 
population are shown here in bold.  LSCT; when murine prostate epithelia are FACS-sorted, the 
Lin-Sca-1+CD49fhiTrop-2hi fraction enriches for a population with stem-like properties (see later).  
Adapted from Oldridge et al. (2012). 
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Limited markers exist for secretory cell differentiation in the mouse prostate but as in humans, 
CK8 has been shown to stain luminal cells in normal mouse prostate (Lukacs et al., 2010).  The 
basal population in histologically normal murine prostates is readily identified by staining with 
CK5 (DiGiovanni et al., 2000, Lukacs et al., 2010) and also CK14 (Kim et al., 2002).  
Immunostaining for chromogranin (Garabedian et al., 1998) and/or synaptophysin (Lukacs et 
al., 2010) demonstrates a minor population of neuroendocrine cells in the normal mouse 
prostate totalling approximately 0.3% (Bostwick et al., 1996). 
1.2.2 Why use a mouse model to study prostate tumourigenesis? 
The mouse and human genomes are approximately 95% identical, and share many structurally 
similar genes and genomic alterations implicated in prostate cancer (Maser et al., 2007).  In 
addition, technology exists to allow prostate-specific genetic modification of the mouse 
genome, such as the Cre-loxP system (see section 1.6.4).  The small size and short gestation 
time of mice, along with their relative affordability, means that large populations to study 
lesions of interest can be generated quickly.  The prostate of both species are androgen 
sensitive and both have glands with three distinct epithelial cell populations and similar 
functions.  Both species also have male accessory organs that develop from the Wolffian ducts 
and the urogenital sinuses.  Even though some aspects of prostate anatomy and histology are 
homologous between the two species, there are also, as already described, marked 
dissimilarities. 
1.2.3 The limitations of using mouse models to study prostate cancer 
No single mouse model has fully recapitulated the molecular and pathological events that 
constitute human prostate cancer through its stages of development and progression.  In 
particular no model describes spontaneous development of bony metastases, which is a 
consistent feature of advanced PCa in men (Mundy, 2002) and the most significant cause of 
morbidity (Singh and Figg, 2005).  Cancers, and therefore metastases, in mice tend to be of 
mesenchymal origin whereas metastases in humans generally originate from epithelial cells 
(DePinho, 2000).  One further consideration is that in mice, as in the human disease, 
tumourigenesis and the time to development of the prostate lesion of interest exhibits 
variability despite established transgenic technologies.  Genetic background in addition to 
environmental factors could conceivably have important effects on lesion development and/or 
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progression in genetically modified models of prostate cancer.  In one study using inbred mice 
(Gingrich et al., 1996), despite each mouse beginning with a similar genetic background, 
stochastic variability in the timing of tumour development and progression was observed.  
Primary pathologies ranged from hyperplasia to adenocarcinoma that arose within a 10 – 24 
week period with metastases occurring by 28 weeks in either the lymph nodes or lungs. 
 
1.3 PROSTATE CANCER 
Prostate cancer (PCa) is acknowledged as one of the most important medical problems facing 
the male population worldwide.  Indeed, it is the commonest cancer diagnosed in men, 
outnumbering both lung and colorectal cancer.   This equates to approximately 25% of newly 
diagnosed UK male cancers (CRUK, 2012) and 23% in Wales (Welsh Cancer Intelligence and 
Surveillance Unit, 2009).  In 2009 over 40,000 British men were diagnosed with PCa, with 
around 2,000 of these in Wales (WCISU, 2009).  It is the 2nd leading cause of cancer death 
worldwide after lung cancer, accounting for approximately 200,000 deaths per year (CRUK, 
2012) with 546 deaths per year on average in Wales (WCISU, 2009). 
The PCa incidence rate has increased in recent years, whereby it crudely affects approximately 
135 per 100,000 UK-wide (CRUK, 2012).  This can be further appreciated in Wales where it 
affects around 162 per 100,000 men, up from 90 per 100,000 in 1995 (WCISU, 2009).  PCa 
shares a strong association with age therefore it is of greater concern in developed countries 
where, like the UK and mainland Europe, there is an ageing population with improving health.  
In the UK, between 2007 and 2009, roughly 75% of PCa cases were diagnosed in men aged 65 
years and over (see figure 7). 
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Figure 7: Prostate cancer incidence as a function of age.  Age-specific incidence rates increase 
sharply from around age 50, peaking in men aged 75 and over (CRUK, 2012). 
 
Similarly substantial increases in incidence have been reported in recent times for many 
countries around the world.  The prostate cancer incidence trend for the UK is shown in Figure 
8. 
 
Figure 8: Prostate cancer age-standardised incidence trend for the UK.  This data illustrates 
how the overall the incidence rate increased by three times between 1975 and 2009; almost 
50% between 1993 and 2005 but remained relatively stable since then. 
 
Incidence trends for younger men have continued to rise year on year since the mid-1970s (see 
Figure 9).  The largest increase has been in men aged 45-54, with the European age-
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standardised rate having increased by eight times between 1975-1977 and 2007-2009.  For men 
aged 85 and over, there has been a decrease in the incidence rate since the mid-1990s, and the 
rate for men aged 75-84 has also decreased slightly since the early 2000s.  Hence increased 
incidence is not applicable to the elderly group, yet the death rate is rising in this population.  
This trend is noted in other countries and is probably an indication of improving health in 
elderly men.  As general health improves, ones chance of dying of PCa, rather than with PCa, 
increases considerably.   
 
Figure 9: Prostate cancer incidence trends for the UK by age group.  For men <75 years, 
incidence trends continue upwards to 2009.  For men aged 75-84 and >85 the incidence has 
decreased and plateaued respectively, after 1996 (CRUK, 2012). 
 
Analysis of incidence trends have concluded that much of the apparent increase in PCa 
incidence is a result of improvements in detection; before 1989 as a consequence of increasing 
rates of transurethral resection of the prostate (TURP), and afterwards through the rising use of 
PSA testing.  This is due to greater awareness of prostate cancer through media publicity and 
focused screening of at-risk individuals despite the lack of a national screening programme such 
as UK screening for breast or cervical cancer.  Similarly the USA has reported that increased 
detection rates through PSA testing has been a major factor (Potosky et al., 1995), to such an 
extent that approximately 75% of US men over 50 years have had a PSA test (Sirovich et al., 
2003).  Published estimates for the level of PSA screening in Europe vary but are much lower, 
estimated at 10-20% (Bray et al., 2010).  The future burden on healthcare services that prostate 
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cancer poses can be appreciated given the current lifetime risk of developing prostate cancer is 
estimated to be 1 in 9 UK-wide, having increased from 1 in 14 in 2004 (CRUK, 2012). 
1.3.1 Making a diagnosis of prostate cancer – Gleason score 
In 1966, American pathologist Donald Gleason created a unique grading system for PCa based 
on tumour morphology.  Specifically it classified the degree of loss of the normal glandular 
tissue architecture (i.e. shape, size and differentiation of the glands) at low power.  (Mellinger 
et al., 1967, Gleason and Mellinger, 1974).  Rather than assign the worst grade as the overall 
tumour grade, each tumour was defined as the sum of the two most common patterns and 
reported as the Gleason score.  It has since been revised (Epstein et al., 2005) because its 
interpretation and application had evolved significantly following its inception.  However it 
remains, over 40 years on, one of the most powerful prognostic factors in PCa (Epstein, 2010).  
The Gleason score is allocated to a prostate needle biopsy or a radical prostatectomy specimen 
by a consultant histopathologist.  It is estimated that upgrading is seen in approximately 1/3 of 
prostatectomy specimens and downgrading is evident in 5%, when compared to the pre-
operative needle biopsy Gleason score, demonstrating some of the limitations of applying a 
Gleason score to needle biopsy samples where tumour heterogeneity may exist. 
 
The classic Gleason scoring diagram (see figure 10) shows five basic tissue patterns that are 
referred to as tumor “grades”, each being represented by a number from 1 to 5.  Grade 1 
represented well differentiated adenocarcinoma with the best prognosis, whereas grade 5 
denoted poorly differentiated or anaplastic adenocarcinomas and thereby the worst grade.  
Originally a score of between 2 and 10 was obtained from adding the first and second most 
predominant patterns i.e. the primary pattern comprised >50% and the secondary pattern 
<50% but >5%.   
 
Currently Gleason grades 1 and 2 are largely obsolete highlighting a paradigm shift in prostate 
cancer reporting that led to the revised Gleason scoring system in use today (Epstein et al., 
2005).  Low grade cancers (scores 2-4) are rarely seen on needle biopsy because they are 
predominantly located anteriorly in the transition zone and tend to be clinically insignificant.   
At TURP for clinical BPH, which samples the transition zone, Gleason score 2–4 cancer may still 
be diagnosed but it is uncommon.  Due to the success of α-adrenergic receptor antagonists for 
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lower urinary tract symptoms TURP in itself is uncommon, further contributing to the rarity of a 
Gleason score 2–4 diagnosis.  For practical purposes this change has translated into the virtual 
disappearance of Gleason score 2–4 on needle biopsy in contemporary practice.  In 1991, 24% 
of pathologists made a diagnosis of Gleason score 2–4 on biopsy, which decreased to 2.4% in 
2001 (Ghani et al., 2005). 
 
In current practice Gleason 3+3=6 is the score with best prognosis.  The original Gleason system 
also predated the use of immunohistochemistry; it is likely that with immunostaining for basal 
cells, many of the original 1+1=2 adenocarcinomas of the prostate would today be regarded as 
adenosis, a benign mimic of prostate cancer (Epstein et al., 2005).  Similarly many of the cases 
historically diagnosed as cribriform Gleason pattern 3 adenocarcinoma would now be called 
cribriform high-grade prostatic intraepithelial neoplasia (PIN) if labelled with basal cell markers 
(Amin et al., 1994). 
 
 
Figure 10: The original Gleason scoring system is outdated.  In Gleason’s era there was no 
screening for prostate cancer other than digital rectal examination; serum prostate specific 
antigen had yet to be discovered.  Typically limited numbers of needle biopsies were taken from 
an area of palpable disease only.  Consequently the grading of prostate cancer in multiple cores 
from different sites of the prostate and/or grading multifocal tumour in a prostatectomy 
specimen was unimportant.  Adapted from Epstein (2010). 
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A number of other important amendments have been made since the Gleason grading system 
was revised (see figure 11).  Secondary patterns of low grade (i.e. pattern 3) are not reported if 
representing less than 5% of tumour volume and a higher grade pattern is present.  Conversely, 
secondary patterns of higher grade disease should always be reported, even if less than 5% in 
total.  There has also specific guidance for needle biopsies, whereby the primary pattern and 
the highest grade should be recorded; secondary pattern should be ignored (Epstein et al., 
2005).  More recently, guidance for prostatectomy specimens states that Gleason score should 
be based on the primary and secondary patterns with a comment on the tertiary pattern if 
present (Epstein, 2010). 
 
 
Figure 11: The modified, updated Gleason scoring system.  Patterns 1 and 2 are largely 
obsolete in contemporary practice but may rarely still be diagnosed following TURP.  Pattern 3 
above displays moderately-differentiated carcinoma with large nuclei and prominent nucleoli, 
variable infiltrative glands that are closely packed but irregularly separated, of relatively 
circumscribed structure.  Pattern 4 demonstrates the pathognomonic cribriform (or bridging) 
pattern with smaller hyperchromatic nuclei, but could have poorly-formed irregular glands.  
Pattern 5 carcinomas possess minimal glandular differentiation, and range from infiltrating 
single cells to solid sheets of tumor cells (as seen here).  Diagram adapted from Epstein (2010).  
Photographs taken from anonymous TURP H&Es courtesy of Dr David Griffiths, Consultant 
Histopathologist, University Hospital of Wales, Cardiff, and were taken at 40x magnification, 
bars represent 100µm. 
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1.3.2 TNM staging 
Prostate cancer is staged using the TNM classification, which is clearly outlined in table 3.  This 
allows assessment of the tumour (T), lymph nodes (N) and metastases (M), which in turns 
affords accurate prognostic information and enables further treatment and/or follow-up to be 
planned. 
T stage    
T1: impalpable or 
undetectable radiologically 
T2: confined to 
prostate 
T3: through prostate 
capsule 
T4: fixed or invades 
adjacent structures 
e.g. rectum/bladder 
T1a: ≤5% of TURP chips T2a: ≤ half of one 
lobe 
T3a: extra prostatic 
extension 
 
T1b: >5% of TURP chips T2b: > half of one 
lobe 
T3b: invades seminal 
vesicles 
 
T1c: Detected on needle 
biopsy 
T2c: both lobes   
N Stage M stage 
Nx: nodes cannot be 
assessed 
Mx: metastases 
cannot be assessed 
N0: lymph nodes clear M0: no evidence of 
metastases 
N1: lymph nodes infiltrated 
with tumour 
M1: distant 
metastases present 
 
Table 3: TNM classification for prostate cancer.  Clinical evaluation of any prostate cancer is 
made using digital rectal examination, however pathological analysis following radical 
retropubic prostatectomy (RRP) with pelvic lymph node dissection allows most accurate T and N 
staging.  For men undergoing prostate-sparing treatments, such as radiotherapy or androgen 
deprivation, final T and N stage is made using a combination of the needle biopsy report and 
radiological assessment, usually with magnetic resonance imaging (MRI).  To rule out or confirm 
the presence of bone metastases, isotope bone scintigraphy is the gold-standard investigation, 
as is computerised topography (CT) for visceral or lymph node metastases beyond the pelvis.  
Adapted from TNM Classification of Malignant Tumours – 7th Edition (UICC, 2009). 
 
Important anatomical implications should be borne in mind for PCa prognosis, namely extra-
prostatic extension (EPE), formerly extracapsular extension.  Standard pathological staging of 
RRP specimens states the absence or presence of EPE, stage pT2 or pT3 tumours respectively, a 
prognostic cut-off for increased risk of disease progression after RRP (Epstein et al., 1996, De 
Marzo et al., 2003).  Nerve bundles, which can enable transmission of EPE, are located in the 
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posterolateral aspect of the gland, with the largest nerve plexus at the base and a smaller one 
at the apex (McNeal, 1992).  Hence the typical site of EPE is the posterolateral aspect of the 
prostate, particularly at the base, which is also the common route for direct invasion into the 
seminal vesicles i.e. stage pT3b (McNeal, 1992). 
 
1.3.3 Treatment of prostate cancer 
1.3.3.1   Localised prostate cancer 
Improvements in detecting early disease and its treatment may have been refined but 
controversy regarding the most appropriate therapy for men with clinically localised PCa   still 
remains (Albertsen et al., 2005).  Established curative treatment options for men with localised 
prostate cancer include radical retropubic prostatectomy (RRP), radical radiotherapy and 
brachytherapy, along with active surveillance (deferred treatment).  Cryosurgical ablation of the 
prostate (CSAP) and high-intensity focused ultrasound (HIFU) have more recently emerged as 
alternative therapeutic options for men with localised PCa (Fahmy and Bissada, 2003, Rees et 
al., 2004, Han and Belldegrun, 2004, Beerlage et al., 2000).  Both HIFU and CSAP have been 
developed as minimally invasive procedures, which have potentially the same therapeutic 
efficacy as established surgical and non-surgical options, with reduced therapy-associated 
morbidity (Heidenreich et al., 2012).  While HIFU is still considered an experimental treatment, 
the American Urological Association considers CSAP a true alternative therapeutic option. 
The discovery of reliable biomarkers will ensure more accurate differentiation between indolent 
and lethal phenotypes to better guide management of men with newly diagnosed prostate 
cancer (Garber, 2011, Cuzick et al., 2011, Ding et al., 2011).  More sophisticated imaging 
modalities will also ensure better imaging for those who choose to defer or forego treatment of 
localised PCa (Zaheer et al., 2009).  Undoubtedly before these technological advances to come 
into fruition, we will be privy to the outcomes of well awaited trials comparing management 
options for localised PCa. 
The Prostate cancer Intervention Versus Observation Trial (PIVOT) randomised 731 men (mean 
age 67 years) with localised prostate cancer to surgery or watchful waiting, and the two main 
endpoints from this trial were overall survival, and PCa-specific survival.  Forty three percent of 
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men had low-risk, 36% had intermediate-risk, and 20% had high-risk prostate cancer (Wilt et al., 
2012).  The most salient results from PIVOT included no apparent difference between RRP and 
observation for men with low-risk PCa, whereas those with high-risk disease demonstrated 
significantly better PCa-specific survival after surgery.  However, PIVOT failed to recruit the 
desired number of study participants, and as such, the trial was underpowered to detect the 
intended differences between RRP and observation (Catalona, 2012).  The on-going ProtecT trial 
(Prostate testing for cancer and Treatment) aims to evaluate the effectiveness, cost-
effectiveness and acceptability of treatments for men with localised prostate cancer; over 
100,000 men with localised PCa have been randomised to active surveillance, radical 
prostatectomy or radical radiotherapy (ProtecT, ISRCTN20141297, Lane et al., 2010).  In the 
hope of determining the most appropriate treatment for localised PCa, primary outcome 
measures will include: disease progression (biochemical and clinical), treatment complications, 
quality of life and sexual function, and ultimately PCa-specific survival and overall survival. 
 
1.3.3.2   Locally advanced prostate cancer 
There is no universally agreed definition of locally advanced prostate cancer (LAPC) (NICE, 
2014).  It includes a spectrum of disease ranging from tumour invading through the capsule of 
the prostate (pT3a) to those with T4 cancer that may be invading the bladder or rectum and/or 
has spread to pelvic lymph nodes (any T, and N1 – see section 1.3.2).  The management of men 
with ‘localised’ prostate cancer but with a high-risk of extracapsular disease (i.e. Gleason 
score ≥ 8, or PSA > 20) may also be considered under this heading.  Few effective treatment 
options for LAPC exist but they include systemic (androgen deprivation) or local therapy.  
Mounting evidence supports the use of a multimodality approach (Lowrance et al., 2012), 
including a combination of external beam radiation therapy (EBRT) with androgen deprivation 
therapy (ADT) or radical retropubic prostatectomy (RRP) with adjuvant EBRT.   
 
Multiple randomised controlled trials (RCTs) have demonstrated a survival advantage to 
combined EBRT and ADT compared with either modality alone (Bolla et al., 2002, Bolla et al., 
1997, D ’ Amico et al., 2008, Pilepich et al., 2005, Roach et al., 2008, Widmark et al., 2009).  To 
further add weight to the growing body of evidence, a systematic review (SR) and meta-analysis 
(MA) concluded that men given neoadjuvant hormone therapy prior to EBRT showed significant 
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improvements in clinical and biochemical disease-free survival as well as overall survival 
(Shelley et al., 2009b).  Most recently, data from the PRO7 Trial co-ordinated by the UK Medical 
Research Council (MRC) have shown that combining EBRT with neoadjuvant ADT in patients 
with LAPC improved the overall survival rate at 7 years (p=0.03) compared with ADT alone 
(Warde et al., 2011).  This multicentre phase III RCT recruited 1,205 patients with LAPC from the 
UK, the USA and Canada and randomised their treatment to either ADT alone or a combination 
of ADT and radiotherapy.  In the latter group there was substantial overall survival and disease 
specific survival benefit, hence in view of these data, the benefits of ADT and EBRT in 
combination should be discussed with all patients considering a curative treatment approach 
(NICE, 2014).   
 
As yet there has been no neo-adjuvant ADT in combination with adjuvant ADT surgical trial, 
which is the most efficacious strategy of androgen deprivation in men treated by EBRT for high-
risk disease (i.e. Gleason score ≥ 8, or PSA > 20) (NICE, 2014).  Neo-adjuvant ADT has so far 
failed to improve outcomes after surgery;  ten studies were analysed as part of a SR and MA to 
compare the effect of neo-adjuvant ADT prior to RRP versus RRP alone (Shelley et al., 2009b).  
Neo-adjuvant ADT prior to RRP resulted in clinical and pathological down-staging along with a 
reduction in positive surgical margin rates (Schulman et al., 2000), however no improvement in 
overall and disease-free survival was seen (Aus et al., 2002, Baert et al., 1998, Klotz et al., 2003).  
Likewise, for men undergoing RRP as primary therapy for LAPC, the addition of adjuvant ADT 
did not improve overall survival in a separate SR and MA (Shelley et al., 2009a), however one of 
only two trails eligible for this review reported a survival advantage in a small cohort of lymph 
node–positive (N1) surgical patients treated with adjuvant ADT (Messing et al., 2006).  More 
recently the control arm of the South West Oncology Group (SWOG) S9921 study identified the 
largest prospective group of men receiving immediate adjuvant ADT after RRP for high-risk 
localised PCa (Dorff et al., 2011).  Originally designed to compare outcomes of adjuvant therapy 
with ADT alone, or in combination with mitoxantrone chemotherapy after RRP, these results 
from the control arm of SWOG S9921 were published early in view of their favourable 5-year 
biochemical failure-free survival and overall survival (92.5%, and 95.9% respectively, median 4.4 
years).  With the main trial outcomes still yet to report, these preliminary data make a 
compelling argument for counselling all men with high-risk PCa after radical RRP about the 
merits of adjuvant ADT. 
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An important aspect of RP in LAPC is to unearth the risk of adverse pathological features, such 
as upgrading/upstaging of disease or margin positivity.  The role and benefit of adjuvant EBRT in 
this context has been demonstrated by three seminal RCTs that randomised men with positive 
margins, seminal vesicle invasion or EPE to receive adjuvant EBRT or conservative management 
(Thompson et al., 2009, Bolla et al., 2012, Wiegel et al., 2014).  Men randomised to adjuvant 
EBRT in all three trials benefitted from improved biochemical progression-free survival and local 
control.  Only one trial demonstrated significant improvements in metastasis and overall 
survival, with a median follow-up of 12.7 years (Thompson et al., 2009).  The initial 
improvement in clinical progression-free survival seen at 5 years by Bolla et al. (2005), was not 
maintained at 10 years (Bolla et al., 2012).  The currently-recruiting Medical Research Council 
RADICALS (Radiotherapy and Androgen Deprivation in Combination after Local Surgery) trial will 
evaluate the advantages of EBRT (adjuvant versus early salvage) and ADT in combination 
following RRP (Parker et al., 2007). 
 
1.3.3.3   Metastatic prostate cancer 
Huggins and Hodges (1941) were first to report the effect of surgical castration and oestrogen 
on the progression of metastatic prostate cancer (mPCa).  Their pioneering work demonstrated 
the responsiveness of PCa/mPCa to ADT (Huggins and Hodges, Feb 2002, Huggins et al., 1941).  
Since then, androgen deprivation strategies have become the mainstay of mPCa management.  
After initially responding to ADT, most men with advanced PCa will eventually progress within 
12-48 months depending on the disease burden, host factors and inherent tumour biology 
(Antonarakis and Eisenberger, 2011).  As such the current gold-standard treatment could be 
seen as being palliation, especially given that there is no conclusive evidence to show that ADT 
extends life (Heidenreich et al., 2012). 
 
After failing ADT, PCa evolves into a new clinically and molecularly heterogeneous androgen-
independent state known as castration-resistant prostate cancer (CRPC), which invariably 
metastasises before becoming fatal (Antonarakis and Eisenberger, 2011).  Androgen receptor 
signalling remains active even at castrate levels of serum testosterone, contrary to original 
understanding that disease progression after gonadal ablation implied androgen-independent 
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escape mechanisms (Chen et al., 2004a).  One way in which CRPC maintains AR signalling is by 
overexpressing CYP17 (17α-hydroxylase/C17,20-lyase), a key enzyme in extragonadal (adrenal, 
prostatic, and intratumoral) androgen biosynthesis.  As a result abiraterone acetate, an oral 
CYP17 inhibitor has been approved for use in the post-docetaxel chemotherapy setting, where 
it has shown an overall survival benefit of 3.9months compared to placebo and prednisolone 
(14.8 vs 10.9m respectively) (de Bono et al., 2011).  Other treatment options for CRPC are 
shown in figure 12. 
 
 
Figure 12: Evidence-based therapies for metastatic CRPC, and selected emerging treatments.  
Isotope bone scans show the typical course of metastatic CRPC from limited bone involvement 
(left) to progressive bone metastases (centre) to widespread metastases (right).  The CT scans 
on the far right show visceral (lung and liver) metastases.  Green boxes indicate agents that are 
currently approved in the USA by the Food and Drug Administration for the treatment of 
metastatic CRPC.  The effects of these agents on disease progression and overall survival are 
shown.  Orange boxes indicate selected agents currently in phase 3 drug development.  Figure 
taken from Antonarakis and Eisenberger (2011). 
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The identification of validated clinical, radiological, biological, and/or genomic biomarkers could 
in future aid PCa management by enabling risk stratification and better patient selection for 
specific therapies, in addition to helping quantify response to treatment by acting as surrogates 
of clinical benefit (Antonarakis and Eisenberger, 2011).   
 
Stem cell (SC) and cancer stem cell (CSC) theory are widely accepted concepts in the 
pathophysiology of many cancers and similarly prostate epithelial stem cells have been assigned 
a role in prostate cancer.  Residual CSCs following conventional therapies such as ADT, EBRT 
and chemotherapy, may be responsible for treatment failure and the development of CRPC.  
Hence, understanding the aetiology and pathophysiology of PCa will help to underpin the 
development of better treatment options for advanced PCa.  More specifically an 
understanding of prostatic epithelial biology is important because the evolution of CRPC may 
reflect a stem–like state of the tumour (Reya et al., 2001). 
 
1.4 STEM CELLS AND STEM CELL THEORY 
Many adult tissues, including blood, skin and intestine, are maintained by a subpopulation of 
cells known as SCs; one that possesses the ability to self-renew (maintenance of an 
undifferentiated state) and produce progeny that undergo further differentiation.  Adult SCs 
generate only the differentiated lineages appropriate for the tissue in which they reside, and 
are thus referred to as either multipotent or unipotent.  Multipotent stem cells have the ability 
to form all the differentiated cell types of a given tissue, such as in the prostate.  In some cases, 
a tissue contains only one differentiated lineage and the SCs that maintain the lineage are 
described as unipotent, such as those in skin.  Tissue homeostasis depends on a balance 
between SC self-renewal and differentiation (Watt and Driskell, 2010). 
 
1.4.1 Human prostate epithelial stem cells 
Evidence in support of the prostate epithelial stem cell (PrSC) niche has been increasing for over 
three decades.  Early androgen depletion/repletion experiments in rats identified populations 
of androgen-independent cells (English et al., 1985, English et al., 1987) with the ability to re-
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form duct-like structures, similar to human prostate acini, in vitro (Montpetit et al., 1988).  
Aspects of their data went on to develop later understanding that the prostatic epithelium is 
maintained by a single cell lineage system in which PrSCs comprise a subpopulation of the basal 
cells.  This notion has more recently been supported by indirect evidence that basal and luminal 
cells are derived from a common precursor (Verhagen et al., 1992, Xue et al., 1998, van 
Leenders et al., 2000, Hudson et al., 2001).  However in contrast, data from other researchers 
has led to the opposing hypothesis that both basal and luminal cells are independently capable 
of self-renewal (Evans and Chandler, 1987).  Nonetheless identification and characterisation of 
PrSCs is important because they may represent a major target of carcinogenesis as well as a 
potential source of benign prostatic hyperplasia (BPH) (De Marzo et al., 1998, Reya et al., 2001).  
BPH and prostate cancer, both disorders of cell differentiation and cell proliferation, are major 
causes of morbidity and mortality in elderly men.  There is evidence that the expansion and/or 
neoplastic transformation of PrSCs is the cause of BPH and/or PCa (Isaacs and Coffey, 1989, 
Schalken and van Leenders, 2003). Therefore, the immunophenotypical characterisation of PrSC 
candidates could provide novel therapeutic targets to use as adjuncts to standard therapies for 
treatment of BPH and PCa. 
 
1.4.1.1   Evidence for epithelial stem cells in normal prostate – rodent androgen cycling studies 
The ground-breaking experiments by English et al. (1985, 1987) defined the temporal effects of 
androgen replacement on prostatic cell population dynamics.  They revealed that ADT in rats 
led to prostate gland atrophy due to apoptosis of almost all terminally-differentiated epithelial 
cells; namely androgen-dependent epithelial, endothelial and periacinar stromal cells.  Upon 
readministration of testosterone, the gland regenerated and resumed normal secretory 
function.  The rodent prostate is able to undergo several cycles of regression/regeneration, 
which postulates for the presence of a robust, androgen-independent population of PrSCs with 
the profound, innate ability for self-renewal and differentiation to an androgen-dependent 
luminal population.  Further advances were made by Montpetit et al. (1988) when clones of 
androgen-independent cells were isolated from primary culture of rat prostate.  When seeded 
into soft agar, these androgen-independent cell lines formed distinct foci suggesting their 
potential for tumourigenesis (Montpetit et al., 1988). 
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Following on from these seminal discoveries, Isaacs and Coffey (1989) proposed a hierarchical 
SC theory of prostate organisation in a precursor-progeny relationship. Slowly proliferating 
androgen-independent SCs within the basal compartment give rise to a second population of 
more rapidly-cycling androgen-independent, but androgen-responsive, transit-amplifying cells 
(TACs).  Their capacity for self-renewal is greatly diminished however when following a limited 
number of population doublings, they were postulated to terminally differentiate into luminal 
secretory cells. 
Experiments in opposition to this “classical” stem cell theory have hypothesised that basal and 
luminal cells are derived from independent lineages – the “two lineage” model (see figure 
below).  A Cardiff group studied the proliferative activity of basal and luminal epithelial cells in 
the rat prostate after castration (Evans and Chandler, 1987).  Although castration induced 
widespread apoptosis of up to 90% of the luminal cells, no compensatory hyperplasia of the 
basal cells was noted in response (Evans and Chandler, 1987).  Instead cell proliferation and 
histological appearances suggested that both the basal and secretory cells entered a quiescent 
state upon castration.  The proliferative potential of luminal cells persisted up to three months 
after castration and during androgen-induced regeneration of the prostate proliferation was 
evident in both basal and luminal cell compartments.  Similarly, it was shown in the rat that 
after castration-induced atrophy, androgen-induced regeneration led to an enhanced 
proliferative response particularly of luminal cells (Evans and Chandler, 1987, English et al., 
1987).  There is also evidence to support the “two lineage” theory in human prostate whereby 
human prostatic luminal cells are capable of self-renewal following repletion of androgen after 
castration (van der Kwast et al., 1998).  These opposing stem cell theories are illustrated in 
figure 13. 
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Figure 13: Schematic representation of the two proposed stem cell theories.  In spite of these 
conflicting stem cell theories, the persistence of luminal secretory cells after androgen cycling in 
the “two lineage” theory does not wholly expunge the “classical” theory.  The two stem cell 
models may be reconciled by assuming that in the presence of androgens, a certain number of 
AR-positive basal cells (Bonkhoff and Remberger, 1993) possess the ability to differentiate into 
luminal cells, to compensate for luminal cell loss following androgen deprivation (van der Kwast 
et al., 1998). 
 
1.4.1.2   Phenotypic relationship between epithelial cell types in the prostate  
Basal and luminal cells were first reported to be distinguishable in the human prostate due to 
their varying affinity to toluidine blue (Dermer, 1978), whereby it exhibits a strong affinity for 
basal cells while secretory cells are poorly stained.  Dermer (1978) went on to describe how 
cells located nearer gland lumina were occupied by cells with a basal like morphology and which 
exhibited a strong affinity for toluidine blue.  These early data suggest that basal cells are 
capable of proliferation and may be a source of luminal cells.  Indeed co-localisation of basal 
cell-specific cytokeratins (denoted by prefix CK) with the proliferation-associated antigen Ki67 
highlighted that the proliferative compartment in the prostate resides within the basal layer as 
evident in normal and hyperplastic tissues (Bonkhoff et al., 1994).  Following on from these 
studies, methods of multiple immunocytological staining were developed that enabled the 
identification of a cell population intermediate from basal and luminal cells by the expression of 
differentiation stage-specific CKs (Verhagen et al., 1992, Xue et al., 1998, van Leenders et al., 
2000, Hudson et al., 2001).  Each group described how basal cells develop a luminal phenotype 
by way of an intermediate population.  Similar experiments later detected a gradual shift from 
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expression of basal to luminal CKs via a transit-amplifying population (Robinson et al., 1998).  
The aforementioned experiments (Verhagen et al., 1992, Xue et al., 1998, van Leenders et al., 
2000, Hudson et al., 2001) describe simultaneous immunocytological staining for up to three 
CKs.  The least-differentiated basal stem cell population, containing stem cells, expresses only 
CK5/14, whereas CK15, 17, and 19 are expressed as the cells differentiate, initially with CK14 
but then without. CK15 and 17 are restricted to intermediate basal cells but CK19 continues to 
be expressed as the cells become CK8/18-positive. The process ends with the loss of CK19, 
leaving only CK8/18 in the fully differentiated secretory population (Hudson et al., 2001).  CK19 
has been implicated in the differentiation of many different epithelial tissues in which there is a 
transition between differentiated phenotypes (Stasiak et al., 1989).  This differentiation process 
is depicted below in figure 14. 
 
Figure 14: Hypothetical differentiation pathway for human prostate epithelial cells based on 
patterns of keratin staining.  The prefix CK is interchangeable with K as used in this figure. 
Basally located undifferentiated cells (K5 and 14 only) give rise to an intermediate transit 
amplifying population expressing K19. These cells differentiate into luminal cells with transient 
co-expression of K19, 8, and 18 before complete differentiation into cells expressing K8/18 only.  
Adapted from Hudson et al. (2001). 
 
1.4.2 Do human prostate epithelial stem cells reside in the basal or luminal layer? 
There is a consistent body of evidence that PrSCs reside in the basal layer.  Here, a small 
subpopulation of cells with the antigenic profile α2β1integrin
HiCD133+ display SC characteristics: 
they are quiescent and have a high proliferative potential in vitro and they are capable of 
constructing functional prostate acini-like structures in vivo (Richardson et al., 2004).  More 
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recent molecular characterisation of these cells by the same group reveals that they do not 
express AR at mRNA level (Maitland et al., 2011), suggesting that they are not dependent on 
androgen for their survival, nor are they androgen-responsive.  In support of a basal location for 
PrSCs, CD49f and Trop2 were identified as candidate surface antigens after interrogation of 
prostate-specific microarray databases (Goldstein et al., 2008).  Trop2 discriminated basal cells 
into 2 populations, both of which were verified as basal cells by quantitative PCR, and only 
Trop2Hi cells were able to efficiently form prostate spheres in vitro (Goldstein et al., 2008) and 
regenerate prostate structures in a xenograft model in vivo (Goldstein et al., 2010). 
 
1.4.3 Epithelial stem cells in the murine prostate 
The preferential survival of prostate basal cells following androgen depletion/repletion 
experiments (English et al., 1987) led to the hypothesis that PrSCs reside within the basal layer 
of the gland (Isaacs and Coffey, 1989).  Furthermore, this notion is supported by the fact that 
mice bearing a germline inactivation of, and therefore are null for, the basal cell marker p63 fail 
to develop a prostate (Signoretti et al., 2000).  This suggests that the PrSC resides within the 
p63-expressing subpopulation.  Later Signoretti et al. (2005) showed that p63 is required for 
commitment to the prostate cell lineage and, importantly, luminal cells of the prostate originate 
from p63-positive basal progenitor cells.  In contrast, another group (Kurita et al., 2004) 
observed that fetal urogenital sinus tissue from p63-null mice transplanted as an allograft 
regenerated prostate ductal tissue in immunodeficient mice that lacked identifiable basal cells 
but did contain cells that expressed typical luminal markers.  Although this finding suggests 
basal and luminal cells are derived from separate lineages, an alternative explanation might be 
that in the absence of p63 the prostate does not develop normal stratified epithelia.   The 
transcription factor p63 is a homologue of the tumour suppressor p53 but unlike p53, which is 
dispensable for normal development, p63 is critical for the development of stratified epithelial 
tissues such as epidermis and breast (Barbieri and Pietenpol, 2006). 
The location of epithelial SCs in the murine prostate has been, and continues to be, a 
contentious issue.  Unlike human prostate, the mouse gland can be subdivided into ventral and 
dorsolateral lobes which are made up of individual ducts that drain into the urethra 
independently.  These ducts can be separated into proximal, intermediate, and distal regions in 
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both mice, which is depicted in figure 15 (Sugimura et al., 1986a, Tsujimura et al., 2002), and 
rats (Jesik et al., 1982, Lee et al., 1990).   
 
Figure 15: Schematic representation of a mouse prostate duct.  The urethra, proximal and 
distal regions of the prostate are highlighted.  Adapted from Korsten et al. (2009). 
 
Label-retention studies on murine prostate have demonstrated that the majority of cells with 
stem-like features are located proximally, whereas greater numbers of luminal cells are found 
more distally at the tips of individual ducts.  Label retention is well reported to be one method 
of mapping the location of stem cells on the assumption that cells displaying stem-like 
properties are quiescent, hence they are able to retain a DNA label for a lengthened period of 
time due to their infrequent entry into the cell cycle.  In contrast, density of the label in 
question is rapidly diminished in actively dividing cells.  
Tsujimura et al. (2002) described that in the proximal portions of the dorsal and ventral 
prostate, a high proportion of both basal and luminal cells were found to retain the BrdU label, 
even after multiple rounds of androgen involution–regeneration.  In addition, Tsujimura et al. 
(2002) claim that the proximal cells of mouse prostatic ducts are quiescent, have a high 
proliferative potential, and give rise to large, glandular structures that produce prostatic 
secretory products in culture.  These data strongly suggest that prostatic epithelial stem cells 
are concentrated in the proximal region of the ducts; however they admit that  the distal region 
of the gland contains a population of actively proliferating cells as supported by others 
(Sugimura et al., 1986b, Cunha et al., 1987).  The distal tips of the dorsal and lateral rat 
prostates undergo significant growth when combined with embryonic UGS mesenchyme and 
Intermediate region 
Distal region 
Proximal region 
Urethra 
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implanted under the renal capsule (Kinbara et al., 1996).  These findings were interpreted to 
mean that SCs reside in the distal region of prostatic ducts; however this experiment failed to 
include tissue from the proximal region for comparison which is a weakness in their study 
design (Kinbara et al., 1996).  The observed growth of the distal region could be explained by 
the presence of young rapidly-proliferating TACs (Tsujimura et al., 2002).  Other tissues exhibit 
the inherent ability of self-renewal, highlighting that a post-stem cell population of young TACs 
are capable of undergoing significant growth.  These include skin (Taylor et al., 2000, Oshima et 
al., 2001), bone marrow (Williams, 1993, Berardi et al., 1995), and liver (Fausto, 2000, Strain 
and Crosby, 2000). 
Enrichment for PrSCs from the proximal region of the mouse prostate has also been performed 
based on Sca-1 (stem cell antigen-1) expression (Burger et al., 2005).  Cells expressing Sca-1 
from the proximal region displayed a 17-fold higher in vivo proliferative potential than Sca-1- 
(p<0.001) and Sca-1+ cells obtained from the remaining ductal regions had far less growth 
potential than Sca-1+ proximal cells (p<0.001) (Burger et al., 2005). 
 
1.4.3.1   Location of murine prostate epithelial stem cells 
In contrast to human prostate, there is still uncertainty as to whether the PrSC population in 
mice has a luminal or basal phenotype, as there is evidence in support of both hypotheses.  As 
discussed earlier (see section 1.4.1.1), and in opposition to a solely basal phenotype, is the 
notion that BrDU- label-retaining cells are present both in the luminal and basal compartments 
(Tsujimura et al., 2002).  Furthermore, using genetic lineage-marking, one study demonstrated 
that castration-resistant Nkx3.1-expressing cells are rare luminal cells that express Nkx3.1 after 
castration, can self-renew in vivo and can reconstitute prostate ducts in a single-cell allograft 
experiment (Wang et al., 2009). 
 
In contrast, there is a greater body of evidence to suggest that mouse prostate SCs possess a 
basal phenotype akin to human prostate.  In both species, a subset of basal cells are androgen-
independent and can exhibit higher proliferative potential than luminal cells (Bonkhoff and 
Remberger, 1996).  In addition, murine basal prostate epithelial cells can differentiate into 
luminal cells both in vitro and in vivo (Xin et al., 2007).  Studies in mice have led to the 
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identification of Sca-1+ cells as a subpopulation of prostate epithelial cells with SC 
characteristics (Xin et al., 2005, Burger et al., 2005).   
 
1.4.4 Prostate epithelial stem cell markers 
The majority of markers used to isolate prostate cells that are capable of displaying stem-like 
qualities, are not shared by both human and mouse.  The prospective identification of enriched 
SC and/or progenitor/transit-amplifying subpopulations in mouse prostate is important for 
investigating the self-renewal properties of SCs.  This will in turn enable their role in cancer 
initiation and propagation to be explored, so as to exploit their potential as novel drug targets 
in the pre-clinical setting.  Notwithstanding, identification of these populations from human 
prostate would be the most sought-after goal and result in greatest therapeutic benefit; that of 
improved PCa survival and ultimately cure.  Therefore, it would be useful to identify antigens 
found on stem/progenitor cells from both the mouse and human prostate. 
 
1.4.5 Human prostate epithelial stem cell markers 
In the normal human prostate, basal cells express CD44, whereas luminal cells express CD57.  
Liu et al (1997) were able to isolate the two major epithelial cell populations by utilising their 
differential expression of surface markers CD44 and CD57 by fluorescence activated cell sorting 
(FACS).  Their work demonstrated that CD44-expressing basal cells were capable of 
differentiation into luminal cells when cultured in combination with dihydrotestosterone, and a 
synthetic mimic of the stromal microenvironment, Matrigel.  This was proven by the detection 
of secreted PSA in the culture medium, which is an innate function of luminal cells but not basal 
cells.  Unsurprisingly CD57+ cells continued to secrete PSA, but interestingly PSA production was 
also noted in the CD57- population.  This was hypothesised to be due to contamination with 
residual luminal cells or differentiation of CD44+ cells.  Given that basal cells exhibit one 
property of SCs, differentiation, (Bonkhoff and Remberger, 1996), they were felt to constitute 
the reservoir of progenitors that mature into luminal cells. 
Following this experiment, cells that express α2β1-integrins were selected from CD44
+ basal cells 
by FACS, and shown to possess features in-keeping with SCs (Collins et al., 2001).  Integrins, 
which mediate attachment of cells to extracellular matrix proteins of the basement membrane, 
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have proven effective in identifying SCs in such tissues as skin and testis.  Epidermal SCs had 
earlier been shown to express higher levels of integrins α2β1, which was used to discover the 
location of SCs within the epidermis, and to isolate them on their ability to adhere to type IV 
collagen in vitro (Jones et al., 1995).  Collins et al (2001) hypothesised that PrSCs could share 
similar molecular properties to other SCs , and thus they questioned whether integrin α2β1 
could facilitate adhesion to type I collagen and laminin-1, in addition to type IV collagen; a 
feature restricted to the basal cells of the prostate (Knox et al., 1994).  They found that basal 
cells expressing this molecular signature comprised up to 15% of the subpopulation.  
Furthermore, high surface expression of the α2-integrin subunit on human prostate epithelium 
correlates with increased colony forming ability in 2D-culture, and the potential to regenerate a 
fully differentiated prostate epithelium in an allograft model.  Immunohistochemical analysis 
revealed colonies predominantly contained cells that stained intensely with the basal cell-
specific marker 34βE12. Luminal cells correctly stained with antibodies against PAP and PSA, in 
addition to AR. 
To further facilitate the isolation and characterisation of prostate epithelial stem cells, the same 
group later showed that by sorting for α2β1-integrin
hiCD133+, they were able to refine a 
subpopulation that expanded both in vitro, and in vivo following transplantation in the flank of 
athymic male mice.  In adherent culture, this population of interest totalled 0.75%.  In a colony-
forming assay, clonal CD133+ cells were enriched at an approximately 10-fold greater efficiency 
than the non-selected basal population, and CD133– cells had a 4 to 5-fold greater efficiency 
than non-selected basal cells.  They later became the first group to successfully isolate and 
characterise the CSC population from human prostate tumours using the antigenic profile 
CD44+α2β1-integrin
hiCD133+ (Collins et al., 2005).  These CSCs, representing a small fraction of 
the total cells comprising the tumour, were capable of self-renewal and proliferation in vitro, 
and differentiated to recapitulate the phenotype of the tumour from which they were derived.  
However, this study lacked the so-called, “ultimate test” of tumourigenicity, transplantation in 
vivo, but went on to state that they had provided compelling evidence that the CD133-derived 
cultures were tumorigenic, as they were shown to be invasive in Matrigel.  The quantity of 
CD133-expressing cells was not influenced by tumour grade, or the source of tumour cells, 
which included primary prostate cancers and metastatic deposits, whereby their proportion 
(approximately 1%) remained small in all experiments. 
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Schmelz et al (2005) aimed to identify subpopulations of prostate epithelial cells with the 
potential for proliferation and differentiation from core biopsies of normal human prostate 
taken from RRP specimens.  The members of the CK6 family are structural proteins associated 
with hyperproliferation and aberrant differentiation, and as such, CK6 expression was tested in 
vivo as a structural marker to identify PrSC candidates.  Evidence in support of CK6a+ cells being 
candidate prostatic stem cells includes: the presence of CK6a+ cells in foetal, juvenile and adult 
prostatic glands; the niche-like distribution pattern; the abundance in the foetal urogenital 
sinus enriched in stem cells; the differentiation potential; the proliferation potential; and finally 
the amplification potential of these CK6a+ cells (Schmelz et al., 2005). 
Work with murine PrSCs has revealed commonalities between them and stem-like cells 
originating from other tissues, including the mammary gland (Lawson et al., 2007).  In breast 
cancer, earlier discovery had identified CD44+CD24- cells as being both clonogenic and 
tumorigenic (Al-Hajj et al., 2003).  These cells were xenografted into the mammary fat pad of 
NOD/SCID mice (see section 1.6.1) and shown to possess the ability to proliferate extensively, 
to give rise to diverse cell types with reduced developmental or proliferative potential, and to 
serially passage in vivo up to four generations (Al-Hajj et al., 2003).  This led another group to 
later question whether CD44+CD24- cells from human prostate cancer defined a population of 
cancer stem cells (Hurt et al., 2008).  They showed that human prostate cancer cells with the 
CD44+CD24- phenotype display stem cell characteristics such as clonogenicity, tumorigenicity, 
and the ability to grow into spherical organoids in non-adherent culture. These organoids 
displayed stem-like gene signatures; over-expression of genes associated with ‘stemness’, 
including Oct-3/4, BMI-1, smoothened, and β-catenin.  Furthermore, tumours from mice 
injected with CD44+CD24- cells were phenotypically similar to tumours resulting from mice 
injected with total cells from the immortalised LNCaP cell line.  This indicates that CD44+CD24- 
cells satisfy the CSC brief.  Additionally, CD44+CD24- cells contain a molecular signature 
originally identified in breast tumorigenic cells (Liu et al., 2007 ), further drawing similarities 
between breast cancer and PCa. 
Despite the growing body of evidence for PrSCs, a fundamental question remains as yet 
unanswered: whether all basal cells possessed stem cell characteristics and could give rise to 
terminally differentiated cells of the organ, or whether only a subpopulation of basal cells have 
tissue regenerative capacity?  Goldstein et al. (2008) attempted to address this by sorting for 
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the marker Trop2Hi, from the population enriched for the antigenic profile CD49f+.  They 
elegantly demonstrated how tumour-associated calcium signal transducer 2 
(TACSTD2/Trop2/M1S1/GA733-1) (Fornaro et al., 1995), allows discrimination between two 
basal cell subpopulations.  Furthermore they provided evidence that not all basal cells have SC 
characteristics; the Trop2Hi cells displayed ‘stemness’ in in vitro and in vivo assays.  The value of 
the Trop2 marker is further enhanced because it can isolate sphere-forming stem/progenitor 
cells from both the human prostate and the murine prostate, the latter of which will be 
discussed later. 
 
Up to this point no group had managed to identify the antigenic profile of a functionally pure 
human PrSC population in order distinguish multipotent SCs from progenitors with more limited 
self-renewal potential.  Guo et al. (2012) served to interrogate combinations of cell surface 
antigens EpCAM, CD44 and CD49f to differentiate SCs from progenitors and luminal cells by way 
of a tissue regeneration assay, in which total benign prostate cells induce tubule formation 
(differentiation) supported by human fetal prostate stroma in a tissue regeneration model.  
They were the first group to report 3 distinct epithelial populations with unique properties: 
 
1. EpCAM+CD44+CD49fhi - basal cells capable of forming abundant spheres 
2. EpCAM+CD44-CD49fhi - basal non sphere-forming cells (true SCs) with significantly 
increased tubule induction activity 
3. EpCAM+CD44-CD49flo – true luminal cells that lack both sphere-forming and tissue 
regenerating potential 
 
 
These data go some way to support those outlined by others (Richardson et al., 2004, Lang et 
al., 2010), whereby CD133 was reported to be a marker of human PrSCs.  Their experiments 
demonstrated how these cells were incapable of forming spheres, but readily formed 
proliferative monolayers in 2D culture.  In addition, α2β1integrin
hiCD133+ cells induced acinar-
like outgrowths in vivo, suggesting that CD133+ cells possess similar properties to the 
EpCAM+CD44-CD49fhi subpopulation.  Moreover, other human studies have reported that 
CD133 does not enrich for sphere-forming cells (Garraway et al., 2010). 
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Few surface molecules are currently available for enriching both murine and human prostate 
tissue stem/progenitor cells, but CD166 is one such antigen (Jiao et al., 2012).  CD166 has been 
shown to enrich the sphere-forming ability of benign primary human prostate cells in vitro and 
induce the formation of tubule-like structures in vivo.  Similarly, its expression is upregulated in 
human PCa, especially in CRPC samples.  Its role as a murine stem/progenitor cell marker will be 
expanded upon later.   
Human PrSC markers are summarised in table 4. 
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Human SC 
marker 
Description 
Source of 
tissue 
Evidence 
CD44 CD44+ cells occupy a basal location.  
Differentiation, as reflected by PSA production, 
can be detected when CD44+ cells are co-
cultured with stromal cells.  Thus, CD44+ basal 
cells possess characteristics of stem cells and are 
candidate progenitors of luminal cells 
Benign glands 
from TURP/RP 
for BPH, or 
cysto-
prostatectomy 
for bladder 
cancer 
Liu et al. 
(1997) 
α2β1-
integrinhi 
Represent ~1% of basal cells but are 
distinguishable from other basal cells by their 
ability to generate prostate-like glands in vivo 
with morphologic and immunohistochemical 
evidence of prostate-specific differentiation 
Benign glands Collins et al. 
(2001) 
α2β1-
integrinhi 
CD133+ 
Possess high proliferative potential in vitro, and in 
vivo where they can reconstitute prostatic-like 
acini in immunocompromised nude mice 
Benign glands Richardson 
et al. (2004) 
CD44+ α2β1-
integrinhi 
CD133+ 
Cells possess the capacity for self-renewal, and 
are capable of forming differentiated cell 
products, such as AR and PAP 
Tumour cells 
from RRP 
specimens 
Collins et al. 
(2005) 
CK6a Possess a high potential for proliferation and 
differentiation ex vivo 
Benign glands Schmelz et 
al. (2005) 
CD44+ 
CD24- 
Cells form tumours when transplanted as 
xenografts and express genes known to be 
important in stem cell maintenance 
LNCaP and  
DU-145 cell 
lines 
Hurt et al. 
(2008) 
Sca1+ 
CD49fhi 
Trop2hi 
Sphere-forming assays were isolated from the 
human prostate using these markers identified in 
the mouse, suggesting conservation of 
interrelated progenitor markers between mouse 
and human 
Benign glands Goldstein et 
al. (2008) 
Trop2hi 
CD49fhi 
CD44+ 
This antigenic combination highlighted cells with 
enriched sphere-forming capability.  Clonally 
derived prostaspheres could be dissociated and 
passaged for multiple generations and induce the 
formation of ductal/acinar-like structures in vivo. 
Benign and 
malignant 
glands from 
RRP and cysto-
prostatectomy 
specimens 
Garraway 
et al. (2010) 
Epcam+CD4
4+/-CD49fhi 
Epcam+CD44+CD49fhi cells demonstrated self-
renewal in 3D culture, but not differentiation in 
allografts; thus felt to represent the PC/TAs.  
However Epcam+CD44-CD49fhi cells were non-
sphere-forming but readily generated tubular 
structures when allografted (differentiation); felt 
to be SCs 
Tumour cells 
from RRP 
specimens 
Guo et al. 
(2012) 
CD166hi CD166hi human prostate cells have higher sphere 
forming capacity in vitro and more graft outgrowth 
in vivo, and up regulated in advanced PCa on gene 
expression and TMA analyses 
Adult and 
foetal benign 
glands 
Jiao et al. 
(2012) 
 
Table 4: A summary of each reported human PrSC marker  
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1.4.6 Mouse prostate epithelial stem cell markers  
Bcl2 is a proto-oncogene that, along with being anti-apoptotic, is often expressed in the 
proliferating zones of long-living cells (Hockenbery et al., 1991).  This and other experiments 
have demonstrated how Bcl2 staining is confined to basal cells of the prostate epithelium 
(Bonkhoff and Remberger, 1996).  Both the expression pattern in the prostate epithelium and 
its role in apoptosis contribute to Bcl2’s potential for being a SC marker.  Moreover, 
experiments using 2D colony-forming assays report that only 2-4% of cells display proliferation, 
and colonies derived from SCs co-express Bcl2 and CK5, further adding weight to the basal 
location of PrSCs. 
As discussed in section 1.4.3, PrSCs responsible for populating epithelial compartments of the 
prostate express p63 (Signoretti et al., 2000), whereas p63-null mice fail to develop prostates.  
Recently the NH2-terminal truncated (ΔN) p63 isoform was studied by the generation of knock-
in mice expressing Cre-recombinase under the control of an endogenous ΔNp63 promoter 
(Pignon et al., 2013).  Genetic lineage tracing experiments concluded that ΔNp63-positive cells 
of the urogenital sinus were responsible for generating all epithelial lineages of the prostate 
and bladder, indicating that these cells represent the stem/progenitor cells of those epithelia 
during development (Pignon et al., 2013). 
Shou et al. (2001) demonstrated that Notch1-expressing cells were associated with the basal 
epithelial cell population in the prostate.  Furthermore, elegant experiments by Wang et al. 
(2004) revealed that elevated Notch1 expression during development suggests that Notch1-
expressing cells define progenitors in the prostate epithelial cell lineage.  These cells were 
shown to be of paramount importance in branching morphogenesis of the developing prostate 
in culture and in re-populating the prostate epithelia upon reintroduction of androgen after 
castration in a transgenic mouse model, concomitant with p63 and CK14 cells (Wang et al., 
2004). 
BrdU label-retaining experiments have previously suggested that slow-cycling PrSCs with high-
proliferative potential are located in the proximal ducts of the mouse prostate (Tsujimura et al., 
2002).  These stem cells were prospectively isolated and purified based on their surface 
expression of stem cell antigen-1 (Sca-1), and shown to possess greater in vivo proliferative 
potential than cells expressing low levels of Sca-1 in a renal capsule allograft model (Burger et 
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al., 2005).  Interestingly, the majority of Sca-1+ cells co-expressed α6-integrin and Bcl-2, both 
known to be important when identifying SCs of other origins (Burger et al., 2005).  Regeneration 
of Sca-1+-enriched prostate regenerative cells (stem-like cells) that were transfected with 
lentivirus that mediated the expression of constitutively active AKT1, resulted in the initiation of 
prostate tumourigenesis (Xin et al., 2005).  In this study, the Sca-1+ subpopulation was shown to 
be largely quiescent (in G0 on FACS) and able to display bipotency; both basal and luminal cell 
lineages were present in regenerated grafts. 
Other papers have gone on to describe how prostate epithelial cells enriched for Sca-1 in 
combination with other cell surface markers, identifies groups of cells capable of displaying 
stem cell characteristics in vivo and ex vivo.  These include Lawson et al. (2007), 
CD45+CD31+Ter119+[Lin-]Sca-1+CD49f+ (LSChi); Leong et al. (2008), Lin-Sca-
1+CD133+CD44+CD117+; Goldstein et al. (2008) and Lukacs et al. (2010), LSChiTrop2hi; and Jiao et 
al. (2012), LSChiCD166hi. 
Finally, prominin (known as CD133 in humans) was identified as being a candidate SC marker in 
murine prostate epithelium for several reasons (Tsujimura et al., 2007).  Firstly it is a cell surface 
marker that is widely used to identify and isolate SCs from various organs, including the 
hematopoietic system.  Secondly, on cDNA microarray analysis, it was enriched greater than 20 
times from the proximal mouse prostate when compared to most of the 4800 genes analysed.  
CD133+ cells formed large glandular structures containing both basal and luminal cells in in vitro 
3D culture that were significantly larger and more branched than CD133- cells, while in contrast, 
prominin-deficient cells from the proximal region did not form ductal structures.  
Murine PrSC markers are summarised in table 5. 
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Mouse SC 
marker 
Description Evidence 
Bcl-2 
 
 
 
 
 
K5 & Bcl-2 
Anti-apoptotic protein expressed in long-living cells 
 
Expressed on basal cells 
 
 
 
Clonogenic cells demonstrated self-renewal and purification 
in vitro  
Hockenbery et 
al. (1991) 
Bonkhoff and 
Remberger 
(1996), Rizzo et 
al. (2005) 
Sawicki and 
Rothman 
(2002) 
p63 p63-null mice fail to develop a prostate, hence p63 is 
essential for development of normal prostate cell 
populations 
 
Urogenital sinus cells positive for the NH2-terminal 
truncated p63 isoform generated all epithelial lineages of 
the prostate, suggesting  that these cells represent the 
stem/progenitor cells 
Signoretti et al. 
(2000) 
 
 
Pignon et al. 
(2013) 
Notch Receptor mapped to basal cells 
 
Ablation of Notch-1 cells in a transgenic mouse model 
severely affected morphogenesis, growth, and 
differentiation in prostate 
Shou et al. 
(2001) 
Wang et al. 
(2004) 
Sca-1  
(stem cell 
antigen-1) 
Cells from the proximal region displayed a 17-fold higher in 
vivo proliferative potential than Sca-1- cells 
 
Cells identified by FACS showed prostate-regenerating 
activity and oncogenic potential over Sca-1- cells 
Burger et al. 
(2005) 
 
Xin et al. 
(2005) 
Lin-Sca-1+ 
CD49f+ (LSC) 
LSC cells demonstrate self-renewal in vitro, in vivo (allograft) 
and differentiation upon administration of testosterone 
Lawson et al. 
(2007) 
CD133 CD133+ cells generated large-branched ducts in 3-D culture, 
whereas CD133- cells formed far fewer such structures 
Tsujimura et al. 
(2007) 
Lin-Sca-1+ 
CD133+ CD44+ 
CD117+ 
Single cells were shown to generate a functional prostate 
after transplantation in vivo 
Leong et al. 
(2008) 
LSCTrop2hi 
(LSCT) 
Trop2 is expressed in the basal fraction.  Trop2 exhibits 
enrichment for stem-like cells in 2-D and 3-D culture 
Trop2hi cells were capable of forming spheres in vitro, over 
and above the efficiency of LSC cells 
Goldstein et al. 
(2008) 
Lukacs et al. 
(2010) 
LSChiCD166hi CD166 can be employed to further enrich stem/progenitor 
cells in wild-type murine prostate 
Jiao et al. 
(2012) 
 
Table 5: A summary of each reported PrSC marker in murine prostate 
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1.4.7 Cancer stem cells 
Just as normal tissues can contain a mixture of dividing cells and cells at different stages of 
terminal differentiation, the same is true for many tumours.  The observed heterogeneity of 
tumours underpins the CSC concept.  The stochastic model opposes this explanation for tumour 
heterogeneity and both theories are depicted in figure 17. 
 
Figure 17: The Cancer Stem Cell model versus the Stochastic model of tumour heterogeneity.  
The stochastic model proclaims that tumour cells are biologically equivalent but the mutations 
that result in their malignant potential occurs at random and is therefore unpredictable.  Thus, 
tumour-initiating cells/progenitor cells/PrSCs cannot be enriched for by sorting cells based on 
antigenic profile.  In contrast, the hierarchical CSC model postulates the existence of classes of 
cells, biologically distinct from one another, with differing functional abilities and behaviour, 
whereby only a subset of cells has the ability to initiate tumour growth, the so-called CSC.  
These cells possess the ability to self-renew and give rise to progeny, which are not necessarily 
malignant, that make up the bulk of the tumour.  This model predicts that tumor-initiating cells 
can be identified prospectively and purified from the rest of the tumour bulk, based on intrinsic 
characteristics.  Adapted from Watt and Driskell (2010). 
 
The CSC concept is an important one in PCa because it has been hypothesised that these cells 
are resistant to conventional ADT, which largely treat the bulk of the tumour only.  
Consequently, and in support of this, CRPC develops, which ultimately proves fatal.  Figure 18 
illustrates this hypothesis. 
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Figure 18: Cancer stem cells as drug targets in prostate cancer.  Cancer stem cells often share 
antigenic profiles with normal PrSC/progenitor cells (Ginestier et al., 2007, Malanchi et al., 
2008). This highlights the importance of identifying primitive cell populations in normal and 
malignant prostate tissue of both mice and humans to act as drug targets for novel therapies 
aimed at killing the CSC. 
 
1.5 MODELLING PROSTATE CANCER IN VITRO 
1.5.1 Cell lines 
Immortalised cell lines are long established in the study of PCa.  They have particularly been 
used to investigate genetic deregulation in support of in vivo findings.  The important historical 
human prostate cancer cell lines such as DU-145 (Stone et al., 1978), PC-3 (Kaighn et al., 1979), 
and LNCaP (Horoszewicz et al., 1980), were originally cultured from metastatic sites, namely 
brain, bone, and supraclavicular lymph nodes respectively.  Being from different sites, and 
possessing varying malignant potential, they have allowed rapid, prospective identification of 
genetic targets and molecular mechanisms in advanced disease.  Perhaps one criticism of cell 
lines is that they preclude analysis of genetic alterations that are responsible for the 
transformation of normal prostate epithelium into adenocarcinoma.  Furthermore, they lack 
the complex paracrine signalling of the tumour microenvironment (Hensley and Kyprianou, 
2012). 
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1.6 MODELLING PROSTATE CANCER IN VIVO 
There is no single mouse strain that fully models all stages of human prostate tumourigenesis.  
These are demonstrated in figure 19.  The fundamental challenge that scientists have failed to 
overcome is the heterogeneity of both human and murine PCa.  To date each mouse model has 
only characterised certain features or stages of the disease, but despite this, most models have 
contributed positively to our contemporary understanding of PCa. 
 
Figure 19: the stages of human prostate cancer.  LGPIN, low-grade prostate intraepithelial 
neoplasia; HGPIN, high-grade PIN; CRPC, castrate-resistant prostate cancer. 
 
Mouse models allow the important early and late phases of prostate tumourigenesis to be 
studied with set kinetics, in a stepwise fashion. Whether or not hyperplasia is a precursor to 
PIN, and whether or not low-grade disease is a precursor of high-grade disease, will not be 
deliberated here.  The important mouse models of PCa are summarised in this section. 
 
1.6.1 Xenograft models of prostate cancer 
Immunodeficient mice have acted as recipients for human material, including cell lines, prostate 
cancer cells or cells from primary culture.  Their genetic modifications render them unable to 
mount an immunological response, resulting in unabated tumour growth that facilitates the 
study of patient specific material.  Xenograft models have been employed in assessing the 
efficacy of novel treatments, along with providing suitable conditions for in vivo passage when 
exploring SC/CSC properties.  Specific xenograft models are countless, limited only by the 
genetic alterations and combinations of interest.  The immunodeficient mice that are most 
commonly used for xenografts in the investigation of PCa are summarised in table 6. 
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Model Description 
Immunological 
deficiency 
Specific features 
Nude mice 
Congenitally 
athymic 
T-lymphocyte 
deficiency 
Orthotopic injection may give a 
truer representation of tumour 
microenvironment  than 
subcutaneous injection 
Severe Combined 
ImmunoDeficient 
mice (SCID) 
Autosomal 
recessive SCID 
mutation 
B- and T-lymphocyte 
deficiency 
Greater immunodeficiency than 
nude mice; NK cells and myeloid 
cells persist 
Non-Obese Diabetic 
(NOD) – SCID mice 
NOD mice 
crossed with 
SCID mice 
Deficient in natural 
killer cells, 
complement and 
antigen presenting 
cells 
Higher graft success rate due to 
greater immunodeficiency than 
SCID mice; NK cells persist 
Renal capsule 
xenograft 
PCa cells 
mixed with 
urogenital 
sinus 
mesenchyme 
injected under 
renal capsule 
Usually NOD or SCID 
mice used 
Used to determine the ability of 
putative PrSCs to generate 
prostatic tissue and ducts. 
Also used to determine the 
physiological significance of genes 
that cannot be studied via 
whole body knockouts due to 
embryonic lethality 
Intrabone injection 
xenograft 
Cells injected 
into tibia or 
femur under 
anaesthesia 
Nude and SCID mice 
reported 
Used to model the invasion and 
growth of PCa cells in bone. 
No mouse model  of PCa 
spontaneously metastasises to 
bone 
 
Table 6: The immunodeficient mice used in the study of PCa and the methods commonly used 
for xenografts 
 
1.6.2 Constitutive/germline knockout models of prostate cancer 
Traditional (whole body) knockout models have allowed the genetic modification of tumour 
suppressor genes felt to be important in PCa, thus enabling their roles in tumourigenesis to be 
defined.  In this manner the whole gene, or a region of DNA essential to a maintain gene’s 
integrity, can be excised.  The major limitation precluding the widespread and continued use of 
this technique is embryonic lethality since many tumour suppressors play important roles in 
embryogenesis.  Despite this, several knockout models have been well characterised, 
highlighting their importance in PCa. 
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PTEN (phosphatase and tensin homolog deleted from chromosome 10) is a tumour suppressor 
gene and negative regulator of the PI3K/Akt/mTOR pathway that has been implicated in many 
human cancers, including PCa.  Germline mutations in the PTEN gene have been associated with 
Cowden syndrome whereby these patients develop hamartomas in various organs that have 
premalignant potential (Liaw et al., 1997, Marsh et al., 1999, Dahia, 2000).  PTEN deregulation is 
strongly implicated in prostate tumourigenesis; PTEN deletions and/or mutations are found in 
30% of primary PCa (Dahia, 2000) and up to 63% of mPCa (Suzuki et al., 1998).  Indeed, PTEN 
mutations have likewise been implicated in the mechanisms of resistance to EBRT (Anai et al., 
2006), and chemotherapy (Priulla et al., 2007), along with recurrence following RRP (Bedolla et 
al., 2007).  Furthermore, in vitro analysis in mice has suggested a critical role for Pten in the 
progression of cancer cells to CRPC (Shen and Abate-Shen, 2007). 
In mice Pten was found to be of paramount importance for early embryonic development, since 
Pten-/- mice are incompatible with life.  In comparison, heterozygotes (Pten+/-) survived up to 1 
year and resulted in broad-ranging phenotypes in various tissues.  These included tumours of 
the gonads, skin, uterus and endometrium, intestine, thyroid and adrenal glands.  Prostatic 
lesions in these Pten+/- mice were classified as PIN, showing that Pten mutation was a critical 
molecular event in PCa development (Podsypanina et al., 1999). At least three other models 
describe knockouts in combination with Pten that have resulted in more aggressive phenotypes.  
These are outlined in table 7. 
Constitutive double 
knockout model 
Terminal stage of 
neoplasia 
Other tissues 
affected 
References 
Pten x p27 Adenocarcinoma Endometrium, 
intestine, thyroid, 
adrenal gland 
Di Cristofano et al. 
(2001) 
Pten x Nkx3.1 LN metastases As for solitary Pten+/- 
model, including 
salivary, bulbourethral 
and adrenal gland 
hyperplasia/dysplasia 
Abate-Shen et al. 
(2003) 
 
Gao et al. (2006) 
Pten x p53 HGPIN As for solitary  Pten+/- 
model 
Couto et al. (2009) 
 
Table 7: Constitutive Pten double knockout mouse models and their consequences 
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To efficiently target deletion of genes within the prostate, and in so doing avoid embryonic 
lethality and multiple phenotypes, the prostate-specific promoter Probasin was exploited.  
Probasin (prostate basic protein, PB) is a prostate-specific gene, originally derived from the rat, 
and it is the most extensively used promoter in PCa research.  It is a member of the lipocalin 
family and is found in the secretions and nuclei of prostate epithelial cells.  It is reportedly 
regulated by androgens and zinc (Kasper and Matusik, 2000, Johnson et al., 2000), and although 
its precise function remains unknown, it is believed to be involved with transporting 
hydrophobic ligands into seminal fluid (Johnson et al., 2000). 
Probasin contains two AR binding sites within the promoter (-236 to -223 and -140 to -117), 
referred to as the androgen responsive region (ARR), to enable full promoter activation (Kasper, 
2005).  Previous work has revealed that PB-driven expression occurred in all lobes of the 
prostate using both elements of the ARR (Gingrich et al., 1996).  In an effort to increase the 
efficiency of the PB-promoter, the isolation and utilisation of a larger 12kb fragment (large PB 
promoter, LPB) resulted in higher expression of the transgene specific to luminal epithelium.  
This occurs because elevated androgen levels during prostate maturation facilitates increased 
activity in the LPB promoter (Yan et al., 1997).  To further augment the specificity of PB, two 
ARRs were added to the LPB, thus creating the now widely used ARR2PB promoter.  This was 
employed to drive Cre-recombinase within the prostate (PBCre4), resulting in superior luminal 
epithelium-specific expression (Wu et al., 2001), which abrogates the neuroendocrine 
phenotype of its predecessor PB-Cre (Maddison et al., 2000, Wu et al., 2001).  PBCre4 will be 
discussed in more detail later in section 1.6.5.  Schematic representations of the ARR2PB and 
ARR2PBCre (PBCre4) constructs are illustrated respectively in figure 20. 
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Figure 20: Structures of (a) the ARR2PB construct and (b) the ARR2PBCre (PBCre4) transgene.  
Each ARR contains two AR binding sites (ARBS) that results in higher transgene expression 
within the prostate epithelium than the outdated 1st generation PBCre construct (not shown), 
which comprised only one ARR.  Adapted from Wu et al. (2001) and Kasper (2005). 
 
1.6.3 Transgenic T-antigen models of prostate cancer 
Early methods employed to genetically engineer mice involved the introduction of DNA 
constructs to induce the expression of oncogenes/oncoproteins under the control of tissue-
specific promoters.  To this effect, the first time PCa was modelled in this fashion was via the 
ectopic expression of simian virus 40 (SV40) Large T antigen (Tag) in the prostate.    SV40 is 
defined as a DNA tumour virus.  Its small genomic size prohibits it from encoding its own DNA 
polymerase and other proteins necessary for DNA replication.  SV40 stimulates DNA synthesis 
through the expression of two viral proteins, the large-T and small-t antigens.  Large-T binds to 
cell cycle ‘gatekeeper’ tumour suppressors within the host cell, such as p53 and pRb 
(retinoblastoma 1).  The binding of T-antigen to both of these proteins, and their subsequent 
stabilisation, is required for the transforming ability of the virus (Chen and Paucha, 1990, Zhu et 
al., 1991) and leads to genetic and cell cycle instability.  Small-t disrupts the activity of 
phosphatase 2A, resulting in constitutive MAPK activity and promoting tumour cell survival 
(Sontag et al., 1993).  Overall, the SV40 antigen has been employed in many transgenic lines to 
promote prostate tumourigenesis, but the commonest two models to use this construct by far 
are the TRAMP and LADY models. 
 
(a) 
(b) 
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The transgenic adenocarcinoma of the mouse prostate (TRAMP) model is one of the most 
widely used transgenic mouse models to study PCa.  Both the large and small SV40 tumour 
antigens (Tag/tag respectively) are controlled by the prostate-specific promoter, PB, to drive 
viral transgene expression solely within the prostate epithelium.  TRAMP mice reportedly 
display prostate tumourigenesis with established kinetics (Gingrich et al., 1996): hyperplasia by 
8-10 weeks, PIN by 18 weeks, and invasive carcinoma by 24 weeks.  After 28 weeks all mice 
displayed lymphatic metastases (albeit rarely to the skeleton as seen in the advanced human 
disease), and of these approximately two-thirds displayed lung metastases (Gingrich et al., 
1996).  Furthermore when mice were castrated, 80% went on to develop prostate cancers that 
displayed more aggressive features and were more poorly differentiated (Gingrich et al., 1996), 
and interestingly were 2-fold more likely to metastasise than their un-castrated counterparts 
(Green et al., 1998) similar to patients with CRPC.  Despite this the TRAMP model is not a 
panacea.  The most frequent malignancy they predispose to is of a neuroendocrine phenotype 
(Chiaverotti et al., 2008), which does not parallel human PCa whereby cells are predominantly 
of epithelial origin.  Regardless of its limitations, the TRAMP model is recognised as the best-
characterised for PCa, having been used to study prevention, treatment, and progression to 
systemic disease. 
The LPB promoter driving the large-T antigen (LADY) model is similar to the TRAMP model, but 
with two fundamental differences (Kasper et al., 1998).  Firstly the LPB promoter was used to 
drive the large T-antigen, creating the LPB-Tag transgene rather than PB-Tag and PB-tag 
transgenes used in the TRAMP model.  While the authors acknowledged that the PB promoter 
was sufficiently prostate specific, the transgene expression was variable between the founder 
cell lines, and thus this variability could be nullified and consistency restored by sole use of the 
LPB (Yan et al., 1997).  Secondly, the LPB promoter was linked to a mutant SV40 T-antigen 
construct that had been erased of its small t-antigen.  PIN develops by 10 weeks of age, and 
adenocarcinoma with neuroendocrine differentiation by 20 weeks.  Metastasis to lymph nodes, 
liver and lungs was detected in several transgenic founder lines (Kasper et al., 1998). 
Models utilising the PB promoter or part thereof, do not represent an ideal environment in 
which to investigate changes in hormone dependence (from androgen dependence to androgen 
independence/castration resistance) during tumour progression, since they employ androgen-
responsive vectors fused to an oncogene.  For example mice in the TRAMP model developed 
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fewer tumours when castrated at an early age, but this reduction in tumour incidence may be 
explained by the overall downregulation of PB, which resulted in a shorter duration of viral 
large-T antigen (Tag) driven expression.  In other words, the tumours which arose in this model 
were androgen-independent from the beginning (Green et al., 1998).  Tumours in the LADY 
model regressed upon castration and had their growth restored upon androgen replenishment, 
suggesting androgen dependency.  Interestingly while no tumours recurred for up to 40 weeks 
in the face of castration, a small population of epithelial cells maintained their proliferative 
state which questioned the potential for castration-resistant growth in these cells (Kasper et al., 
1998). 
 
1.6.4 Cre-LoxP Technology 
Before describing the evolution of conditional knockout models of PCa, it is important to 
consider the origin of Cre-LoxP technology.  The Cre-LoxP system circumvents embryonic 
lethality, the major limitation of constitutive knockout models, as it is more specific to the 
organ of interest.  ‘Cre’ is a gene that ‘causes recombination’, and catalyses site-specific DNA 
recombination in genes that are engineered with flanking ‘LoxP’ sites (locus of phage crossing 
over), which are synthetic 34-base pair sequences (Valkenburg and Williams, 2011).    The 
system was first established after Cre recombinase was isolated from E. coli bacteria 
transfected with plaque-forming P1 phage (Sternberg et al., 1981, Sternberg and Hamilton, 
1981).  Eventually the technology was made more sophisticated for genetic recombination in 
eukaryotic cells; firstly yeast, and later in mice (Sauer and Henderson, 1989).  Upon 
recombination, whereby floxed (flanked by LoxP sites) DNA is excised, a single LoxP site remains 
in the linear DNA.  Meanwhile the process of reciprocal recombination produces a circular now 
redundant fragment of DNA containing the other LoxP site, which is rapidly degraded.  These 
processes are depicted in figure 21. 
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Figure 21: Schematic representation of the Cre-LoxP technology.  Site-specific recombination 
through use of the Cre-LoxP technology can result in either (a) gene ablation or (b) gene 
activation.  To this effect, exons essential for the normal functioning of a gene may be excised 
thus rendering it inactive, also known as a “conditional knockout”.  This is commonly used to 
silence tumour suppressor genes by flanking them with LoxP sites (floxing).  Alternatively, 
signals that prevent gene expression, such as a “STOP” codon, may be silenced upstream of a 
target gene, resulting in transcription of a mutated proto-oncogene and thus its constitutively 
active protein.  Adapted from Maddison and Clarke (2005) 
 
The Rosa26 reporter construct has been widely used as a proxy of confirming the success (or 
otherwise) of endogenous recombination in the desired tissue (Soriano, 1999).  The system 
employs a floxed NEO-STOP cassette located upstream of the LacZ reporter gene, and upon 
recombination, excision of the STOP codon results in transcription of β-galactosidase.  
Successful expression of Cre-recombinase is monitored thus by the appearance of a blue 
product in the tissue of interest after staining with X-gal (Soriano, 1999).  The Rosa26 gene is 
constitutively expressed in every cell of the embryo and adult, but does not encode a functional 
LacZ product in the absence of recombination.  Figure 22 is an illustrative representation of the 
Rosa26 reporter construct. 
(a) (b) 
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Figure 22: Mechanism of action of the Rosa26 reporter system.  In (a) the absence of the 
Rosa26 locus, transcription will not occur due to the presence of the floxed STOP codon.  Upon 
DNA recombination (via a tissue/site specific Cre recombinase), the STOP codon is excised (b) 
and LacZ is constitutively activated resulting in the expression of β-galactosidase and the 
formation of a blue product when stained with X-gal.  Adapted from Soriano (1999).  See mouse 
model chapter for utilisation of this technique. 
 
DNA recombination that results from Cre-LoxP technology is typically under the control of a 
tissue-specific promoter, which serves to drive Cre recombinase expression either 
constitutively, or by induction.  This enables the study of genes of interest in tissues of interest, 
which has led to the extensive search for powerful, specific promoters that minimise 
background recombination in other tissues. 
 
1.6.5 Conditional knockout models of prostate cancer 
Prostate-specific antigen has been employed as a promoter to drive Cre recombinase (PSA-Cre) 
expression in two important models of prostate tumourigenesis, namely conditional knockouts 
of Nkx3.1 (Abdulkadir et al., 2002) and Pten (Ma et al., 2005).  Mice from the former model 
develop lesions consistent with hyperplasia and PIN thus supporting a role for Nkx3.1 in the 
early stages of PCa.  Pten knockout mice also display hyperplasia to PIN transformation, and 
also progress to invasive carcinoma but with infrequent lymph node metastases. 
The ARR2PB-Cre (PBCre4) transgene is the most widely used promoter in PCa conditional 
knockout models.  It has successfully facilitated recombination in all lobes of the murine 
(a) 
(b) 
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prostate but not in the embryo; >95% of the lateral lobe of the prostate, 50% of the ventral 
lobe, and about 10% and 5% of the epithelium of the dorsal and anterior lobes respectively (Wu 
et al., 2001).  Many genes implicated in human PCa have been knocked out in this fashion and 
the important models driven by the PBCre4 transgene are shown in table 8 below.  To date 
however, the only model reported to span the continuum from PCa initiation to locally invasive 
carcinoma and metastatic disease is the PBCre4PTENflox knockout model (Wang et al., 2003).    
 
Conditional 
Knockout Model 
(PBCre4) 
Terminal stage of 
neoplasia 
Other tissues affected References 
 Ptenflox LN & lung metastases None Wang et al. (2003) 
 Rbflox Hyperplasia None 
Maddison et al. (2004), 
Zhou et al. (2006) 
 LSL-Ph15LO-1 
(FLiMP) 
PIN None Kelavkar et al. (2006) 
 p53flox Rbflox 
LN, lung, liver, and 
adrenal metastases 
None 
Maddison et al. (2004), 
Zhou et al. (2006) 
 APCflox 
Locally invasive 
adenocarcinoma 
None Bruxvoort et al. (2007) 
 IGF-1flox Hyperplasia None Sutherland et al. (2008) 
Catnb+/lox(ex3) 
 
 
Kras+/V12 
 
 
Catnb+/lox(ex3)Kras+/V12 
Locally invasive 
adenocarcinoma 
 
LGPIN 
 
Locally invasive 
adenocarcinoma 
Metaplasia of G.U.T. 
accessory glands 
 
None 
 
As above 
 
Pearson et al. (2009) 
Catnb+/lox(ex3) HGPIN None 
Yu et al. (2009), 
Francis et al. (2013) 
 BRCA2flox p53flox HGPIN None Francis et al. (2010) 
 Ptenflox KrasG12D/W LN & lung metastases None Mulholland et al. (2012) 
Catnb+/lox(ex3) Ptenflox 
Locally invasive 
adenocarcinoma 
None Francis et al. (2013) 
 
Table 8: The conditional knockout models of PCa governed by the PBCre4 transgene 
 
The Pten gene is one of the most scrutinised in PCa, particularly in the pre-clinical setting since 
the creation of the conditional knockout mouse (Trotman et al., 2003, Wang et al., 2003).  It has 
been shown that the degree of Pten knockdown on tumour progression is dose-related 
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(Trotman et al., 2003), given that Pten is a negative regulator of the PI3K/Akt pathway (see 
section 1.8.2).  Loss of heterozygosity of Pten leads to a shortened latency of PIN formation, 
which is of higher grade when comparing the constitutively active heterozygote Pten mouse 
(Pten+/-) with Pten hypomorphs (Ptenhy/-).  Furthermore, conditional inactivation of Pten has 
complete penetrance, with the resulting carcinomas being poorly differentiated and diffuse.  A 
separate group has reported how the PBCre4Ptenflox mouse progressed through stages of 
prostate tumourigenesis with set kinetics, eventually developing metastatic disease (Wang et 
al., 2003).  In addition, evidence for castration resistant cells was strengthened in this model.  
Invasive Pten null prostate cancer cells responded to androgen ablation, as indicated by 
increased apoptosis, similar to most human PCa.  However, even though the survival of Pten 
null prostate cancer cells was seen to be androgen sensitive, their proliferation continued in the 
face of castration (Wang et al., 2003).  Thus the property of androgen-independent growth 
observed in Pten null prostate cancers may contribute to CRPC formation.  Although prostate 
tumours in the PBCre4Ptenflox mouse do not metastasise to bone, it still continues to be one of 
the most useful models in the study and characterisation of PCa. 
Two models have been created by knocking out tumour suppressors Rb and p53, alone or in 
combination.  As a solitary knockout, the most severe prostate phenotype observed from 
solitary Rb deletion was hyperplasia and low-grade PIN, concluding that Rb loss alone was 
insufficient to cause progression to carcinoma (Maddison et al., 2004).  A similar conclusion was 
drawn from the conditional p53 knockout (Zhou et al., 2006), but in combination, both Rb loss 
and p53 loss synergised to form metastatic PCa (Zhou et al., 2006) suggesting that they 
cooperate in the prostate during tumour progression and metastasis.  Therefore, the 
PBCre4p53floxRbflox mouse embodies a valuable model for studying PCa short of skeletal 
metastasis. 
The Wnt pathway has also been identified as being important in PCa development.  To 
investigate the effect of deregulated Wnt signalling on the prostate, a conditional APC 
(adenomatous polyposis coli) knockout mouse has been created.  APC is a known negative 
regulator of the Wnt pathway, and hence its knockout will result in constitutively active Wnt 
signalling.  Locally invasive adenocarcinoma was the terminal stage of disease seen in the 
PBCre4APCflox model (Bruxvoort et al., 2007).  In this model, that contained experiments 
analogous to those in the PBCre4Ptenflox paper (Wang et al., 2003), castration after the onset of 
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tumourigenesis resulted in retention of adenocarcinoma, indicating that although tumours are 
androgen dependent for their initiation, they may be androgen-independent during tumour 
maintenance and progression (Bruxvoort et al., 2007).  Later, models to explore the role of Wnt 
signalling in PCa employed the β-catenin knock-in model (Pearson et al., 2009, Yu et al., 2009, 
Francis et al., 2013), whereby β-catenin is overexpressed in its constitutively active form 
(PBCre4Catnb+/lox(ex3)).  Due to the accumulating evidence that the Wnt pathway/β-catenin is 
upregulated in PCa, this model remains worthwhile.  There is conflicting evidence between 
groups that have worked with the PBCre4Catnb+/lox(ex3) mouse on the highest stage of 
tumourigenesis.  As a solitary mutation, this has been reported to display HGPIN (Yu et al., 
2009, Francis et al., 2013) and invasive adenocarcinoma (Pearson et al., 2009). 
T-antigen models have predominantly been utilised to overexpress activating mutations in Ras 
isoforms, principally Hras.  In so doing, they have generated a variety of low-grade prostate 
phenotypes, including hyperplasia, low-grade PIN, and intestinal metaplasia, probably reflecting 
subtle differences in the transgenes and the genetic background used (Barrios et al., 1996, 
Scherl et al., 2004).  Conditional knock-in models have focused on activating mutations of Kras 
due to the more recent discovery of its higher incidence in PCa.  Similarly these support the 
notion that Kras activation is sufficient to drive the RAS/MAPK pathway but is insufficient to 
initiate cancer, amounting to LGPIN only.  Together, these models show that activated Ras can 
facilitate prostate tumourigenesis and early stage tumour development.  However, in 
combination with other alleles to form double mutants, Kras has demonstrated synergy to 
promote progression to invasive carcinoma in the PBCre4Catnb+/lox(ex3)Kras+/V12 mouse (Pearson 
et al., 2009), and even metastatic disease in the PBCre4Ptenflox KrasG12D/W model (Mulholland et 
al., 2012).  This appears to parallel the findings displayed in human PCa that RAS/MAPK 
pathway activation contributes toward progression of advanced disease.   
 
Figure 23 quantifies the incidence of some of the more important aberrations seen in human 
PCa, which further adds weight to the relevance of studying these mutations in conditional 
knockout mouse models. 
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RB signalling PI3K signalling MAPK signalling 
Primary Metastatic Primary Metastatic Primary Metastatic 
34% 74% 42% 100% 43% 90% 
            
RB1 PTEN KRAS 
5% 37% 4% 42% 8-10% 32% 
 
Figure 23: Three of the most commonly altered pathways in PCa: RB, PI3K, and RAS/RAF.   
Copy number alteration, transcriptome, and mutation data were combined to conduct analysis 
of core pathways.  Alteration frequencies are shown for individual genes and the entire 
pathway in primary and metastatic tumours.  The incidence of inactivation/downregulation 
highlighted shown in blue, whereas activation/upregulation is shown in red.  Adapted from 
Taylor et al. (2010). 
 
1.7 β-CATENIN 
β-Catenin is a dual function protein, encoded by the CTNNB1 gene on chromosome 3 in humans 
and chromosome 9 in the mouse.  It is a sub-unit of the cadherin complex and so plays a key 
role in regulating cell-cell adhesion, in addition to its role as an intra-cellular signal transducer in 
the Wnt signalling pathway where it is responsible for governing gene transcription. 
 
1.7.1 The structure and function of β-catenin 
The structure of β-catenin can be simplified into three main regions: an N-terminus, a central 
core, and a C-terminus.  The N-terminal domain comprises of 130 amino acids and possesses 
phosphorylation sites that are targets of casein kinase 1α or 1ε (epsilon) (CK1α/ε), and GSK-3β, 
in addition to an α-catenin binding site (Kolligs et al., 2002).  The N-terminus is also critical for β-
catenin degradation owing to the conserved location of the short linear motif responsible for 
binding β-TrCP E3 ubiquitin ligase upon its phosphorylation.  The central core is the best 
characterised of all three regions.  It consists of 12 armadillo repeats, each being 42 amino acids 
long, which adopt a super-helical shape with a positively-charged groove running along its 
length (Clevers, 2006).  This region interacts to form complexes with molecules such as axin, 
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APC, E-cadherin, and TCF (T-cell factor)/LEF (lymphoid enhancer factor) proteins, which all bind 
to this region in a mutually exclusive fashion (Clevers, 2006).  The C-terminus appears to be a 
powerful transactivator of Wnt target genes when recruited into DNA, but it has also 
demonstrated interactions with transcriptional inhibitors, highlighting its importance in 
regulating the level of gene transcription (Xing et al., 2008).  The C-terminal domain may also 
form interactions within the central armadillo repeat domain of its own β-catenin molecule to 
regulate ligand binding (Cox et al., 1999, Piedra et al., 2001, Castano et al., 2002, Solanas et al., 
2004).  The structure of the β-catenin molecule is depicted in figure 24. 
 
Figure 24: The molecular structure of β-catenin.  The N and C termini of β-catenin serve as 
transcriptional activators.  The central highly homologous armadillo repeats mediate most 
interactions with other proteins.  Serine and threonine residues 33, 37 and 41 (see lighter 
insert) are the GSK-3 phosphorylation sites, whereas serine 45 is the CK1 phosphorylation site.  
Mutation of one of these residues prevents degradation of β-catenin.  Adapted from Kolligs et 
al. (2002). 
β-catenin is found in three distinct pools (Nollet et al., 1996) – at the membrane, along with cell 
adhesion molecules such as E-cadherin and α-catenin; in the cytoplasm; and in the nucleus, to 
where it translocates in response to Wnt signalling before driving gene transcription of 
downstream Wnt targets.  Other well-known catenin molecules worthy of note are are α-, γ-
catenin (or plakoglobin) and p120 catenin (p120ctn).  β- and γ-catenin are members of the 
armadillo family and are mammalian orthologues of Armadillo (Arm), the historical name of the 
β-catenin gene found in the fruit fly Drosophila (Clevers, 2006).  Both of these armadillo family 
proteins as well as p120ctn bind to E-cadherin in adherens junctions via their armadillo repeat 
sequences, while α-catenin binds to β-catenin to link the cadherin:catenin complexes to actin 
filaments (Niessen, 2007).  The cadherin:catenin complexes are one of the two basic units of 
adherens junctions (along with nectin:afadin complexes) (Niessen, 2007), and it is well regarded 
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that β-catenin is critical to the maintenance of epithelial cell adhesion.  Figure 25 demonstrates 
the spatial arrangement of the molecules that comprise a normal adherens junction. 
 
 
Figure 25: the structure of adherens complexes.  Adapted from Niessen (2007) 
β-catenin is the fundamental mediator of Wnt signalling.  Three different Wnt pathways are in 
existence and are activated in the presence of Wnt ligand; the canonical Wnt pathway, the non-
canonical planar cell polarity pathway (PCP) pathway, and the non-canonical Wnt/Ca2+ pathway.  
The canonical pathway is the best characterised of all three and will be explored in more detail 
here. 
In the absence of Wnt ligand the degradation complex forms, comprising of APC, GSK3β and the 
important scaffold protein axin (Bienz and Clevers, 2000).  CK1 is then recruited to the complex 
where it can phosphorylate β-catenin at Ser45 in preparation for further phosphorylation at 
Ser33, Ser37, and Thr41 by GSK3β (Hagen and Vidal-Puig, 2002).  In turn, β-TrCP (a dedicated 
SCF-type (Skp, cullin, F-box) E3 ubiquitin ligase) joins the complex (Maniatis, 1999), which 
results in the ubiquitination and destruction of β-catenin by the proteosome (Aberle et al., 
1997).  GSK3β is a powerful phosphorylator, capable of also phosphorylating axin to regulate its 
stability (Yamamoto et al., 1999), and APC to maintain its binding efficiency to β-catenin 
(Rubinfeld et al., 1996).  To ensure that TCF-mediated transcription does not occur in the 
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absence of Wnt ligand, the molecule Groucho binds TCF (Roose et al., 1998, Cavallo et al., 1998) 
and thereby recruits histone deacetylases to promote chromatin compaction (Chen et al., 1999) 
and inhibit transcription. 
Wnt proteins are a diverse family of secreted cysteine-rich, lipid-modified signaling 
glycoproteins that are 350–400 amino acids in length, and highly conserved throughout most 
mammalian species (Cadigan and Nusse, 1997).  Lipid modification is essential because it 
initiates targeting of the Wnt protein to the plasma membrane for secretion and it allows the 
Wnt protein to bind its receptor due to the covalent attachment of fatty acids.  In Wnt signaling, 
these glycoproteins act as ligands to activate the different Wnt pathways via paracrine and 
autocrine routes (Nusse and Varmus, 1992, Komiya and Habas, 2008).   
When present, extracellular Wnt ligand binds to Frizzled (Fz) a seven-pass transmembrane 
receptor, and in doing so it cooperates with co-receptors of the low density lipoprotein 
receptor (LRP) family, namely LRP-5 or LRP-6 (Clevers, 2006).  Upon activation, Fz recruits 
dishevelled (Dsh) to the inner cell membrane by its phosphorylation (Axelrod et al., 1998, Lee et 
al., 1999b, Smalley et al., 1999, Boutros et al., 2000), which in turn activates axin by direct 
binding (Smalley et al., 1999, Kishida et al., 1999).  Actin translocates to the membrane where it 
disintegrates the APC/Axin/GSK-3β complex by articulating with the LRP intracellular tail, 
resulting in the inhibition of GSK-3β-dependent phosphorylation of β- catenin and therefore its 
stabilisation (Kishida et al., 1999).  Within the nucleus, β-catenin displaces groucho from its 
binding with TCF and takes its place to form a transcription complex (Behrens et al., 1996, 
Molenaar et al., 1996) that drives the expression of numerous Wnt target genes including CD44 
(Wielenga et al., 1999), cyclin D1 (Shtutman et al., 1999), c-myc (He et al., 1998) and MMP-7 
(Crawford et al., 1999).  The mechanism of action in the Wnt signalling pathway is illustrated in 
figure 26.   
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Figure 26: The Wnt pathway.  In the absence of Wnt ligand (a) β-catenin is phosphorylated and 
therefore inactivated by the destruction complex.  Following ubiquitination by β-Trcp it is 
targeted for rapid destruction by the proteasome.  Meanwhile in the nucleus, groucho 
represses gene transcription.  When Wnt ligand is present (b) the destruction complex is 
inhibited allowing β-catenin to accumulate in the cytoplasm.  Upon its translocation into the 
nucleus, it binds Tcf/Lef to stimulate transcription of downstream Wnt targets.  Adapted from 
MacDonald et al. (2009). 
 
1.7.2 The role of β-catenin in cancer 
Dysregulation of Wnt signalling is implicated in many types of cancer.  Mutations in the proto-
oncogene β-catenin specifically have been detected in around 5% of prostate cancers (Voeller 
et al., 1998), as well as cancers of the colon and rectum (Iwao et al., 1998), liver (Miyoshi et al., 
1998), gallbladder (Yanagisawa et al., 2001), ovary (Wright et al., 1999) and melanocytes in the 
skin (Rimm et al., 1999).  The most common mutation to be studied in these cancers occurs on 
exon 3 of the CTNNB1 gene that encodes for β-catenin.  Other mutations of the CTNNB1 gene 
outside exon 3 that may result in altered Wnt signalling remain under investigation, such as the 
sequence encoding the section of β-catenin that interacts with a molecule responsible for its 
ubiquitination, Siah-1 (Yardy and Brewster, 2005).  Generally speaking the role of stabilising 
(a) (b) 
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mutations of β-catenin in carcinogenesis could be attributed to a combination of one or more of 
the following mechanisms:  (a) nuclear accumulation of β-catenin leading to over-expression of 
Wnt target genes responsible for driving proliferation, survival and cell migration, (b) 
interruption of the role β-catenin plays in cell to cell adhesion complexes with E-cadherin 
resulting in increased cell motility and possibly metastasis, and finally (c) the role of activated β-
catenin in SC maintenance and/or differentiation. 
 
1.8 PTEN 
Pten has been discussed in some detail earlier in the “constitutive/germline models of PCa” 
section.  Here we will talk about its structure and function, along with its role in the 
PI3K/Akt/mTOR pathway, and finally evidence for its role in carcinogenesis. 
1.8.1 PTEN structure and function 
PTEN is a 403-amino-acid-long phosphatase that can act on both polypeptide and 
phosphoinositide substrates (Song et al., 2012).  Detailed insight into the complex three-
dimensional folding of PTEN was demonstrated by crystallography (Lee et al., 1999a).  
Simplified, the important features of its structure are the phosphatase-binding domain, a 
phosphatase domain, and the C2 domain.  The substrate-binding loop at the bottom of the 
active pocket, that is both deep and wide in shape and positively-charged, is important for the 
accommodation of phosphoinositide substrates (Song et al., 2012).  This primitve PTEN-specific 
binding pocket is formed by folding of its β-sheet configuration, and appears to be 
evolutionarily conserved.  It is the site of cancer-associated PTEN mutations that lead to a 
reduction of its phosphatase activity (Maehama and Dixon, 1998, Stambolic et al., 2000).  
Meanwhile the C2 domain binds the phospholipid membrane along its length, thus bringing the 
active site to the membrane-bound PIP3 to de-phosphorylate it (Song et al., 2012). 
As a participant in the PI3K/Akt/mTOR pathway, PTEN has many physiological roles in the 
normal cell including, (a) participation in glucose metabolism, cell motility and cell polarity, (b) 
induction and maintenance of cellular senescence, (c) involvement in the self-renewal capability 
of SC/CSCs, and (d) control of genomic stability and cell cycle progression within the nucleus 
(Song et al., 2012).  PTEN also has effects independent of PI3K/Akt/mTOR signalling including 
activation of the JNK pathway in response to inflammation and UV radiation (Vivanco, 2007), 
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and activation of non-receptor tyrosine kinases that are important in immune system signal 
transduction (Zhang, 2011).  The structure of PTEN is shown in figure 27. 
 
Figure 27: The structure of PTEN.  (a) PTEN is a protein comprised of five domains; a PIP2 
binding domain (PBD), a phosphatase domain, a C2 domain, a carboxy terminal tail, and a 
postsynaptic-density protein of 95 kDa, discs large, zona occludens-1 binding domain (a protein-
interaction domain that often occurs in scaffolding proteins).  (b) The overview of the PTEN 
protein structure allows spatial awareness of how the phosphate-binding loop (encircled red) is 
housed deep within the active pocket of the phosphatase domain (dark blue).N, N-terminal 
region; C, C-terminal region.  Adapted from (Chalhoub and Baker, 2009) and Song et al. (2012). 
 
1.8.2 The role of PTEN in PI3K/Akt/mTOR signalling 
The powerful catalytic phosphatidylinositol (3,4,5)-triphosphate (PIP3) lipid phosphatase 
activity of PTEN makes it one of the most important tumour suppressors reported, as 
highlighted in figure 28.  Following PTEN loss, excessive PIP3 recruits and activates Akt and 
PDK1 to cell membranes.  Akt isoforms are activated by phosphorylation at two different 
residues: PDK1 phosphorylates Akt at Thr308 (Manning and Cantley, 2007), and Ser473 is 
phosphorylated by mammalian target of rapamycin complex 2 (mTORC2; composed of mTOR, 
DEP domain-containing mTOR-interacting protein (DEPTOR), mammalian lethal with SEC13 
protein 8 (mLST8), stress-activated MAP kinase-interacting protein 1 (mSIN1; also known as 
MAPKAP1), Pro-rich protein 5 (PRR5; also known as PROTOR) and rapamycin insensitive 
companion of mTOR (RICTOR)) (Zoncu et al., 2011).  Active Akt drives cell survival, proliferation 
(b) 
(a) 
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and cellular metabolism through inhibitory phosphorylation of downstream proteins, including 
glycogen synthase kinase 3 (GSK3), forkhead box O (FOXO), peroxisome proliferator-activated 
receptor-γ (PPARγ) co-activator 1α (PGC1) and p27, and through activatory phosphorylation of 
ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5), sterol-responsive element-
binding protein 1C (SREBP1C), AS160 and S phase kinase-associated protein 2 (SKP2) (Manning 
and Cantley, 2007).  AKT can also directly phosphorylate tuberous sclerosis protein 2 (TSC2; also 
known as tuberin), which in a complex with TSC1 largely inhibits the RAS-related small GTPase 
RAS homologue enriched in brain (RHEB).  Phosphorylation of TSC2 by Akt results in the 
activation of RHEB, which then stimulates the phosphotransferase activity of mTOR (Guertin 
and Sabatini, 2007).  Akt is capable of activating mTORC1 (composed of mTOR, DEPTOR, mLST8, 
40 kDa Pro-rich AKT1 substrate 1 (PRAS40; also known as AKT1S1) and regulatory associated 
protein of mTOR (RAPTOR)) by inducing the inhibitory phosphorylation of PRAS40, which is a 
negative regulator of mTORC1 (Vander Haar et al., 2007, Zoncu et al., 2011).  Active mTORC1 
phosphorylates p70 ribosomal protein S6 kinase (S6K; also known as RPS6K) to activate protein 
translation in the ribosome (Ma and Blenis, 2009). 
 
1.8.3 PI3K/Akt/mTOR signalling in cancer 
The contribution of aberrant PI3K/Akt/mTOR signalling towards cancer development can be 
appreciated in three broad areas: firstly the cellular processes regulated by AKT, secondly 
characteristic cancer processes that exploit PI3K/Akt signalling, and finally the genetic 
alterations that can influence the pathway. 
Akt impacts upon the function of numerous molecules involved in the regulation of cell survival, 
cell cycle progression and cellular growth, and their aberrant activation can result in a richly 
pro-tumourigenic environment (Fresno Vara et al., 2004).  Abundant Akt induces various cell 
survival mechanisms; inactivation (by phosphorylation) of the pro-apoptotic factors Bcl-2 
associated agonist of cell death (BAD) and caspase-9, as well as the Forkhead family of 
transcription factors that induce the expression of pro-apoptotic factors such as Fas ligand 
(Testa and Bellacosa, 2001).  Other Akt targets such as GSK3β, mTOR, insulin receptor 
substrate-1 (IRS-1), the cyclin-dependent kinase inhibitors p21CIP1/WAF1 and p27KIP1, and Raf1, are 
all involved in protein synthesis, glycogen metabolism and cell cycle regulation (Blume-Jensen 
and Hunter, 2001). 
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Figure 28: The PI3K/Akt/mTOR signalling pathway.  Upstream activation of Akt by receptor 
tyrosine kinases (RTK) and insulin-like growth factor-1 receptor (IGF-1-R) trigger pathway 
signalling.  Once activated, Akt phosphorylates a number of substrates in the cytoplasm and 
nucleus.  Akt targets include: the pro-apoptotic Bcl-2 family member Bad, and procaspase-9; 
tuberous sclerosis complex 2 (TSC-2); glycogen systhesis kinase-3 (GSK3β), the forkhead family 
of transcription factors (FOXO), peroxisome proliferator-activated receptor-γ (PPARγ) co-
activator 1α (PGC1) and the CDK inhibitor p27 through inhibitory phosphorylation; and through 
activatory phosphorylation ectonucleoside triphosphate diphosphohydrolase 5 (ENTPD5), 
sterol-responsive element-binding protein 1C (SREBP1C), AS160 and S phase kinase-associated 
protein 2 (SKP2). The p85 and p110 subunits are collectively known as PI3K.  Black lines – direct 
activation, blue dotted lines – activation by phosphorylation, red lines – activation by inhibitory 
phosphorylation.  Adapted from (Chalhoub and Baker, 2009) and Song et al. (2012). 
 
Akt-regulated signalling plays a prominent role in numerous processes which are known to be 
characteristic of cancer (Fresno Vara et al., 2004).  Akt overexpression may result in the 
following: increased ambient levels of growth factors causing growth autonomy, insensitivity of 
antiproliferative signals, heightened telomerase activity and thus greater replicative potential 
by phosphorylation of hTERT, stimulated angiogenesis through endothelial nitric oxide 
synthetase activation, secretion of  matrix metalloproteinases and progression to metastasis by 
creation of tumour-permissive stroma (Trimboli et al., 2009). 
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Amplification is the major alteration described to occur in PI3KC (located in the chromosome 
3q26), the gene that encodes for the p110a subunit of PI3K, and this alteration has been 
implicated in ovarian (Shayesteh et al., 1999) and cervical cancer (Ma et al., 2000).  No 
mutations in the Akt gene have been discovered in humans but studies have reported 
amplifications in breast, ovarian, pancreatic, and stomach cancers (Bellacosa et al., 1995, Cheng 
et al., 1996). 
 
1.9 RAS: THE PROTO-ONCOGENE  
Ras is a small membrane-bound GTPase that is involved in cellular signal transduction ultimately 
leading to cellular proliferation.  In this section the structure and function will be discussed, 
followed by the role of Ras in MAPK signalling, and finally its role in tumourigenesis. 
1.9.1 The structure and function of Ras 
In humans, three RAS genes encode four distinct Ras proteins of similar structure: HRAS (Harvey 
rat sarcoma viral oncogene homolog), NRAS (neuroblastoma RAS viral oncogene homolog), and 
KRAS (Kirsten rat sarcoma 2 viral oncogene homolog), where KRAS4A and KRAS4B are 
alternative splice variants of the KRAS gene (Pylayeva-Gupta et al., 2011).  The four Ras isoforms 
are similar throughout the G domain (amino acids 1–165).  The first 85 amino acids are identical 
in all four proteins and specify the guanosine diphosphate (GDP) and guanosine triphosphate 
(GTP) binding site.  This includes the phosphate-binding loop (P loop), amino acids 10–16, 
responsible for binding the γ (gamma)-phosphate of GTP, and switches I (amino acids 32–38), 
and II (amino acids 59–67) which regulate binding to Ras regulators and effectors.  Amino acids 
85–165 show approximately 85–90% sequence homology, whereas the C-terminal 
hypervariable domain (amino acids 165–188/189) specifies membrane localisation unique to 
each isoform (Schubbert et al., 2007, Pylayeva-Gupta et al., 2011).  An illustration of its 
structure can be seen in figure 29. 
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Figure 29: The structure of the four Ras isoforms.  Given that a significant proportion of the G-
domain (amino acids 85-165) is up to 90% homologous between isoforms, these sections have 
been truncated for Nras and Kras.  Most somatic missense Ras mutations found in human 
cancers introduce amino acid substitutions at positions 12, 13 and 61.  The P loop articulates 
with GTPase activating proteins (GAPs) that mediate the Ras-GTP hydrolysis reaction.  Switches I 
and II are important for binding to Ras effectors.  Amino acids in the hypervariable region: C, 
cysteine; I, isoleucine; K, lycine; L, Leucine; M, methionine; S, serine; and v, valine.  Adapted 
from Pylayeva-Gupta et al. (2011) and (Prior et al., 2012). 
 
 
Upon the binding of growth factors to membrane-bound receptor tyrosine kinases (RTKs) 
guanine nucleotide exchange factors (GNEFs) are free to activate GTPases.  In this fashion 
GTPases (such as Ras proteins) can cycle between ‘on’ and ‘off’ conformations by the binding of 
GTP and GDP, respectively.  Under physiological conditions GNEFs stimulate GDP for GTP 
exchange, whereas GTPase-activating proteins (GAPs) accelerate GTP hydrolysis back to GDP 
(Pylayeva-Gupta et al., 2011).  In the case of Ras, activated RTKs stimulate the binding of 
intracellular proteins that possess SH2 (Src homology 2) domains such as SHC (SH2-containing 
protein), GRB2 (growth factor receptor-bound protein 2), and Gab (GRB2-associated binding), 
which when bound to activated RTKs, can recruit additional proteins.  GRB2 binds a GNEF called 
SOS1 (son of sevenless) that is capable of activating Ras by stimulating it to release GDP in 
exchange for GTP.  This process is depicted in figure 30. 
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Figure 30: Schematic representation of Ras activation.  SOS1 (a GNEF) functions to dissociate 
GDP from inactive Ras proteins and once released, GTP generally binds in its place because the 
cytosolic ratio of GTP to GDP is 10:1 (Bos et al., 2007).  Formation of Ras-GTP releases SOS1 and 
thus renders it free to re-activate a new Ras protein.  GAPs serve to inactivate GTPases by 
increasing their intrinsic rate of GTP hydrolysis, and neurofibromin (NF1) is one specific negative 
regulator of Ras signalling that is capable of exploiting this mechanism. 
 
1.9.2 The role of Ras in MAPK signalling 
Ras-GTP regulates a complex signalling network that modulates cell behaviour by binding to and 
activating many distinct classes of effector molecules.  Perhaps the best described of these is 
the Raf–Mek–Erk signalling cascade (also known as the MAPK (mitogen activated protein 
kinase) pathway).   There are three Raf serine/threonine kinases (ARAF, BRAF and RAF1) that 
can activate Mek, which in turn activates Erk by phosphorylation.  Activation of these 
transcriptional regulators can lead to the expression of proteins responsible for control of cell-
cycle progression, such as cyclin D1 (Pylayeva-Gupta et al., 2011). 
 
1.9.3 The role of Ras in cancer 
The COSMIC (Catalog of somatic mutations in cancer) dataset confirms that K-ras is the most 
frequently mutated isoform (Forbes et al., 2011).  It was found to be present in 22% of all 
tumours analysed, compared with 8% for N-ras and 3% for H-ras (Prior et al., 2012). 
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The aberrant function of oncogenic Ras is typically associated with a single missense mutation 
at codon 12, 13, or 61.  The predominant outcome of these somatic mutations is the 
attenuation of GTP hydrolysis by hindering the action of GAPs.  The outcome of these 
substitutions therefore is the persistence of the GTP-bound state of Ras and, as a consequence, 
the constitutive activation of a multitude of RAS-dependent downstream effector pathways 
(Schubbert et al., 2007, Pylayeva-Gupta et al., 2011, Prior et al., 2012). 
The extent to which specific mutations affect the biological behaviour of Ras remains to be 
established (Pylayeva-Gupta et al., 2011).  In colorectal and lung cancers, KRASG12V mutations 
have been associated with a poorer prognosis than KRASG12D mutations, raising the possibility 
that particular amino acid substitutions might dictate specific transforming characteristics of 
oncogenic Ras alleles (Keohavong et al., 1996, Andreyev et al., 1998).  However in studies on 
leukaemia (Perentesis et al., 2004), bladder cancer (Kompier et al., 2010), and pancreatic cancer 
(Burmer et al., 1991) failed to identify a correlation between the occurrence of specific RAS 
mutations and the aggressiveness of the disease, suggesting that the different RAS mutations 
may lead to a common pathophysiological end point in these tissues. 
It is unsurprising that constitutive activation of RAS fuels cell proliferation because Ras proteins 
are mediators of mitogenic stimuli.  Oncogenic Ras displays pro-survival features, such as 
independence from extracellular growth factors and growth inhibitors thereby promoting exit 
from the resting phase of the cell cycle, progression through G1 and entry into the S phase, 
before nullifying the effect of the G2 DNA damage checkpoint.  Oncogenic Ras can result in 
replicative stress from the hyperproliferative state that results in DNA damage and entry into 
either a senescent or apoptotic state.  Furthermore, inaccurate repair of DNA damage can lead 
to mutations and chromosome aberrations that escape the p53 damage checkpoint and 
thereby contribute to tumourigenesis (Schubbert et al., 2007, Pylayeva-Gupta et al., 2011). 
The effect of oncogenic Ras on apoptotic pathways and its role in carcinogenesis is well 
documented (Cox and Der, 2003).  For example the elimination of inducible oncogenic HRASG12V 
and KRASG12D expression in mice resulted in the regression of melanomas and lung tumours 
respectively, as evidenced by massive tumour cell apoptosis (Chin et al., 1999, Fisher, 2001).  
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These experiments demonstrated the importance of Ras in tumour maintenance.  
Mechanistically also the PI3K and Raf effector pathways activated by oncogenic Ras can 
downregulate pro-apoptotic mediators or upregulate anti-apoptotic molecules.  Other ways 
oncogenic Ras promotes and perpetuates tumourigenesis is by directly contributing to 
metabolic reactions that promote the use of glucose as an anabolic substrate for cellular growth 
(Jones and Thompson, 2009).  Ras also effectively manipulates the cellular microenvironment to 
encourage tumour initiation and progression by upregulation of VEGFA, HIF1α and COX-2 
(Tsujii, 1998, Blancher et al., 2001, Lee et al., 2002).  Furthermore, oncogenic Ras is particularly 
sophisticated at evading the host adaptive immune response; it expresses reduced levels of 
antigen-presenting major histocompatibility complexes (MHC) on cancer cells (Maudsley et al., 
1991, Lohmann et al., 1996, Seliger, 1996), and it recruits immunosuppressive regulatory T cells 
and myeloid-derived suppressor cells to the tumour site (Clark, 2007, Tran Thang, 2010). 
Many metastatic tumours (such as lung, pancreas and colon tumours) contain RAS mutations, 
which has implicated RAS in the various complex processes that result in metastases.  Therefore 
multiple experiments have been undertaken in these tissues aimed at better understanding 
how oncogenic Ras endows cells with metastatic potential.  Steps in postulated mechanisms 
include: weakening of cell-cell adhesion by destabilisation of E-cadherin–β-catenin complexes 
and the nuclear translocation of β-catenin, and the upregulation of extracellular matrix (ECM) 
proteases (along with the downregulation of protease inhibitors) by Ras effectors to aid 
penetration of the ECM (Pylayeva-Gupta et al., 2011).  It is likely however that solitary RAS 
mutations are rarely sufficient for the development of metastatic disease; instead it contributes 
to the overall genetic events crucial to the metastatic phenotype in combination with 
mutation(s) of other key signalling pathways.  Evidence to support this notion exists for 
colorectal cancer (Janssen et al., 2006) and PCa (Pearson et al., 2009, Mulholland et al., 2012). 
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Chapter 2: Hypothesis, and Thesis Aims 
2.1 HYPOTHESIS 
Deregulation of the Wnt, PI3K/Akt/mTOR, and MAPK pathways are all sufficient to drive 
prostate cancer initiation and progression, and that there is synergy between these pathways in 
tumourigenesis.  Furthermore it is thought that combinatorial mutants will more aggressive PCa 
with a metastatic phenotype.  The profile of mutations used in the mouse model may be useful 
in both identifying aggressive disease and in stratifying risk in men with prostate cancer. 
One mechanism by which these pathways may synergise is by altering either the pool of normal 
prostate epithelial stem cells (PrSCs) or the pool of cancer stem cells (CSCs).  Conventional 
understanding suggests that deregulation of these pathways may alter the pool of ‘cells of 
origin’, whereas an alternative theory is that pathway synergy may drive expansion of the 
tumour initiating/SC/CSC population. 
 
2.2 THESIS AIMS 
The main aims of this thesis are three-fold: 
1. To determine the extent of synergy between signal transduction pathways important in 
human PCa to afford better understanding of the molecular events that underpin the 
disease 
a. To employ Cre-LoxP technology to create novel conditional transgenic mouse 
models in which β-catenin, PTEN, and Kras are genetically modified in the 
prostate, alone and in combination, through action of the rat probasin promoter 
b. To characterise the phenotype of these mutations at different time points with 
immunohistochemistry 
2. To evaluate the extent by which these observations are seen in human PCa 
a. To analyse deregulation of the PI3K/Akt/mTOR, Wnt and MAPK pathways in a 
human PCa tissue microarray by immunohistochemistry 
3. To assess the capacity of stem cells or stem-like cells within both histologically normal 
prostate and pre-malignant prostates 
83 | P a g e  
 
a. To validate proposed SC/CSC markers in these models of prostate cancer by 
using immunohistochemistry 
b. To optimise a primary, 3D tissue culture assay to explore the self-renewal 
capacity of histologically normal and pre-malignant prostates in vitro 
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Chapter 3: Materials and Methods 
3.1 MOUSE COLONY 
Mice with prostate epithelium-specific probasin-driven Cre recombinase were sourced from the 
National Cancer Institute Mouse Model for Human Cancer Consortium (NCI, Frederick).  This 
line, named PB-Cre4, carries the Cre transgene under the control of a composite promoter, 
ARR2PB which is a derivative of the rat prostate-specific probasin (PB) promoter (Wu et al., 
2001).  The conditional, constitutively active β-catenin mutant strain was created by Makoto M. 
Taketo (Harada et al., 1999).  Mice with the conditional activating mutation of K-ras were 
derived by Mariano Barbacid (Guerra et al., 2003).  PTEN was highlighted for LoxP-targeted 
homozygous deletion (Suzuki et al., 2001).  The creation of these transgenic mice is depicted in 
figure 31: 
 
 
Figure 31: The technology used to facilitate prostate-specific genetic modification.  PTEN is 
‘floxed out’ upon recombination due to it being flanked by LoxP sites.  Critical phosphorylation 
sites on exon 3 of β-catenin have been deleted, which does not halt its transcription albeit in 
mutated form.  Similarly the excision of the ‘STOP’ codon upstream of exon 1 results in 
oncogenic Kras. 
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Including wild-type mice, the experimental cohorts studied in this thesis are outlined in table 9: 
Single Mutants Double Mutants Triple Mutant 
PBCre+Catnb+/lox(ex3) PBCre+Catnb+/lox(ex3)PTENflox  PBCre+Catnb+/lox(ex3PTENfloxK-ras+/V12 
PBCre+PTENflox PBCre+Catnb+/lox(ex3)K-ras+/V12  
PBCre+K-ras+/V12  PBCre+PTENflox K-ras+/V12  
 
Table 9: Cohorts studied in this thesis 
Mice were fed the Harlan standard diet (Scientific Diet Services) and water provided al libitum.  
All animal studies were conducted under the auspices of the UK Home Office (PPL 30/2737; PIL 
30/9754). 
3.1.1 Genotyping 
Mice were genotyped by PCR using DNA extracted from ear biopsies at weaning, when deemed 
suitable size and age (usually ≥4 weeks).  Genotypes were re-confirmed at necropsy.   
3.1.2 Genotyping primers 
Allele primer Sequence (5’-3’) Product size (bp) 
Β-catenin (Primer3) 
 
Ctnnb1: CTGCGTGGACAATGGCTACT 
Ctnnb2: TCCATCAGGTCAGCTGTAAAAA 
WT: 324 
HOM: 500 
Β-catenin recombined  
(Harada et al., 1999) 
AS5: ACGTGTGGCAAGTTCCGTCATCC 
GF2: GGTAGGTGAAGCTCAGCGCAG 
WT: 900 
Rec: 700 
Cre 
 
CreA: TGACCGTACACCAAAATTTG 
CreB: ATTGCCCCTGTTTCACTATC 
Cre: 1000 
KrasV12  
(Guerra et al., 2003) 
510: AGGGTAGGTGTTGGGATAGC 
3Ex1: CTCAGTCATTTTCAGCA 
103rev-2: CTGTCCTTTACTGAAGGCTC 
WT: 403 
Floxed: 621 
Rec: 669 
LacZ 
 
LacZa: CTGGCGTTACCCAACTTAAT 
LacZb: ATAACTGCCGTCACTCCAAC 
LacZ: 500 
PTEN 
(Suzuki et al., 2001) 
Pten1: CTCCTCTACTCCATTCTTCCC 
Pten2: ACTCCCACCAATGAACAAAC 
WT:228 
HOM: 335 
 
Table 10: Primers used to perform genotyping 
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3.2 TISSUE HARVESTING  
3.2.1 For immunohistochemistry (paraffin) 
The genitourinary tract, retroperitoneal lymph nodes, lungs, liver, and kidneys were harvested, 
and then placed into ice cold 10% neutral buffered formalin for 24 hours, before finally being 
submitted for sectioning in 70% ethanol at 4°C.  They were embedded in paraffin wax using an 
automated tissue processor (Leica TP1050).  Sections were cut (5-10μm thick) onto poly-L-lysine 
coated slides using a microtome.  Samples adhered to the slides after placing onto a hot plate 
for up to 30 minutes, and then baked in an oven at 45-60°C for a minimum of 24 hours. 
3.2.2 For primary tissue culture 
The deceased mouse was submerged in 70% ethanol and pinned out onto a board that had 
likewise been cleaned with 70% ethanol.  Sterile instruments, that had been autoclaved, were 
used each time, and stood up in 70% ethanol when not in use.  The GU tract was excised as 
before, and placed immediately into ice cold D10 medium until mechanical digestion were to 
begin. 
3.3 IMMUNOHISTOCHEMISTRY (PARAFFIN) 
Formalin-fixed, paraffin-embedded sections were dewaxed in xylene (2 x 5 min), then 
dehydrated in decreasing concentrations of ethanol (2 x 5min 100%; 1 x 2min 95%; 1 x 2min 
70%) before a 5min wash in dH20.  Once samples had been fully stained, dehydration in 
preparation for mounting took place in reverse order, finishing in xylene.  All of the above took 
place in a fume extraction hood. 
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3.3.1 Primary antibodies 
Antibody Host Manufacturer 
Manufacturer 
code 
Dilution Method 
Activated Notch1 Rabbit Abcam ab8925 1:300 A 
p-Akt (Ser473) XP Rabbit Cell Signalling 
Technology (CST) 
4060 1:50 B 
p-Akt (Thr 308) Rabbit CST  1:50 B 
AR Rabbit Labvision Neomarkers RB -1358 1:100 A 
B-catenin Mouse BD Transduction 
Laboratories 
610154 1:200 D 
Cleaved Caspase-3 Rabbit CST  9661 1:200 A 
CD44 Mouse Pharmingen 550392 1:50  
CD44 Rat Pharmingen 550538 1:50 D 
CXCR4 Rabbit Abcam ab2074 1:100 A 
EpCam Rabbit Abcam ab71916 1:100 A 
p-Erk 
(Thr202/Tyr204) 
Rabbit CST 4376 1:100 B 
FRMD4a Rabbit c/o Prof Fiona Watt N/A 1:500 A 
Integrin B1 Goat Santa Cruz sc-9936 1:100 A 
Keratin 5 Rabbit Covance  PRB-160P 1:1000 B 
Keratin 8 Chicken Abcam ab14053 1:500 E 
Keratin 14 Rabbit Covance PRB-155P 1:1000 B 
Keratin 18 Mouse Progen 61528 1:50 D 
Ki67 Mouse Vector Labs VP-K452 1:20 D 
LRIG1 Rabbit Abcam ab36707 1:100 A 
Notch4 Rabbit Santa Cruz sc-5594 1:200 A 
p63 Mouse Neomarkers MS-1081-P1 1:50 C 
p-Mek (Ser221) Rabbit CST  2338 1:75 B 
p-mTOR (Ser2448) 
XP 
Rabbit CST 5536 1:100 B 
Pten Rabbit CST 9559 1:100 B 
p-Rps6 
(Ser240/244) XP 
Rabbit CST 5364 1:200 B 
p-S6k (Thr421/424) Mouse CST 2317 1:200 B 
Trop2 Goat R&D Systems AF1122 1:200 B 
 
Table 11: Primary antibodies utilised for IHC.  FRMD4a antibody was kindly donated by 
Professor Fiona Watt, Wellcome Trust Centre for Stem Cell Research, University of Cambridge. 
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3.3.2 De-wax and rehydrate slides for immunohistochemistry 
Selected slides were de-waxed in xylene for 2 x 5 min washes and then hydrated by washing in 
decreasing concentrations of alcohol; 2 x 3 min washes in 100%, 1 x 3 min wash in 95% and 1 x 
3 min wash in 70% alcohol.  Slides are then bathed in distilled H20 (dH20) prior to following 
primary antibody-specific staining protocol (see Methods A – D) 
3.3.3 Method A: Rabbit polyclonal primary antibodies (Envision) 
Antigen unmasking was performed by microwave heating slides on full power in 1X citrate 
buffer for 10mins before leaving to cool for 30mins and rinsing in dH20.  A border is drawn 
around the prostate tissue with a DAKO pen and slides are then covered for 20mins with 
Envision Kit Peroxidase Block to inhibit endogenous peroxidase activity.  Slides were then 
washed for 3 x 5mins in 1X TBS/Tween and incubated with 10% normal goat serum (NGS) 
diluted in 1X TBS/T for 40mins to eradicate background staining.  Rabbit polycloncal primary 
antibody (diluted to the desired concentration in NGS and TBS/T) was added for 2hours at room 
temperature followed by a further 3 x 5min washes in 1X TBS/T.  Detection of primary antibody 
was achieved by horseradish peroxidase (HRP)-conjugated polymer (Rabbit Envision Kit, DAKO) 
for 1hour and washed in 1X TBS/T for 3 x 5mins to remove excess polymer.  Visualisation of 
positive staining was identified by applying Diaminobenzidine (DAB) solution (K3467, DAKO) for 
2-10mins and checking colour development regularly, until brown staining was visualised.  
Slides were then washed for 3 x 5mins in dH20 before counterstaining in Meyer’s haematoxylin 
for 30-60secs, rinsing in running tap water for 5mins, then dehydrating in increasing 
concentrations of alcohol before being mounted with DPX. 
3.3.4 Method B: Rabbit polyclonal primary antibodies (Biotin) 
Antigen unmasking was performed by microwave heating slides on full power in 1X citrate 
buffer for 15mins.  Slides were then cooled for 30mins prior to drawing a border around the 
prostate tissue with a DAKO pen prior to inhibiting endogenous peroxidase activity with 1.5-3% 
H202 (Sigma) in dH20 for 20mins.  Slides were then washed for 3 x 5mins in 1X TBS/Tween and 
incubated with 10% normal goat serum (NGS) diluted in 1X TBS/T for 40mins to eradicate 
background staining.  Rabbit polycloncal primary antibody (diluted to the desired concentration 
in NGS and TBS/T) was applied overnight at 4°C.  The following day slides were washed 
thoroughly for 3 x 5mins in 1X TBS/T.  Detection of primary antibody was achieved by adding 
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biotinylated goat-anti-rabbit secondary antibody (E0432, DAKO) 1:200 in 10% NGS in 1X TBS/T 
for 30mins at room temperature then washed in 1X TBS/T for 3 x 5mins.  Staining signal 
amplification was performed by using the Vectastain ABC (Avidin Biotin Complex) kit (Vector 
Labs, Burlingame, CA) for 30mins at room temperature before washing 3 x 5mins in 1X TBS/T.  
Visualisation of positive staining was identified by applying DAB solution (K3467, DAKO) for 2-
10mins and checking colour development regularly, until brown staining was visualised.  Slides 
were then washed for 3 x 5mins in dH20 before counterstaining in Meyer’s haematoxylin for 30-
60secs, rinsing in running tap water for 5mins, then dehydrating in increasing concentrations of 
alcohol before being mounted with DPX. 
3.3.5 Method C: Mouse monoclonal primary antibodies (Envision) 
Antigen unmasking was performed by microwave heating slides on full power in 1X citrate 
buffer for 10mins before leaving to cool for 30mins and rinsing in dH20.  A border is drawn 
around the prostate tissue with a DAKO pen and slides are then covered for 20mins with 
Envision Kit Peroxidase Block to inhibit endogenous peroxidase activity.  Slides were then 
washed for 3 x 5mins in 1X TBS/Tween and incubated with 10% normal rabbit serum (NRS) 
diluted in 1X TBS/T for 40mins to eradicate background staining.  Mouse monoclonal primary 
antibody (diluted to the desired concentration in NRS and TBS/T) was added for 2hours at room 
temperature followed by a further 3 x 5min washes in 1X TBS/T.  Detection of primary antibody 
was achieved by adding horseradish peroxidase (HRP)-conjugated polymer (Mouse Envision Kit, 
DAKO) for 1hour and washed in 1X TBS/T for 3 x 5mins to remove excess polymer.  Visualisation 
of positive staining was identified by applying DAB solution (K3467, DAKO) for 2-10mins and 
checking colour development regularly, until brown staining was visualised.  Slides were then 
washed for 3 x 5mins in dH20 before counterstaining in Meyer’s haematoxylin for 30-60secs, 
rinsing in running tap water for 5mins, then dehydrating in increasing concentrations of alcohol 
before being mounted with DPX. 
3.3.6 Method D: Mouse/Rat polyclonal (Biotin) 
Antigen unmasking was performed by microwave heating slides on full power in 1X citrate 
buffer for 15mins.  Slides were then cooled for 30mins prior to drawing a border around the 
prostate tissue with a DAKO pen prior to inhibiting endogenous peroxidase activity with 1.5-3% 
H202 (Sigma) in dH20 for 20mins.  Slides were then washed for 3 x 5mins in 1X TBS/Tween and 
incubated with 10% normal rabbit serum (NRS) diluted in 1X TBS/T for 40mins to eradicate 
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background staining.  Mouse (or rat for anti-CD44) polycloncal primary antibody (diluted to the 
desired concentration in NRS and TBS/T) was applied overnight at 4°C.  The following day slides 
were washed thoroughly for 3 x 5mins in 1X TBS/T.  Detection of primary antibody was achieved 
by adding rabbit-anti-mouse biotinylated secondary antibody (E0464, DAKO), or for anti-CD44 
rabbit-anti-rat biotinylated secondary antibody (E0468, DAKO), 1:200 in 10% NRS in 1X TBS/T 
for 30mins at room temperature then washed in 1X TBS/T for 3 x 5mins.  Staining signal 
amplification was performed by using the Vectastain ABC (Avidin Biotin Complex) kit (Vector 
Labs, Burlingame, CA) for 30mins at room temperature before washing 3 x 5mins in 1X TBS/T.  
Visualisation of positive staining was identified by applying DAB solution (K3467, DAKO) for 2-
10mins and checking colour development regularly, until brown staining was visualised.  Slides 
were then washed for 3 x 5mins in dH20 before counterstaining in Meyer’s haematoxylin for 30-
60secs, rinsing in running tap water for 5mins, then dehydrating in increasing concentrations of 
alcohol before being mounted with DPX. 
3.3.7 Method E: Chicken polyclonal primary antibody (Biotin) 
Antigen unmasking was performed by microwave heating slides on full power in 1X citrate 
buffer for 15mins.  Slides were then cooled for 30mins prior to drawing a border around the 
prostate tissue with a DAKO pen prior to inhibiting endogenous peroxidase activity with 1.5-3% 
H202 (Sigma) in dH20 for 20mins.  Slides were then washed for 3 x 5mins in 1X TBS/Tween and 
incubated with 10% normal rabbit serum (NRS) diluted in 1X TBS/T for 40mins to eradicate 
background staining.  Chicken polycloncal primary antibody (diluted to the desired 
concentration in NRS and TBS/T) was applied overnight at 4°C.  The following day slides were 
washed thoroughly for 3 x 5mins in 1X TBS/T.  Detection of primary antibody was achieved by 
adding rabbit-anti-chicken biotinylated secondary antibody (12-341, Upstate) 1:200 in 10% NRS 
in 1X TBS/T for 30mins at room temperature then washed in 1X TBS/T for 3 x 5mins.  Staining 
signal amplification was performed by using the Vectastain ABC (Avidin Biotin Complex) kit 
(Vector Labs, Burlingame, CA) for 30mins at room temperature before washing 3 x 5mins in 1X 
TBS/T.  Visualisation of positive staining was identified by applying DAB solution (K3467, DAKO) 
for 2-10mins and checking colour development regularly, until brown staining was visualised.  
Slides were then washed for 3 x 5mins in dH20 before counterstaining in Meyer’s haematoxylin 
for 30-60secs, rinsing in running tap water for 5mins, then dehydrating in increasing 
concentrations of alcohol before being mounted with DPX. 
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3.4 HISTOPATHOLOGICAL CHARACTERISATION 
3.4.1 Haematoxylin and eosin staining 
Slides were immersed in Meyer’s haematoxylin for 1 min and rinsed in water for 5 mins, before 
counterstaining with 1% aqueous eosin for 30sec. 
3.4.2 LacZ stain of prostate wholemounts 
Male mice were euthanised and the GU tract was dissected out and washed in 1X PBS.  The GU 
tract was fixed for 40min in whole mount fixative (0.2% Glutaraldehyde, 5mM EGTA, and 2mM 
MgCl2 in 0.1M phosphate buffered saline [pH 7.3]) on ice.  The specimen was rinsed 3 x 15 min 
in detergent rinse (0.02% Igepal, 0.01% sodium deoxycholate, and 2mM MgCl2 in 0.1M PBS [pH 
7.3]) and stained by immersion in 1mg/ml X-gal staining solution (0.02% Igepal, 0.01% Sodium 
Deoxycholate, 5mM Potassium Ferricyanide, 5mM Pottassium Ferrocyanide, and 2mM MgCl2 
diluted in 0.1M phosphate buffer [pH 7.3]) overnight at 37°C in the dark.  The X-gal staining 
solution was prepared ahead of time, stored at room temp in the dark, and 1mg/ml X-Gal in 
N,N-dimethylformamide (Promega) added immediately prior to use.  The GU tract was washed 
in 1X PBS for 15mins, and post-fixed in 4% paraformaldehyde in 1X PBS at 4°C.  The 
wholemount was then ready to bephotographed and submitted in 70% ethanol for sectioning 
as required. 
3.4.3 Characterisation of murine prostate tumours 
All histopathological analysis and tumour grading was undertaken with Dr David Griffiths, 
Consultant Histopathologist, University Hospital of Wales, Cardiff. 
3.4.4 Scoring proliferation  
The percentage of positive cells for AR, Caspase-3, H&E (apoptosis and mitosis), Ki67, and p63 
were scored by dividing the number of positively-stained cells by the total number of cells 
counted (positive and negatively-stained cells) from 20 acini, or in prostate lesions (PIN and 
tumours) 20 random 2500μm2, and a running mean calculated.  Photographs were taken using 
Motic Images Plus 2.0 software at 40x magnification, and all counting performed in ImageJ 
(Schneider et al., 2012).  A minimum of 1000 cells/mouse were counted (n=3).  The median 
score for each genotype at each time point underwent statistical analysis using the non-
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parametric Mann-Whitney U test (95% confidence interval, p<0.05), using SPSS 20 software 
(IBM). 
3.5  3D PRIMARY PROSTATE EPITHELIAL STEM CELL CULTURE  
The technique for prostate sphere assay was adapted from Lukacs et al. (2010).   
3.5.1 Creation of a prostate epithelial single cell suspension 
The GU tract (bladder, seminal vesicles, prostate and urethra) of male mice aged 90 – 100 days 
was harvested under sterile conditions, and quickly placed into an un-skirted 15ml centrifuge 
tube containing 10ml dissecting medium.  Micro-dissection to isolate only the prostate was 
performed in a tissue culture hood on a clean 10cm Petri dish.   Two pairs of fine non-toothed 
forceps were used to separate all 4 prostate lobes intact from the seminal vesicles, bladder and 
urethra.  Prostates were minced into paste after undergoing 3-4 passes through a tissue 
chopper.  The tissue paste was then placed into a clean 50ml centrifuge tube containing 
dissection medium (see box below for reagent setup) and collagenase (Life Technologies; cat no 
17018-029) in a ratio of 1:9:1 per prostate (e.g. 3 prostates, 27ml of dissecting medium, along 
with 3ml of collagenase solution), and incubated on a gentle orbital shaker at 37°C overnight. 
Dissecting medium: to 500 ml Dulbecco’s modified Eagle’s medium (DMEM; Invitrogen/Gibco, 
12100-061), add 50 ml fetal bovine serum (Sigma; F7524) (10% (vol/vol), 5 ml 100X GlutaMAX 
(Invitrogen/Gibco, 35050-038) (1X final concentration), and 5 ml 100X penicillin-
streptomycin(Invitrogen/Gibco; 15140-122)  (1X final concentration).  Stored at 4 °C and used 
within 1 month. 
The following morning, the tissue was spun down at 1300rpm for 5 minutes at room 
temperature; the supernatant was discarded before 5mls of warm trypsin/0.05% EDTA 
(Invitrogen/Gibco; 25300-062) was added to dissociate the cell pellet.  The mixture was 
thoroughly mixed using with a P1000 pipette and placed in an incubator at 37°C for 5 minutes. 
Next, the cell suspension was mixed with a P1000 pipette and 3ml dissecting media containing 
500U (25µl of 10mg/ml) DNase I (Roche; 10 104 159 00) added to inactivate the trypsin and 
break up any DNA released from dead cells.  The suspension was then gently passed through an 
18-G needle 5 times.  If any chunks of prostate tissue were to remain, then 1ml (10mg/ml) 
collagenase was added for 1 hour and the process up to this point was repeated.  If the cell 
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suspension appeared well digested and cells were fully in suspension, then the trypsin/EDTA 
stage was repeated again, to maximise cellular yield. 
Next, the mixture was filtered through a 40µm nylon mesh filter into a 50ml centrifuge tube, 
and the 15ml centrifuge tube washed out with dissection media.  This was spun down at 
1300rpm for 5 minutes at room temperature and the pellet re-suspended in 2ml dissecting 
media for counting by trypan blue exclusion on a haemocytometer.  10µl of suspended cells 
was mixed with 10µl trypan blue in a 1.5ml Eppendorf tube.  10µl of this sample was taken and 
placed on haemocytometer, at which point live and dead cells were counted and recorded.   
3.5.2 Unsorted prostate epithelial cells 
Unsorted cells were diluted to 2.5×10E5 cells per ml in PrEGM.  40µl cell mixture (10E4 cells) 
was thoroughly mixed with 60µl cold Matrigel (BD Biosciences; 354234) and the 100 µl mix 
pipetted around wells of a 12-well plate.  Plates were swirled to evenly distribute the mixture 
around the rim and once complete they were incubated for 30minutes at 37°C to allow the 
Matrigel to solidify.  Once time had lapsed and the Matrigel was solidified, 1ml of warm PrEGM 
(see box below for reagent setup) was added to each well by aiming the pipette at the centre of 
the well in order to not disturb the Matrigel ring.  Plates were checked daily for infection and 
spheres monitored for 7-10days depending on their destiny.  A media change was performed 
every 3rd day by tilting the plate to 45 degrees and replacing half of the spent PrEGM with 500µl 
of fresh, warm PrEGM.   
Spheres were counted using an inverted microscope by following the rim of Matrigel around 
the wells.  When many spheres were present, a single field was counted, and the whole well 
total estimated by multiplying by 14.5 if viewed at 4X or multiplying by 36 if viewed at 10X. 
PrEGMTM: a commercial preparation (Lonza Walkersville, Inc.; CC-3166) that requires addition of 
the inclusive SingleQuotsTM growth supplements (Lonza; CC-4177) (Bovine pituitary extract, 2 ml; 
hydrocortisone, 0.5 ml; human epidermal growth factor, 0.5 ml; epinephrine, 0.5 ml; transferrin, 
0.5 ml; insulin, 0.5 ml; retinoic acid, 0.5 ml; triiodothyronine, 0.5 ml; gentamicin-amphotericin-B 
1000, 0.5 ml) to a 500 ml bottle of prostate epithelial cell basal medium (Lonza; CC-3165).  
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3.5.3 FACS enrichment: sorted prostate epithelial cells 
FACS was facilitated and supervised by Dr Kirsty Richardson PhD, FACS manager, School of 
Biosciences, Cardiff University on a BD FACS Aria cell sorter. 
 
3.5.4 Sorted cells 
Five hundred microlitres of dissecting medium was aliquoted into five Eppendorf tubes and 
5×10E4 cells added to each tube; these were used to set up the compensation for sorting.  The 
remaining cells are divided into new Eppendorf tubes up to 3×10E6 cells per tube in a 1 ml total 
volume; these are stained for sorting. 
For compensation, FMO (Fluorescence-Minus-One) compensation was carried out when 
calibrating gates for the first time.  The following antibodies were added to individual 
compensation tubes:  
1. Unlabelled cells 
2. 1μl CD49f–PE-Cy5  (BD Pharmingen; cat no 551129) 
3. 1μl Sca-1–PE–Cy7  (BioLegend; 122514) 
4. 2μl Trop2–biotin (R&D Systems; AF1122) 
5. 1μl CD31-FITC  (eBioscience; 11-0311-85) 
6. 1μl CD45–FITC  (eBioscience; 11-0451-85) 
7. 1μl Ter119–FITC (eBioscience; 11-5921-85) 
8. 1μl each of CD31-FITC, CD45–FITC and Ter119–FITC to the fifth tube 
9. 1 μl DAPI  (Invitrogen; D21490) 
 
To the sample tube(s) for sorting, the following were added together: 
 3μl CD49f–PE 
 2μl Sca-1–PE–Cy7 
 10μl Trop2–biotin 
 4μl each of CD31–FITC, CD45–FITC and Ter119–FITC 
 2μl DAPI 
 
All tubes are then wrapped in aluminium foil and placed on a shaker at 4°C for 20min. 
Cells were pelleted in a bench top centrifuge at 2,300rpm for 2min at room temperature.  
Media were aspirated off and cells were re-suspended in 500μl of fresh dissecting medium for 
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the compensation cells and 1 ml for the sorting sample cells.  All samples were kept on ice 
where possible throughout. 
1μl SA–APC (BD Biosciences; cat no 554067) secondary antibody was added to its own 
compensation tube, with 1μl SA–APC to the Trop2-APC compensation tube (now 10 
compensation tubes in total), and 5μl SA–APC antibody to each of the sample tubes.  Tubes 
were wrapped in aluminium foil and placed on a shaker at 4°C for 15min.  Cells were then 
pelleted in a bench top centrifuge at 2,300rpm for 2min at room temperature.  Media were 
aspirated off and cells re-suspended in 500μl fresh dissecting medium for the compensation 
cells and 1ml for the sorting sample cells.  Cells were transferred back to the tissue culture hood 
in either 0.3% BSA in 1X PBS or dissecting medium on ice. 
After completing the compensation, the following populations were sorted using the FACS Aria 
cell sorter and cells collected into 15 ml centrifuge tubes containing 5ml FACS collection 
medium:  
1. FITC-PE-Cy7+PE-Cy5+APChi (Lin-CD49f+Sca-1+Trop2hi; Trop2Hi) 
2. FITC-PE-Cy7+PE-Cy5+APClo (Lin-CD49f+Sca-1+Trop2lo; not Trop2Hi or Trop2lo) 
3. FITC-PE-Cy7-PE-Cy5- (Lin-CD49f-Sca-1-; not CD49f/Sca-1+) 
 
Upon return to the tissue culture suite, cells were pelleted at 1,300rpm for 5min at room 
temperature, re-suspended in 500μl PrEGM, and again counted using a haemocytometer.  At 
this point cells were ready for in vitro culture. 
The 3 cell populations were diluted to 2.5×10E5 cells per ml in PrEGM.  40µl cell mixture (10E4 
cells) was thoroughly mixed with 60µl cold Matrigel and the 100 µl mix pipetted around wells of 
a 12-well plate, identical to that used to plate unsorted cell as above.  Each population was 
plated in triplicate at 1x10E4/well and the rest of the cells plated at 10E5/well in bulk.  
3.5.5 Passage of prostate epithelial stem cells in vitro 
After 7 days, the prostate spheres were ready to be dissociated into single cell suspension and 
re-cultured to assess self-renewal. 
96 | P a g e  
 
PrEGM was aspirated from each well and 1ml Dispase (Invitrogen/Gibco; 17105-041) added.  
The plate was incubated at 37°C for 1 hour to digest the Matrigel.  Spheres were collected into a 
15ml centrifuge tube and pelleted at 1300rpm for 5mins at room temperature.  The sphere 
pellet was re-suspended in 1ml trypsin/0.05% EDTA and transferred into a 1.5ml Eppendorf 
tube and incubated at 37°C for 5 minutes.  Spheres were gently passed through a 1ml syringe 
with a 27-G needle five times to dissociate cells and then centrifuged at 2300rpm for 2minutes 
at room temperature.   
The Trypsin/0.05% EDTA was aspirated off and the pellet re-suspended in 1ml PrEGM before 
again passing cells through a 1ml syringe with a 27-G needle five times, then centrifuging again 
at 2300rpm for 2 minutes at room temperature.  Cells were finally re-suspended in 0.5ml fresh 
PrEGM.  Cells were counted on a haemocytometer and plated as before at 1x10E4 and bulk to 
maximise passage success through further generations. 
3.5.6 Quantifying self-renewal 
The size of 50 spheres per well, chosen at random, were measured and recorded at days 1, 4, 
and 7 after primary plating and each re-plating following passage.  When assessing prostate 
organoid size, a cut-off of 40μm was set – the growth of structures smaller than this ceased at 
or around day 5 and so not counted as PrSC organoids.  Similarly, sphere number was counted 
on day 7 and averaged.  Photographs were taken on AnalySIS software on an inverted light 
microscope, measurements and counts performed in ImageJ (Schneider et al., 2012), all results 
were collated in Microsoft Excel 2010, and all statistical analysis performed in SPSS20 (IBM).  
The median score for each population (n=4) at each time point underwent statistical analysis 
using the non-parametric Mann Whitney U-test (95% confidence interval, p<0.05), using SPSS 
20 software (IBM). 
Sphere-forming units (SFU) were calculated at each generation by using the following formula: 
SFU = number of spheres formed per well / number of cells plated per well X 100% 
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Chapter 4: Investigating the interactions between the Wnt, 
PI3K/Akt/mTOR, and MAPK pathways in prostate tumourigenesis 
 
4.1 INTRODUCTION 
Several important molecular lesions have been associated with human prostate cancer, 
including deregulation of the Wnt pathway (Yang et al., 2006, Wang et al., 2008, Kypta and 
Waxman, 2012, Lee et al., 2013), the PI3K/Akt/mTOR pathway (Mulholland et al., 2006, Sarker 
et al., 2009, Elfiky and Jiang, 2013), and the MAPK pathway (Weber and Gioeli, 2004, Prior et al., 
2012).  Given that there is extensive evidence for crosstalk between these pathways in both 
tumour development and resistance to therapy, the interplay between them remains largely 
unmodelled and poorly characterised in the pre-clinical setting.  This chapter explores the 
interplay between the Wnt, PI3K/Akt/mTOR, and MAPK pathways in mouse models of prostate 
tumourigenesis. 
4.1.1 PTEN is implicated in human prostate cancer 
PTEN (phosphatase and tensin homolog deleted from chromosome 10) is a potent tumour 
suppressor and negative regulator of the PI3K/Akt/mTOR pathway.  PTEN deregulation is 
strongly implicated in prostate tumourigenesis and therefore it is one of the most interrogated 
molecular lesions in prostate cancer.  PTEN deletions and/or mutations are found in 
approximately 30% of primary prostate cancers (Dahia, 2000) and up to 63% of  metastatic 
prostate cancers (Suzuki et al., 1998).   
PTEN loss of function is well described in both localised and metastatic prostate cancers and 
includes homozygous deletions, loss of heterozygosity (LOH), and inactivating somatic 
mutations.  However, the reported frequency and mode of inactivation at different stages of 
prostate cancer vary, along with the techniques employed to identify the prevalence of the loss 
of function within the tumour.  Examples are given in table 12. 
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Reference Tumour type Finding Prevalence 
in tumour 
Techniques 
used 
Yoshimoto et 
al. (2007) 
Primary PCa Homozygous deletion 5% FISH 
Heterozygous deletion 39% 
Somatic mutation 70% 
Verhagen et al. 
(2006) 
Locally-advanced PCa Homozygous deletion 30-38% PCR-SSP, 
IHC Heterozygous deletion 20% 
Cairns et al. 
(1997) 
Localised Pca and 
lymph node 
metastases 
Homozygous deletion 7.5% DNA 
sequencing, 
PCR, FISH 
Heterozygous deletion 21% 
Dong et al. 
(1998) 
Primary T2, and T3 PCa Homozygous deletion 15% DNA 
sequencing, 
PCR 
Heterozygous deletion 0% 
Somatic mutation 2.5% 
Yoshimoto et 
al. (2006) 
Primary PCa from RRP 
specimens 
Homozygous deletion 6% FISH, IHC 
Heterozygous deletion 63% 
Dong et al. 
(2001) 
Primary PCa Somatic mutation 16% PCR-SSP, 
DNA 
sequencing 
Metastatic PCa Somatic mutation 33% 
Feilotter et al. 
(1998) 
Primary PCa Heterozygous deletion 49% PCR-SSP, 
DNA 
sequencing 
Somatic mutation 2% 
Halvorsen et al. 
(2003) 
Primary PCa from RRP 
specimens 
Absence of PTEN 
expression 
27% IHC 
McMenamin et 
al. (1999) 
Primary PCa from RRP 
and TURP specimens 
Absence of PTEN 
expression 
20% IHC 
Suzuki et al. 
(1998) 
Metastatic PCa Homozygous deletion 11% DNA 
sequencing, 
PCR-SSP, 
FISH 
Heterozygous deletion 56% 
Somatic mutation 63% 
 
Table 12: The frequency of PTEN loss of functions are outlined to include the type of 
mutation, and the techniques used for investigation. FISH, fluorescence in situ hybridisation; 
PCR-SSP, Polymerase chain reaction – Sequence-specific amplification; IHC, 
immunohistochemistry. 
 
PTEN mutations have likewise been implicated in the mechanisms of resistance to radiotherapy 
(Anai et al., 2006), and chemotherapy (Priulla et al., 2007), along with recurrence following 
prostatectomy (Bedolla et al., 2007). 
4.1.2 The PI3K/Akt/mTOR pathway and human prostate cancer 
Further to the incapacitation of PTEN, the PI3K/Akt/mTOR pathway has been identified as 
playing important other roles in the genetics and pathophysiology of prostate cancer. 
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The p110β subunit of PI3K in particular has been identified as a critical molecule in prostate 
tumourigenesis.  Both p85α and p110β appear to influence androgen-induced AR 
transactivation and impact on cell proliferation and tumour growth (Zhu et al., 2008).  Studies 
of p110β conditional knockout mice evaluated the impact of its deletion.  Prostates were 
normal upon p110β loss but had universal high-grade PIN in the anterior lobe by 12 weeks in 
the absence of PTEN alone.  However, ablation of p110β prevented the tumourigenesis caused 
by PTEN loss; this led to increased Akt phosphorylation in the prostate, whereas ablation of 
p110β had the opposite effect (Jia et al., 2008).  These changes were p110β-specific because 
p110α knockout did not abrogate tumour formation or Akt phosphorylation, supporting a 
potential avenue for p110β inhibitors in prostate cancer treatment to be explored. 
Proteins of the ETS family are related signal-dependent transcriptional regulators that mediate 
cellular proliferation, differentiation and tumourigenesis (Seth and Watson, 2005).  In human 
prostate cancer, genomic alterations of ETS-related genes (principally ERG), as a result of a 
fusion between an androgen receptor–regulated gene promoter of TMPRSS2 and ETS 
transcription factors, is present in approximately 50-70% of prostate cancers (Tomlins et al., 
2005, Sarker et al., 2009).  Thus, overexpression of ETS factors may represent a crucial event in 
prostate tumourigenesis. However, important details of the biological role of aberrant ETS 
expression in prostate cancer initiation and progression have yet to be elucidated. 
Data have shown that loss of PTEN cooperates with TMPRSS2:ERG activation in both human and 
murine prostate cancer in dose-dependent fashion.  Transgenic mice expressing TMPRSS2:ERG 
in the prostate failed to develop PIN or invasive prostate cancer (King et al., 2009).  However, 
when these were crossed either with PTEN+/- mice, or prostate-specific Akt transgenic mice, PIN 
but not invasive cancer developed. In another strain of transgenic mouse overexpressing ERG, 
both PIN and invasive cancer developed only when crossed with PTEN-deficient mice (Carver et 
al., 2009).  In addition, this study showed that prostate cancer specimens containing the 
TMPRSS2:ERG rearrangement (∼40%) are significantly enriched for PTEN loss.  These data 
implicate PTEN loss and ERG rearrangements as associated events that act in tandem to 
promote prostate cancer progression, potentially by inducing transcription of downstream 
checkpoint genes involved in promoting cell proliferation, senescence, and survival. 
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Reports suggest that PI3K/Akt/mTOR signalling may play a critical role in the development of 
CRPC (Mulholland et al., 2006).  The transgenic mouse models that recapitulate features of 
PI3K/Akt/mTOR-dependent PCa (Shen and Abate-Shen, 2007), demonstrated an initial response 
to androgen deprivation therapy, and eventual tumour growth despite castration (Wang et al., 
2003).  Thus PI3K/Akt/mTOR signalling may contribute to continued AR gain-of-function despite 
reduced steroid ligand levels (Mulholland et al., 2006), by triggering a downstream cascade of 
events that are likely to interact with AR transcriptional activity e.g. Wnt pathway/β-catenin 
(Sarker et al., 2009). 
Chemokines have been associated with prostate carcinogenesis, by impacting cancer cell 
proliferation, survival, adhesion, and invasion (Balkwill, 2004) through their stimulation of 
transmembrane-spanning receptors involved in the PI3K/Akt/mTOR pathway and the resultant 
activation of downstream p110β signalling (Richter et al., 2005).  Chemokines such as CCL2 
(monocyte chemo-attractant protein) have also been reported to stimulate 
monocyte/macrophage migration into tumours, potentially fuelling tumour growth, 
propagation of angiogenesis, and the inhibition of autophagy (Roca et al., 2008). 
4.1.3 Βeta-catenin is implicated in human prostate cancer 
The observation that β-catenin is a target for mutation in PCa originated from a study of 104 
PCa samples, of which 5 were found to harbour specific mutations in exon 3 of the CTNNB1 
gene (Voeller et al., 1998).  This 5% mutation rate was later corroborated by another study 
(Chesire et al., 2000), but smaller studies contradict this prevalence and reported differing 
frequencies ranging from 0% in eight CRPC samples (de la Taille et al., 2003), to 33% (2/6) in 
locally-advanced tumours (Gerstein et al., 2002).  Thus mutations that directly activate Wnt/β-
catenin signalling are reportedly rare in PCa, suggesting that other mechanisms may account for 
its over-expression (Kypta and Waxman, 2012).  These may include mutations in APC and 
AXIN1, which are likewise rare in PCa.  Whilst occurring in 25% of xenograft cell lines derived 
from bone metastases (Gerstein et al., 2002), mutant APC alone was not seen in 49 samples of 
advanced PCa, but mutation of the APC-binding domain of axin-1 was seen in 4% (Yardy et al., 
2009).  Furthermore APC is frequently hypermethylated in PCa progression (Jeronimo et al., 
2011), which may result in increased Wnt signalling by reduction of APC expression (Kypta and 
Waxman, 2012). 
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The low frequency of β-catenin mutations is at odds with reports that aberrantly-expressed or 
localised β-catenin is commonly found in PCa.    Table 13 summarises the frequencies and 
expression patterns reported. 
Participants (n) 
and PCa 
grade/stage 
Expression Change in localisation Reference 
122 T2 
90 CRPC 
Increased Increased nuclear and cytoplasmic in 30% 
PCa overall 
de la Taille et al. 
(2003) 
232 T2 
26 metastatic 
Decreased Decreased membranous and nuclear 
expression but cytoplasmic expression 
unchanged in men with metastatic PCa 
Horvath et al. 
(2005) 
73 T2 
25 T3/4 
3 metastatic 
No change 88% diffuse membranous expression, and 
12% negative 
Bismar et al. 
(2004) 
80 BPH 
35 Gleason 6 
33 Gleason 7 
77 Gleason 8-10 
Increased Increased intensity in all membranous, 
cytoplasmic, and nuclear compartments 
Nuclear expression: 37% BPH, 14% 
Gleason<7, 9% Gl 7, 5% Gl>7 
Whitaker et al. 
(2008) 
47 T2 
65 T3/4 or 
metastatic 
Decreased Decreased overall expression was 
observed in 4% PCa, and commoner with 
high grade PCa 
Kallakury et al. 
(2001) 
49 T2 
18 T3/4 or 
metastatic 
Increased Cytoplasmic and nuclear staining in 43% 
Gl 6 and 7, and 78% Gl>7 
Staining density correlated with stage and 
grade 
Chen et al. 
(2004b) 
 
Table 13: The prevalence and expression patterns seen for β-catenin at IHC.  Gl, Gleason grade 
(6-10). 
There is no clear conclusion as to the prevalence of nuclear localisation of β-catenin in PCa, nor 
its clinical relevance.  Hypotheses to account for the dissimilarities in reports could include 
intra- and inter-tumoural heterogeneity (Chesire et al., 2000, Chesire et al., 2002), and variance 
in immunohistochemical staining protocols (Whitaker et al., 2008).  Nevertheless, expression at 
all stages of prostate tumourigenesis suggests that β-catenin activation plays an important role 
in disease progression. 
Synergy between AR and β-catenin pathways has been well documented (Lee et al., 2013), 
whereby β-catenin and AR regulate one another.  AR binds β-catenin directly to stimulate AR-
mediated gene transcription (Song and Gelmann, 2005), and the AR gene itself is a 
transcriptional target of β-catenin (Yang et al., 2006). 
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Recent studies have revealed that Wnt signalling is a significantly deregulated pathway in the 
lethal phase of PCa (Grasso et al., 2012).  Furthermore, enhanced crosstalk between AR and β-
catenin has been observed in mouse models of CRPC (Wang et al., 2008).  CSCs may resist 
androgen deprivation therapy, and recent studies have identified Wnt/β-catenin signalling as 
being highly active in CSCs (Chen et al., 2007, Woodward et al., 2007, Vermeulen et al., 2010, 
Wang et al., 2010), perhaps further identifying a role for β-catenin in an androgen-independent 
environment. 
4.1.4 The Wnt pathway and human prostate cancer 
Genetic changes alone may not be necessary for the activation of Wnt signalling.  Variation in 
the expression of Wnt ligands could also have an effect.  When Wnt/β-catenin signalling is 
activated (see figure 26 in chapter 1.7.1), Wnt ligands induce LRP phosphorylation and 
recruitment of axin and Dvl proteins to the plasma membrane.  This disrupts the β-catenin 
ubiquitination complex, thus enabling β-catenin stabilisation and its translocation to the 
nucleus.  Studies have demonstrated upregulation Wnt-1 (Chen et al., 2004b), and Wnt-7b (Li et 
al., 2008), in both primary tumours and metastases and their prevalence correlate with disease 
progression.  More recently, expression of Wnt-16b in PCa was shown to mitigate the effects of 
cytotoxic chemotherapy in vivo, promoting tumour cell survival and disease progression (Sun et 
al., 2012).  Furthermore, the down regulation of secreted Wnt antagonists has also been 
identified as a contributing factor toward β-catenin stabilisation, however their influence has 
proven to be complex and their involvement in PCa formation remains unknown (Kypta and 
Waxman, 2012).  In view of these data, Wnt ligands play an important albeit largely unclear role 
in β-catenin/Wnt pathway signalling during prostate tumourigenesis. 
4.1.5 KRAS and MAPK pathway signalling are implicated in human prostate cancer 
Ras proteins are proto-oncogenes that are frequently mutated in many human cancers (Prior et 
al., 2012), but RAS mutations have long been identified as rare in PCa (Carter et al., 1990).  
Indeed in human PCa the incidence of RAS isoform mutations overall in contemporary genomic 
studies is 15%; 8-10% of which occur in KRAS (Taylor et al., 2010, Forbes et al., 2011, Pylayeva-
Gupta et al., 2011, Prior et al., 2012).  Paradoxically, aberrations that result in upregulated 
MAPK pathway signalling are among the commonest seen in PCa (Taylor et al., 2010, Selvaraj et 
al., 2014), suggesting that Ras effectors represent a convergence point for numerous diverse 
103 | P a g e  
 
extracellular signals (Gioeli et al., 2008) particularly in metastatic disease and CRPC 
development. 
Data from mouse models suggest that Ras mutations is necessary to initiate the early stages of 
prostate tumourigenesis and to maintain the phenotype, whereas progression to invasive PCa 
requires a second hit from synergistic mutations.  Transgenic mice expressing activated H-Ras 
from the human T24 human bladder carcinoma cell line (Ha-RasT24) under control of the PB 
promoter developed atypical hyperplasia (AH) of the prostate before 12 months (Barrios et al., 
1996).  Later, Scherl and colleagues (2004) showed that mice expressing a G12V point mutation 
in cH-Ras (termed H-RasV12), under the control of the minimal PB promoter, developed low-
grade prostate intraepithelial neoplasia (LG-PIN) that displayed intestinal metaplasia by 3 
months.  At 12 months, the H-RasV12 transgene was not detected in this model, coinciding with 
a decrease in PIN incidence. 
Thus to summarise, the Wnt, PI3K/Akt/mTOR, and MAPK pathways have been implicated in 
prostate cancer, but the interplay between them in prostate tumourigenesis remains poorly 
modelled and poorly understood.   
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4.2 CHAPTER AIMS 
Following on from previous discoveries regarding the activation of the Wnt and MAPK pathways 
in murine prostate epithelium (Pearson et al., 2009), it was hypothesised that the additional 
over-activation of the PI3K/Akt/mTOR pathway by PTEN knockout, would initiate metastatic 
disease.   
The aims of this chapter were therefore: 
1. To employ Cre-LoxP technology to create conditional transgenic mouse models in which 
β-catenin, Pten, and Kras are genetically modified in the prostate alone and in 
combination through action of the rat probasin promoter 
2. To subsequently investigate the impact of mutating these critical lesions within the Wnt, 
PI3K/Akt/mTOR, and MAPK pathways respectively, to define the interplay between 
them in prostate tumourigenesis 
3. To employ immunohistochemistry to characterise the phenotype of these mutations at 
different stages of tumourigenesis 
4. To explore whether the same pathway deregulations and/or synergy are seen in human 
PCa to substantiate its usefulness as a pre-clinical model of the human disease 
 
 
4.3 RESULTS 
4.3.1 The probasin-Cre (PBCre4) transgene mediates DNA recombination of target alleles 
within the prostate epithelium 
In order to decipher the pattern of PBCre4-mediated recombination in the murine GU tract, 
wholemounts and frozen sections of wild-type mice with and without both the PBCre4 
transgene and the Rosa26 reporter locus underwent staining with Xgal (see figure 32).   
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Figure 32: Wholemounts and their sections were used to assess for LacZ 
staining/recombination in the murine prostate.  The Rosa26 reporter locus permits staining 
with Xgal to assess gross recombination.  Note that in PBCre4+Rosa26R+ mice, the appearance 
of a blue product signifies successful DNA recombination.  On wholemount the ventral lobe 
appears spared but recombination is confirmed in all four lobes on frozen sections.   PBCre4-
Rosa26R- mice demonstrated occasional non-specific staining for ß-galactosidase.  All images 
were taken at 40x magnification, and scale bars represent 100µm. 
 
Expression of ß-galactosidase (blue product), a surrogate marker of recombination at the 
Rosa26 reporter locus was detected in the luminal epithelial cells of all four lobes of the 
prostate in PBCre+Rosa26+ mice, with sparing of the basal cells. Elsewhere in the GU tract, 
recombination was detected in the testis and epididymis, whereas no recombination was seen 
in the seminal vesicles or bladder (photographs not shown).  In contrast, PBCre-Rosa26- mice 
demonstrate rare, non-specific expression of ß-galactosidase.  These findings are consistent 
with those of Wu et al. (2001). 
To allow monitoring of disease progression, mice were dissected at 100 days (n=6), while the 
majority (n=12) were aged in survival cohorts until their terminal endpoint or 500 days, 
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whichever was sooner.  The prevalence with which they developed prostate phenotypes is 
shown in table 14. 
 
Table 14: Prevalence of disease stage seen in each mouse model at both time points.  Note 
that due to rapid progression to lethal PCa in the triple mutant (mean survival 76 days), any 
alive at 100 days were found to be ‘mosaic males’ with normal prostates and discounted.  Apart 
from wild-type males, all other genotypes that exhibited normal prostates at endpoint were 
also due to mosaicism.  See below for full explanation of mosaic male phenotype development. 
 
4.3.2 Beta-catenin and Pten single mutant mice display reduced survival, whereas Kras 
single mutant mice do not  
To investigate the potential for cooperation between the pathways of interest, an appreciation 
of the outcomes of single mutations first had to be established.  To this end, cohorts of single 
mutant mice were generated (n=12-15); heterozygous for activating mutations of β-catenin 
(PBCre4+Catnb+/lox(ex3)) or Kras (PBCre4+Kras+/V12), or homozygously-deleted PTEN 
(PBCre4+Ptenflox).  Mice were aged and sacrificed using schedule 1 methods when symptomatic 
of disease.  
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Figure 33: Kaplan-Meier survival estimates comparing normal controls vs single mutant mice.  
Note that β-catenin (PBCre4+Catnb+/lox(ex3)) and Pten (PBCre4+Ptenflox) single mutants and mice 
develop lethal prostate tumours, whereas controls (wild-type and PBCre4- mice) and Kras single 
mutant mice (PBCre4+Kras+/V12) do not.  Statistical analysis was performed in SPSS 20 (Armonk, 
NY: IBM Corp). 
 
Controls (true wild-type and PBCre4- mice) and Kras single mutants (PBCre4+Kras+/V12) mice 
were censored at the 500d endpoint as they did not succumb to PCa.  As previously reported 
(Pearson et al., 2009), Kras single mutant mice develop PIN thereby implicating Kras in the early 
stages of prostate tumourigenesis.  Therefore Kras mutants will not be discussed in further 
detail as a single mutation here.  Beta-catenin (PBCre4+Catnb+/lox(ex3)) and Pten (PBCre4+Ptenflox) 
single mutants survived to median 352 and 389 days respectively, as seen in figure 33. 
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4.3.3 Dominant, stablilised β-catenin results in progression from HGPIN to invasive 
adenocarcinoma associated with keratinised squamous metaplasia 
When compared to wild-type, β-catenin single mutant mice (PBCre4+Catnb+/lox(ex3)) develop a 
diffuse, HGPIN in all lobes of the prostate by 100 days that is associated with keratinising 
squamous metaplasia.  Lesions demonstrated nuclear atypia, with occasional apoptotic bodies, 
active mitosis, and keratin deposition.  At endpoint, lesions had progressed to bulky locally-
invasive, non-metastatic adenocarcinomas akin to human Gleason pattern 3, also with 
keratinising squamous metaplasia.  Tumours were macroscopically found to be large and solid 
in nature, with associated enlargement of bulbourethral glands (BUGs), which were also found 
to be globally infiltrated with keratinising squamous metaplasia (photographs not shown).  
Lesions from β-catenin single mutants can be seen in figure 34. 
 
Figure 34:  Dominant stabilisation of β-catenin governed by PBCre4 mimics human disease 
progression to locally-advanced PCa.  Histological analysis of formalin-fixed, paraffin-
embedded sections of prostate stained with H&E from mice aged 100 days and at endpoint.  
Early lesions (a) are comparable with human HGPIN, but with keratin formation within 
squamous metaplastic foci (inset).  Lesions are confined to the basement membrane and 
occasional apoptotic bodies are seen within (black arrow head).  When mice succumb to 
disease (b), lesions can be seen to invade the stroma (red broken lines) in gland-forming 
fashion, which is pathognomonic of Gleason pattern 3.  Tumours contain frequent mitosis (red 
arrow head), and apoptotic bodies (black arrow head), along with squamous metaplasia (not 
shown here).  Nuclei are pleomorphic and contain large, prominent nucleoli.  All images were 
taken at 40x magnification, and scale bars represent 100µm. 
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4.3.4 Homozygous loss of Pten results in progression from HGPIN to invasive 
adenocarcinoma 
When compared to wild-type, Pten single mutants (PBCre4+Ptenflox mice) develop diffuse HGPIN 
in all four prostate lobes by 100 days.  Lesions are phenotypically distinct from those seen in β-
catenin single mutants (PBCre4+Catnb+/lox(ex3)) at 100 days, in that they do not display squamous 
metaplasia.  However, Pten-deficient HGPIN displays regular mitoses and apoptotic bodies, 
along with considerable cellular atypia compared with normal prostate epithelium.  Upon loss 
of Pten at endpoint, locally-invasive, non-metastatic tumours develop, often with large dilated 
glands containing secretions.  Often mice were noted to have turbid urine prior to deterioration 
in their health.  In further contrast with β-catenin single mutants, there is no bulbourethral 
gland enlargement in Pten-deficient mice at endpoint.  The lesions that arose within the 
prostates of Pten single mutants are shown in figure 35. 
 
4.3.5 Combinatorial mutations in β-catenin and/or Kras, with/without Pten loss, accelerates 
prostate tumourigenesis to lethal locally-advanced adenocarcinoma  
When compared with single mutant mice, those bearing combinatorial oncogenic mutations 
displayed dramatically reduced survival due to PCa.  Both double and triple mutant 
combinations developed lethal high grade, locally invasive adenocarcinomas; β-catenin/Pten 
mutants (PBCre4+Catnb+/lox(ex3)Ptenflox mice) survived to 140 days; β-catenin/Kras mutants 
(PBCre4+Catnb+/lox(ex3)K-ras+/V12) survived to 251 days; Pten/Kras mutants (PBCre4+PtenfloxK-
ras+/V12) survived to 185 days; while triple mutants (PBCre4+Catnb+/lox(ex3)PtenfloxK-ras+/V12) 
survived to 76 days.  This acceleration in prostate tumourigenesis is demonstrated in figure 36. 
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Figure 35: Pten-deletion, within murine prostate, leads to adenocarcinoma when governed by 
the PBCre4 transgene.  HGPIN lesions (a) demonstrate diffuse nuclear atypia with prominent 
mitoses (red arrow heads) and the presence of protein-rich secretions (*).  Invasive 
adenocarcinoma (broken red lines) at endpoint (b) is consistent with Gleason pattern 3, with 
occasional apoptotic bodies (black arrow head).  Pten-deficient invasive adenocarcinoma (c) is 
associated with a marked fibroblastic stromal reaction as evidenced by the abundant spindle-
shaped cells with pale nuclei suggestive of myelofibroblasts (broken yellow lines); this is a 
common response to tumour (broken red line).  Tumours can be suspected clinically in Pten-null 
prostates by the presence of turbid urine (d), and tumours appear to consistently be cystic in 
nature and contain copious protein-rich secretions (e); PT prostate tumour, SV seminal vesicles, 
T testes, and U cut end of urethra.  Images a-c were taken at 40x magnification, and scale bars 
represent 100µm.  Images d-e were taken with an Olympus digital camera following necropsy 
(Olympus, Japan). 
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Figure 36: (a) Kaplan-Meier survival estimates for all cohorts of mutant mice for comparison, 
and (b) a locally-advanced lethal prostate tumour causing obstructive uropathy.  Compound 
mutant mice display reduced survival compared to single mutants and/or wild-type mice.  
Numbers of mice that died for each genotype are shown in brackets.  Compound mutants 
develop aggressive locally-advanced, non-metastatic prostate tumours from which the causes 
of death tend to be either from general tumour burden probably with significant cytokine 
release, or obstructive uropathy as in (b).  Note the distended bladder and prolapsed penile 
lesion here.  Statistical analysis was performed in SPSS 20 (Armonk, NY: IBM Corp).  Image (b) 
was taken with an Olympus digital camera following necropsy (Olympus, Japan). 
(a) 
(b) 
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No metastatic lesions were identified in the major organs of compound mutant mice, however 
all combinatorial mutants displayed reactive retroperitoneal lymphadenopathy (see figure 37). 
 
 
Figure 37: All combinatorial mutants develop reactive retroperitoneal lymphadenopathy.  
Enlarged lymph nodes were readily identifiable in the retroperitoneum, as identified by forceps 
in (a).  Histological analysis of formalin-fixed, paraffin-embedded sections of lymph nodes 
stained with H&E was performed (b and c).  Normal lymph nodes possess two zones: the cortex 
and medulla.  Here (b) the medulla displays discrete germoid centres and prominent lymphoid 
follicles within.  Peripheral sinuses are evident in the cortex (not shown).  By comparison, 
enlarged lymph nodes from compound mutant mice (c) are seen to demonstrate loss of nodular 
architecture and cortico-medullary differentiation.  The node is infiltrated with a mixed 
population of small and large lymphocytes, with an appearance similar to that of human 
lymphoma.  Image (a) was taken with an Olympus digital camera following necropsy (Olympus, 
Japan), while images (b) and (c) were taken at 40x magnification, and scale bars represent 
100µm. 
 
4.3.6 Double and triple mutant mice model rapid disease progression from HGPIN to high-
grade prostate cancer 
At the 100 day time point, all double mutant mice display either HGPIN or a combination of 
early/low-volume invasive carcinoma of high-grade (see figure 38) with HGPIN.  Here HGPIN is 
the most prevalent lesion at 100 days regardless of genotype.  By endpoint, mice develop 
locally-advanced high-grade adenocarcinomas analogous to Gleason pattern 4 in the human. 
It is worthy of not that all prostate lesions, whether HGPIN or invasive adenocarcinoma, contain 
keratinised squamous metaplasia if their genotype contains a dominant stabilising mutation of 
β-catenin.  This can be seen from the photographs in figure 38. 
 
113 | P a g e  
 
 
Figure 38: Double mutation of β-catenin and/or Kras, with/without Pten loss promotes the 
promotes the progression to high grade PCa from HGPIN.  Histological analysis of formalin-
fixed, paraffin-embedded sections of prostate stained with H&E from mice aged 100 days and 
at endpoint.  At 100 days double mutant mice display a large volume of HGPIN (see a, d, g) with 
evidence of focal invasive PCa (see b, e, h); broken red/yellow lines highlight early but high-
grade, invasive adenocarcinoma. HGPIN demonstrates obvious nuclear atypia that fills duct 
lumens with cribriform patterning (best seen in a, and g), and occasional apoptotic bodies 
(black arrowheads) and mitoses (red arrowheads).  Such is the bulk of HGPIN here that there is 
bulging with surrounding stromal distortion.  At endpoint (see images c, f, and i), high-grade PCa 
has no demonstrable glandular architecture due to gland fusion; instead there are irregular 
nests of cells in cribriform arrangement or sheets of pleomorphic carcinoma cells with 
prominent hyperchromatic nucleoli, increased angiogenesis, and frequent mitoses and 
apoptotic bodies.   All images were taken at 40x magnification, and scale bars represent 100µm. 
 
Prostate tumours that arose in triple mutant mice (PBCre4+Catnb+/lox(ex3)PtenfloxK-ras+/V12) can 
likewise be seen to be bulky, locally-advanced, and high-grade.   It is important to note that 
because triple mutant mice survive to median 76 days, none survived to the 100 day time point.  
Thus no PIN was analysed in these mice.  Characterisation of triple mutant tumours is described 
in figure 39. 
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Figure 39: Mutations in all three alleles synergistically promotes the rapid development of 
high-grade adenocarcinoma.  Note that these tumours contain discreet pockets of keratinising 
squamous metaplasia (a).  The tumours formed are morphologically similar to human Gleason 
pattern 4 (b) in that there are irregular nests of cells in cribriform arrangement with occluded 
gland lumens, and pleomorphic cells with prominent hyperchromatic nucleoli.  All images were 
taken at 40x magnification, and scale bars represent 100µm. 
 
4.3.7 The probasin-Cre transgene exhibits mosaic genetic deletion when transmitted 
maternally 
When transmitted paternally, probasin-Cre (PBCre4) is expressed exclusively in the male 
prostate epithelium, leading to intended prostate-specific phenotypes.  However it was noted 
that when transmitted maternally, recombination of loxP-flanked alleles arose in a variety of 
tissues in both male and female offspring, termed “mosaic” recombination.  The effects of 
mosaic PBCre4 activity can be seen in the survival cohorts (as shown in figure 40) leading to 
adversely prolonged survival in all genotypes.  The effect on the prostate phenotype was 
similarly unreliable as outlined in table 14. 
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Figure 40:  Kaplan-Meier curves demonstrate the effect of pronged survival in all cohorts 
when PBCre4 is transmitted maternally.  Upon closer inspection the PBCre4 transgene was 
functioning incorrectly, and so all mosaic males were censored from final survival analyses, 
dramatically reducing the size of some most cohorts; the result of this can be seen in figure 
36(a).  Statistical analysis was performed in SPSS 20 (Armonk, NY: IBM Corp).   
 
Given that there was substantial variation between the prostate tumours observed compared 
with those expected, a Chi-square cross tabulation analysis was performed as shown in figure 
41.  This ultimately supported the hypothesis that the PBCre4 transgene is not transmitted 
equally between parents (χ2 = 39.37, p<0.001).  Taken together these data suggest that 
paternally inherited loxP-flanked alleles are inefficiently recombined by maternal PBCre4, giving 
rise to mosaic expression patterns in the offspring.  These findings have since been 
corroborated (Birbach, 2013). 
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Figure 41: Chi-square cross-tabulation analysis to determine whether or not the PBCre4 
transgene is equally transmitted both maternally and paternally.  Pairings that resulted in 
prostate tumours were compared with those that led to absent prostate tumourigenesis and/or 
unwanted phenotypes.  From the original 111 mice allocated to 8 cohorts, 39 were excluded 
from the Chi-square test; 15 were wild-type, 13 Kras, 1 mouse was lost to follow-up, and 10 
were found dead with no cause.    Analysis was performed in SPSS 20 (Armonk, NY: IBM Corp). 
 
No evidence of tumourigenesis was visible within the prostate of mosaic males (photographs 
not shown).  However, some male mice developed rapidly-growing tumours from within the 
mammary gland which attenuated their survival.  Photographs of mosaic male mammary 
tumours are shown in figure 42. 
 
Figure 42: Maternal transmission of the PBCre4 transgene leads to unwanted lymphoid 
phenotypes in male offspring.  In the absence of prostate tumourigenesis, rapid enlargement 
of mammary gland lymph nodes can be detected when assessing the health of mosaic males.  
Upon histological analysis of formalin-fixed, paraffin-embedded sections, it can be seen that 
lymph nodes (a) and (b) are flooded with a mixed population of small and large lymphocytes.  
The mammary wholemount photograph (c) demonstrates the location of the central lymph 
node within the gland that stained with Xgal, whereas staining is absent from the ducts.  Images 
(a) and (b) were taken at 40x magnification, and scale bars represent 100µm.  Image (c) was 
taken with an Olympus digital camera (Olympus, Japan). 
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4.3.8 Progression of prostate tumourigenesis in these mouse models correlates with Ki67 
expression  
Ki67 is a marker of cellular proliferation; it is present during all active phases of the cell cycle 
(G1, S, G2, and mitosis), but absent from resting cells (G0).  Figure 43 demonstrates proliferation 
within murine prostate tumours of various stages. 
 
Figure 43: Immunohistochemistry to detect cellular proliferation by Ki67 expression in 
prostate lesions.  It can be seen from IHC that Ki67 staining is rare in normal wild-type 
epithelium (a).  In both low-grade (b), and high-grade PIN (c), cells nearer the basement 
membrane stain avidly for Ki67.  In both low-grade (d) and high-grade adenocarcinoma (e), the 
distribution of Ki67+ cells is more random, with the greatest level of expression being in the 
high-grade tumours.  The percentage of Ki67+ prostate epithelial cells were scored for PIN and 
adenocarcinomas of each genotype (f), n=3 mice.  Columns depict median, while error bars 
represent SD; statistical analysis was carried out using the non-parametric Mann-Whitney U 
test, p<0.05 (95% confidence interval).  Analysis was performed in SPSS 20 (Armonk, NY: IBM 
Corp). 
 
It can be seen in figure 43(a) that physiological levels of Ki67 expression in wild-type mice are 
low, with little change between 100 days (light blue – PIN) and the 500 day endpoint (dark blue 
– tumour) seen in 43(f).  Expression levels are increased significantly in PIN lesions of all 
genotypes compared to wild-type, see 43(b), (c), and (f).  Moreover, upon progression from PIN 
to adenocarcinoma there is further elevation in Ki67 expression among all genotypes.  As seen 
in figure 43(d), and (e), Ki67 also appears to correlate with adenocarcinoma grade: high grade 
adenocarcinoma (from double and triple mutants) reveals a significantly greater level of Ki67 
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expression than low-grade adenocarcinoma (in single mutant tumours), p=0.011.  Triple mutant 
tumours express significantly more Ki67 than single β-catenin (p=0.0404, Mann Whitney U test, 
n=3) and PTEN (p=0.404, n=3) mutants but not more than double mutant combinations.  This 
suggests that Ki67 correlates with tumour grade. 
4.3.9 Progression of prostate tumourigenesis in these mouse models correlates with AR 
expression  
AR is expressed by differentiated luminal epithelial cells that appear to comprose the tumour 
bulk.  This is highlighted in figure 44. 
 
Figure 44: Immunohistochemistry to detect AR expression in prostate lesions.  It can be seen 
from IHC that AR staining is infrequent in normal wild-type epithelium (a).  In both low-grade 
(b), and high-grade PIN (c), cells located centrally stain avidly for AR, while thos located basally 
are relatively spared.  The level of AR positivity increases from low-grade (d) to high-grade 
adenocarcinoma (e).  The percentage of AR+ prostate epithelial cells were scored for PIN and 
adenocarcinomas of each genotype (f), n=3.  Columns depict median, while error bars represent 
SD; statistical analysis was carried out using the non-parametric Mann-Whitney U test, p<0.05 
(95% confidence interval).  Analysis was performed in SPSS 20 (Armonk, NY: IBM Corp). 
 
Baseline levels of AR expressed in wild-type prostate on IHC are low, as seen in figure 44(a).  
These levels are significantly increased in PIN across all genotypes which does not statistically 
differ between them (Mann-Whitney U test, n=3 mice), as seen in 44(b), (c), and (f).  
Furthermore it can be seen in figure 44(f) that disease progression in β-catenin and PTEN single 
mutants causes a non-significant rise in AR expression, whereas disease progression in double 
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mutants from PIN to high-grade adenocarcinoma is associated with a significantly elevated rate 
of AR expression (p=0.0404 for all combinations).  Triple mutant tumours revealed a non-
significant decrease in level of AR expression compared to double mutants, possibly reflecting 
their androgen-independent state.  AR also appears to correlate positively with tumour grade 
given that level of AR expression is significantly greater in combinatorial mutants (high-grade 
adenocarcinoma, n=12) compared with single mutants (low-grade adenocarcinoma, n=6), 
p=0.001, Mann-Whitney U test. 
4.3.10  Progression of prostate tumourigenesis in these mouse models negatively correlates 
with p63 expression  
Tumour protein p63 is a member of the tumour-suppressor p53 gene family, and is expressed 
by basal cells in both human and mouse prostate.  The levels of p63 expression seen in prostate 
lesions are evident in figure 45. 
 
Figure 45: Immunohistochemistry to detect p63 expression in prostate lesions.  It can be seen 
from IHC that p63 reliably stains basal cells in normal wild-type epithelium (a).  In both low-
grade (b), and high-grade PIN (c), there is an upsurge in p63+ cells but the overall percentage 
decreases due to a greater proliferation of p63- (luminal) cells.  In low-grade adenocarcinoma 
(d), invasive disease lacks p63 expression, which is further corroborated in high-grade 
adenocarcinoma (e).  The percentage of p63+ prostate epithelial cells were scored for PIN and 
adenocarcinomas of each genotype (f), n=3.  Columns depict median, while error bars represent 
SD; statistical analysis was carried out using the non-parametric Mann-Whitney test, p<0.05 
(95% confidence interval).  Analysis was performed in SPSS 20 (Armonk, NY: IBM Corp). 
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Physiological levels of p63 expression range from 10 to 15% in wild-type mice.  Universally in 
murine PIN the rate of p63 positivity appears to drop non-significantly to between 5 and 8% 
across all genotypes; this can be seen in figure 45(e).  Progression from PIN to adenocarcinoma 
negatively correlates with p63 expression for all genotypes individually (p=0.0404 except 
Pten/Kras double mutants, p=0.05) and when all PIN lesions (n=15) are compared with 
adenocarcinoma (n=18), p<0.001.  The absence of p63 staining is a hallmark of prostate cancer 
in humans.  Beta-catenin/Kras double mutants and triple mutants do not express p63, perhaps 
reflecting greater differentiation into p63- luminal cells.  However adenocarcinomas of other 
genotypes express p63 at low level.  In mice, basal cell markers can be retained by cancer cells 
so the presence of such staining does not exclude PCa (Ittmann et al., 2013).  Likewise complete 
loss of p63 in a focus that is histologically compatible with prostate cancer supports this 
diagnosis. 
 
4.3.11   Caspase-3 staining correlates with the number of pathways activated and disease 
progression, but not tumour grade 
Caspase-3 is an antigen expressed by cells undergoing apoptosis.  An alternative method of 
quantifying apoptosis would be to count apoptotic bodies after H&E staining.  One 
disadvantage of this latter technique is that usually only end-stage apoptotic cells can be 
observed; pre-apoptotic cells are very difficult to detect unless caspase-3 is utilised (Eckle et al., 
2004).  In addition, counting apoptotic bodies after H&E staining is both time-consuming and 
more prone to bias.  Demonstration of the Caspase-3 expression patterns in both normal 
murine prostate and tumour is provided in figure 46. 
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Figure 46: Immunohistochemistry to detect for the presence of apoptotic bodies by Caspase-3 
expression in prostate lesions.  It can be seen from IHC that apoptosis in normal wild-type 
prostate epithelium is uncommon (a).  In both low-grade (b), and high-grade PIN (c), caspase-3+ 
cells are notably more prevalent, but there is little difference according to the severity of PIN.  
Apoptosis occurs more regularly in adenocarcinoma than PIN but this is not dose dependent 
when comparing low-grade adenocarcinoma (d), with high-grade disease (e).  The percentage of 
caspase-3+ apoptotic cells were scored for PIN and adenocarcinomas of each genotype (f), n=3 
mice.  Columns depict median, while error bars represent SD; statistical analysis was carried out 
using the non-parametric Mann-Whitney test, p<0.05 (95% confidence interval).  Analysis was 
performed in SPSS 20 (Armonk, NY: IBM Corp). 
 
When all three pathways are activated in the triple mutant (n=3), caspase-3 expression levels 
were significantly increased compared with double (p=0.013, n=9), or single pathway activation 
(p=0.020, n=6).  The rate of apoptosis also correlated with disease progression from PIN (n=18) 
to adenocarcinoma (p=0.003, n=15) across all genotypes.  However the increased level of 
apoptosis observed between low-grade (n=6) and high-grade (n=12) adenocarcinoma as per 
caspase-3 positivity was not significant (p=0.349), shown in figure 46(f). 
 
4.3.12   The pattern of expression of cytokeratins corroborates the expression of AR and p63 
in each stage of prostate tumourigenesis 
Upon the stepwise progression from normal prostate to PIN to invasive adenocarcinoma, a 
progressively more luminal phenotype develops, reflecting the human disease.  Cytokeratins 
(CK) 8 and CK18 are markers of differentiated luminal epithelial cells, while CK5 and CK14 stain 
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undifferentiated basal cells.  Figure 47 highlights this change, which further supports the 
findings of figures 44 and 45, wherein AR expression was upregulated and p63 downregulated 
in parallel with disease progression respectively, confirming a tendency towards luminal 
differentiation. 
 
Figure 47: Immunohistochemistry for cytokeratins enables further characterisation of 
prostate lesions.  Histological analysis of formalin-fixed, paraffin-embedded sections of wild-
type, PIN, and invasive adenocarcinoma was performed to assess differentiation.  It can be seen 
that upon progression from normal prostate to invasive disease there is over-expression of CK8 
and 18, clearly highlighting the proliferation of terminally differentiated luminal cells.  
Conversely there is a trend towards loss of the basal undifferentiated phenotype, but note the 
increase in the number of CK5 and 14+ cells in both PIN lesions, prior to a clear reduction in 
basal cells in invasive adenocarcinoma.  Also note the high background staining in the CK5 WT, 
CK14 PIN, and CK14 invasive adenocarcinoma photographs.  All images were taken at 40x 
magnification, and scale bars represent 100µm. 
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4.3.13   Beta-catenin single mutant mice display simultaneous activation of the Wnt, 
PI3K/Akt/mTOR, and MAPK pathways 
As expected (and demonstrated in figure 48.1) β-catenin single mutant mice were shown to 
activate the Wnt pathway; recognisable by over-expression of nuclear β-catenin (48.1(c)) and its 
downstream counterpart CD44 (48.1(d)) when compared to wild-type (48.1(a)) and (48.1(b)).  
Surprisingly, dominant stabilised β-catenin, resulting in its constitutive activation, appears to 
demonstrate concurrent over-expression of proteins from both the PI3K/Akt/mTOR (48.2(h-j) 
and (n-p)), and MAPK pathways (48.3(s&t)).  This suggests that there is synergy between these 
pathways in prostate tumourigenesis.   
 
 
Figure 48.1: Beta-catenin single mutant prostate tumours demonstrate activated Wnt 
signalling.  IHC to detect nuclear β-catenin and CD44 was performed, which indicates 
deregulation of the Wnt pathway in β-catenin single mutants (PBCre4+Catnb+/lox(ex3)).  Wild-type 
β-catenin (a) exhibits membranous localisation, whereas activated β-catenin, resulting from the 
monoallelic deletion of exon 3 and its subsequent stabilisation, is recognisable by nuclear 
localisation (c).  CD44+ cells are rare in wild-type epithelium (b), but over-expression of CD44 
demonstrates strong membranous localisation (d).  All images were taken at 40x magnification, 
and scale bars represent 100µm. 
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Figure 48.2: Beta-catenin single mutant prostate tumours demonstrate activated 
PI3K/Akt/mTOR signalling.  IHC to detect Pten and its downstream targets was performed, 
which indicates deregulation of the PI3K/Akt/mTOR pathway in β-catenin single mutant mice 
(PBCre4+Catnb+/lox(ex3)).  Despite intact Pten (h), p-Akt is over expressed with cytoplasmic 
localisation (i and j), in addition to p-mTOR (n), and downstream p-RpS6 (o and p) suggesting β-
catenin-dependent activation of the PI3K/Akt/mTOR pathways. All images were taken at 40x 
magnification, and scale bars represent 100µm. 
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Figure 48.3: Beta-catenin single mutant prostate tumours demonstrate activated Ras/MAPK 
signalling.  Compared to wild-type mice where there is little expression of activated Mek (q) and 
Erk (r), dominant, stabilised β-catenin results in over-expression of these important Ras/MAPK 
signalling proteins in cytoplasmic and cytoplasmic/nuclear fashion respectively.  All images were 
taken at 40x magnification, and scale bars represent 100µm. 
 
4.3.14   PTEN single mutant mice display simultaneous activation of the Wnt, 
PI3K/Akt/mTOR, and MAPK pathways 
Upon homozygous loss of PTEN, as anticipated, there is confirmatory loss of Pten expression at 
IHC (see figure 49.1(d)) with concurrent over-expression of its downstream counterparts p-Akt 
(49.1(e&f)), and p-mTOR (49.1(j)).  There is also evidence of activated MAPK signalling as shown 
by the upregulation of Mek and Erk expression (see figure 49.2(o&p)). 
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Figure 49.1: PTEN-null prostate tumours demonstrate activated PI3K/Akt/mTOR signalling.  
IHC to detect Pten and its downstream targets was performed, which indicates deregulation of 
the PI3K/Akt/mTOR pathway in Pten-null prostate lesions.  Upon loss of Pten (d), a negative 
regulator of the PI3K/Akt/mTOR pathway, p-Akt is dramatically over expressed (e and f), in both 
a nuclear and cytoplasmic fashion.  This is in contrast to the solely cytoplasmic staining seen in 
β-catenin mutants (see figure 48.2(i) and (j)).  Expression of p-mTOR (j) and p-RpS6 (k and l) are 
also increased to further add weight to this notion. Note that IHC for p-RpS6Ser240-244 (i and j) 
displays significant background signal.  All images were taken at 40x magnification, and scale 
bars represent 100µm. 
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Figure 49.2 PTEN-null prostate tumours demonstrate activated Ras/MAPK signalling.  
Compared to wild-type mice, where there is little evidence of activated Mek and Erk (m and n 
respectively), PTEN single mutant mice display up-regulation of Ras/MAPK pathway signalling 
proteins in both cytoplasmic and cytoplasmic/nuclear expression respectively.  Pten-loss-
dependent Ras/MAPK pathway activation is most likely to occur through the metabolically-
active p-Akt, but substantiation of this claim requires further investigation.  All images were 
taken at 40x magnification, and scale bars represent 100µm.  
 
 
It can also be seen in figure 49.3 that Pten loss results in elevated Wnt signalling, by the 
upregulation of nuclear β-catenin (49.3(s)) and CD44 (49.3(t)).   
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Figure 49.3: PTEN-null prostate tumours may demonstrate activated Wnt signalling.  IHC to 
detect nuclear β-catenin and CD44 was performed, which suggests deregulation of the Wnt 
pathway in Pten-null prostate lesions.  Wild-type β-catenin expression (q) is exhibited in the 
localised disease in (s), but the focus of invasive PCa (inset) clearly exhibits nuclear localisation 
to suggest Wnt activation.  This is supported by over-expression of its downstream 
transcriptional target CD44 in (t).  All images were taken at 40x magnification, and scale bars 
represent 100µm.  
 
Taken together, data in this thesis suggest that in the presence of Pten loss, crosstalk between 
the three pathways is mediated by a molecule downstream of Pten, such as p-Akt, or mTOR.  
However it remains unconfirmed whether or not Pten deletion truly results in over-expression 
of β-catenin because findings at IHC were inconsistent in this thesis.  Two out of three (66%) 
tumours appeared to demonstrate upregulation of nuclear (activated) β-catenin, whereas the 
other displayed membranous (wild-type) staining.  Furthermore there was even heterogeneity 
within individual tumours, and examples of intra-tumour variability are shown in figure 50. 
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Figure 50: PTEN-null prostate tumours display intra-tumoural heterogeneity for nuclear β-
catenin expression.  It can be seen that there is evidence of variable staining for nuclear β-
catenin within the same tumours from Pten single mutants (compare tumours 1 and 2 above).  
Whether or not Pten loss truly results in synergistic activation of nuclear β-catenin should be 
explored further using PCR and/or western blot analysis.  This may only be accurately addressed 
by the use of laser-capture microdissection to select areas for comparison within the same 
tumour if expression of nuclear β-catenin remains heterogeneous in ongoing experiments.  All 
images were taken at 40x magnification, and scale bars represent 100µm.  
 
4.3.15   Activated Wnt, PI3K/AKt/mTOR and Ras/MAPK pathways synergise to accelerate 
prostate cancer progression 
It was hypothesised that simultaneous oncogenic transformation of the Wnt, PI3K/Akt/mTOR, 
and/or the MAPK pathways would result in synergistic hyperactivation of their downstream 
transcriptional targets. To address this, IHC was performed on all double and triple mutant 
combinations to compare the expression of important molecules within each signalling pathway 
of interest.  The fact that survival is reduced upon deregulation of more than one pathway 
suggests there is cooperation between these signalling pathways resulting in accelerated 
prostate tumourigenesis.   
In this section, figures 51(a) and (b) demonstrate the synergistic outcomes identified at IHC.
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Figure 51(a): Immunohistochemistry in compound mutant prostate tumours. Images were taken at 40x magnification, scale bars represent 100µm. 
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Figure 51(b): Immunohistochemistry in compound mutant prostate tumours.  All images were taken at 40x magnification, and scale bars represent 100µm. 
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Beta-catenin/PTEN double mutants (PBCre4+Catnb+/lox(ex3)Ptenflox) develop higher grade 
PCa than either of its component single mutants (see figure 36).  Nuclear localisation of β-
catenin (figure 51(a), A1) and elevated levels of its downstream transcriptional target CD44 (A2) 
confirm that activation of the Wnt pathway is contributory to these invasive carcinomas.  
Likewise over-expression of p-Akt (A6&7) and p-RpS6 (A9&10) confirm that PI3K/Akt/mTOR 
signalling is enhanced.  Furthermore these lesions unexpectedly demonstrated elevated 
expression of p-Mek1/2 and p-Erk1/2 (A3-A4).  These activated proteins suggest that Ras/MAPK 
signalling has also been switched on by Wnt and PI3K/Akt/mTOR cooperation. 
In β-catenin/Kras double mutant mice (PBCre4+Catnb+/lox(ex3)K-ras+/V12) there is 
confirmatory over-expression of activated Wnt signals nuclear β-catenin and CD44 (B1-B2).  
There is also activation of the MAPK cascade through upregulation of p-Mek and p-Erk, albeit at 
a lower intensity than seen in Beta-catenin/PTEN double mutants 
(PBCre4+Catnb+/lox(ex3)Ptenflox mice).  Interestingly there was retained staining of the Pten 
antigen (a negative regulator of Akt), alongside p-Akt staining that was upregulated at Thr308 
but absent at Ser473.  Expression of mTOR was suppressed in the presence of upregulated 
downstream p-RpS6.  This supports synergistic Wnt and MAPK-dependent PI3K/Akt signalling 
that serves to activate Akt (at Thr308) independent of mTOR.  See chapter discussion for 
explanation of this mechanism. 
PTEN/Kras double mutant mice (PBCre4+PtenfloxK-ras+/V12) display co-activation of all three 
pathways.  Firstly Mek and Erk are greatly over-expressed signifying active Ras/MAPK signalling 
(C3-C4).  Secondly, while there is up-regulation of PI3K/Akt/mTOR signalling (C6-C10), there also 
appears to be some residual nuclear Pten expression (C5) of either irregular invasive carcinoma 
cells or stromal cells.   
When analysing the staining pattern of the triple mutant mouse 
(PBCre4+Catnb+/lox(ex3)PtenfloxK-ras+/V12), it can be seen that there is activation of all 
pathways, but some molecules are not as strongly over-expressed as might have been 
expected.  For example, Mek and Erk signalling is somewhat suppressed at IHC in the triple 
mutant, whereas Wnt signalling is greatly overexpressed.   
A summary of the expression profile identified at IHC for each genotype is provided in table 15. 
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Table 15: A summary of the expression profile for each tumour genotype at 
immunohistochemistry.  Legend: - absent staining; -/+ heterogeneous expression with areas of 
absent and positive staining; + universally low level of expression; +/++ heterogeneous 
expression with areas of both low and high staining intensity; ++ high or intense level of 
expression; n=3 for each genotype analysed. 
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4.4 CHAPTER CONCLUSION 
4.4.1 Dominant, stabilisation of β-catenin in murine prostate epithelium predisposes to 
adenocarcinoma and keratinising squamous metaplasia formation 
Given that aberrant Wnt signalling has been identified as having a role in prostate 
tumourigenesis, this thesis aimed to investigate the consequences of mutating β-catenin alone 
and in combination with mutations in other key pathways identified as also playing important 
roles in the human disease.  A conditional transgenic mouse model was created leading to the 
dominant stabilisation of β-catenin in prostate epithelium that resulted in oncogenic 
transformation.  Male mice demonstrated reduced longevity due to overwhelming tumour 
burden, in the absence of metastatic disease (median 352 days).  Tumours were characterised 
by the upregulation of activated β-catenin, which localised to the nucleus, and subsequent 
over-expression of its downstream transcriptional target, CD44.  These results support previous 
work using the PBCre4 transgene model (Pearson et al., 2009), however these findings are 
disputed by others who claim that β-catenin single mutants (PBCre4+Catnb+/lox(ex3) mice) at 
worst develop PIN (Yu et al., 2009, Francis et al., 2013).  Regardless of this understandably 
subjective staging, the use of transgenes under the influence of other promoters have further 
supported the notion that dominant, stabilisation of β-catenin plays an important role in 
progression from PIN to invasive adenocarcinoma (Gounari et al., 2002, Bierie et al., 2003, Yu et 
al., 2011), using MMTV-Cre (Cre transgene under control of the mouse mammary tumour virus), 
MMTV-LTR-Cre (Cre transgene under control of the mouse mammary tumour virus-long 
terminal repeat), and LPB-Tag (large probasin promoter directed SV40-large T-antigen) 
respectively. 
Even though squamous metaplasia is rarely associated with human PCa, monoallelic deletion of 
exon 3 and subsequent stabilisation of β-catenin results in the prominent development of 
keratinising squamous metaplasia.  This finding has been widely reported in mouse models of 
prostate tumourigenesis, therefore in the human disease it is hypothesised that other events 
need to take place to allow β-catenin to drive disease progression without squamous formation.  
These events are yet to be identified or modelled in the mouse.  It has been shown in the 
present study that even when combined with other mutations, an intrinsic property of high 
levels of activated β-catenin drives squamous transdifferentiation (Francis et al., 2013). 
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The mechanisms by which activated β-catenin co-activates both the PI3K/Akt/mTOR and 
Ras/MAPK pathways are poorly reported in the literature, and remain unclear following work in 
this thesis.  Βeta-catenin-dependent activation of PI3K/Akt/mTOR signalling may result from the 
upregulation of Wnt effectors c-myc and cyclinD1, both of which are capable of triggering the 
cell cycle and metabolic reprogramming (see figure 52).  The metabolic activation in cancer cells 
leads to the production of reaction oxygen species (ROS), which activate the forkhead box 
protein O (FoxO), responsible for carbohydrate metabolism by insulin signalling.  FoxO is the 
transcription factor of RICTOR, one of the key components of mTORC2 recognised as the kinase 
that phosphorylates Akt on Ser473 (Vadlakonda et al., 2013).  This may result in elevated 
PI3K/AKT/mTOR signalling at, or downstream of, p-Akt.  This hypothesis could be addressed 
with further IHC for other Wnt effectors such as c-myc, cyclinD1, MMP-7, Foxa1, and COX-2, 
along with qRT-PCR and western blotting for the respective molecules. 
 
Figure 52: A schematic representation of the synergy that results in Wnt-dependent 
activation of PI3K/Akt/mTOR pathway.  Note that broken green lines represent hypothesised 
cooperation, whereas black lines represent known activation, and red lines depict inhibition.  
Adapted from Vadlakonda et al. (2013). 
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Previous studies have linked Wnt pathway activation to increased MAPK signalling in colorectal 
cancer cell lines and Cre-virus-induced Apc knockout in primary Apcflox/flox mouse embryonic 
fibroblasts (Park et al., 2006), and in NIH3T3 fibroblast cells transfected with either murine β-
catenin or Erk1 siRNA (Yun et al., 2005).  The former study concluded that MAPK activation by 
β-catenin was reduced by co-expression of APC, indicating that APC inhibits the ERK pathway by 
an action on β-catenin.  RAS-induced activation of the MAPK pathway was reduced by the 
dominant negative form of Tcf4, indicating that the MAPK pathway regulation by Wnt signalling 
is caused by effects on β-catenin/Tcf4-mediated gene expression (Park et al., 2006).  The latter 
study suggests that MAPK pathway activation by Wnt signalling could occur at multiple levels.  
These include β-catenin-independent direct signalling resulting from increased Wnt 3a ligand 
levels, and β-catenin/Tcf-4-dependent post-gene transcriptional events (Yun et al., 2005).  
Given that Wnt ligand 3a is not over-expressed in the dominant, stablilised β-catenin model 
used in this thesis (PBCre4+Catnb+/lox(ex3) mice), a post-transcriptional point of synergy is 
more likely.  This synergistic interaction is demonstrated in figure 53.  These findings are 
contrary to previous results (Pearson et al., 2009), whereby activated MAPK signalling proteins 
p-Mek1/2 and p-Erk1/2 were expressed at wild-type levels in β-catenin single mutant prostate 
tumours. 
It is known that exogenous oestrogen promotes the formation of squamous metaplasia in male 
mice by inducing aberrant proliferation in the basal layer (Risbridger et al., 2001), and this is 
usually reversible upon its removal (Cunha et al., 2004).  Two oestrogen receptors (ERs) have 
been identified in existence, ERα and ERβ, which are predominantly expressed in the prostatic 
stroma and epithelium respectively (Chang and Prins, 1999), while induction of prostatic 
squamous metaplasia is mediated through the former (Cunha et al., 2004).  In the murine 
uterus, ER signalling has been linked to elevated Wnt signalling by the upregulation of Wnt 
ligands, and Wnt receptors that collectively promote uterine growth (Hou et al., 2004).  Taken 
together the evidence suggests that the keratinising squamous metaplasia exhibited in β-
catenin mutant mice (PBCre4+Catnb+/lox(ex3)) may be the result of disruption in the homeostatic 
mechanisms that control AR and ER signalling in prostate epithelium (Risbridger et al., 2007). 
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Figure 53: A schematic representation of the mechanism by which Wnt signalling may 
synergise with the Ras/MAPK pathway.  A β-catenin/Tcf-4-dependent post-transcriptional 
event is the likely trigger for cooperation with the Ras/MAPK pathway, but the level at which 
this occurs in the latter is unknown.  Ras/MAPK signalling may also result from binding Wnt 
ligand.  Broken green lines represent hypothesised cooperation, whereas black lines represent 
known activation, and red lines depict inhibition. 
 
Accepting that ERα signalling stimulates proliferation of basal cells, intuitively these cells 
express p63.  Ectopic expression of p63 resulted in squamous metaplasia transdifferentiation in 
an inducible transgenic mouse model of lung tumourigenesis (Romano et al., 2009).  
Furthermore, elevated expression of p63 has been associated with the early stages of 
squamous cell carcinoma (SCC) and β-catenin has been shown to regulate this protein in 
oesophageal SCC (Hu et al., 2002) and HCC (Ruptier et al., 2011).  One study claims that 
dominant, stabilised β-catenin induces high levels of p63 to drive the transdifferentiation 
process towards a squamous fate (Francis et al., 2013), however there is evidence to both 
support and refute this.  Beta-catenin/Kras mutants (PBCre4+Catnb+/lox(ex3)Kras+/V12) 
examined in this thesis had no demonstrable p63 expression at IHC, in the presence of small 
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foci of squamous metaplasia (as shown in figure 38).  One paper reported that these tumours 
do not display squamous metaplasia (Pearson et al., 2009).  In addition, tumours in β-catenin 
single mutants (PBCre4+Catnb+/lox(ex3)) express very low levels of p63 but contain copious 
keratinising squamous metaplasia.  Moreover triple mutant mice display abundant squamous 
metaplasia but very little p63 expression.  In contrast, β-catenin/PTEN double mutants 
(PBCre4+Catnb+/lox(ex3)Ptenflox mice) display increased expression of p63 in metaplastic foci 
but at levels lower than wild-type due to the concurrent increased number of luminal p63- cells.  
In light of these conflicting views future analysis of tumours from mice entered into these 
aforementioned survival cohorts should seek to clarify the association of p63 and the presence 
of squamous metaplasia. 
4.4.2 Homozygous loss of PTEN predisposes mice to invasive adenocarcinoma of the 
prostate 
Pten-deficient prostate tumours were non-metastatic in contrast to findings by others (Wang et 
al., 2003), however they were consistent with locally-advanced adenocarcinoma.  Reasons to 
account for this discrepancy could include the different genetic background of mice, and the 
use in outbred rather than inbred mice in this thesis, and/or contaminated surroundings leading 
to poorer health status and predisposition to infection.  Mice displayed reduced median survival 
due to tumour burden at 359 days.  Tumours were characterised by the expected over-
expression of the PI3K/AKt/mTOR signalling but the unexpected over-expression of the Wnt, 
and MAPK signalling cascades.  It is interesting to note that the pattern of p-Akt expression in 
PTEN-null prostate tumours was both nuclear and cytoplasmic, in contrast with cytoplasmic 
only staining in β-catenin mutant mice.  In thyroid cancer (Vasko et al., 2004) and non-small cell 
lung cancer (Shah et al., 2005), nuclear-localisation of p-Akt was a feature of poor prognostic 
outcome.  Meanwhile in PCa, it has been demonstrated that the degree of nuclear p-Akt 
increased according to disease progression (Van de Sande et al., 2005).  Furthermore, the 
extent of Akt nuclear localisation correlated with the Gleason grade, the most powerful 
predictor of disease progression after RRP (Montironi et al., 2005).  This observation suggested 
that nuclear Akt could be used as biomarker for PCa prognosis.  Additional signs of 
PI3K/Akt/mTOR signalling were highlighted in this thesis by the over-expression of p-mTOR, and 
its downstream substrate p-RpS6 (see figure 49.1). 
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In the present study, PTEN-null PCa demonstrated evidence for activation of Wnt signalling by 
the upregulation of nuclear β-catenin, and its downstream transcriptional target CD44, albeit in 
heterogeneous fashion.  However, not all Pten-null tumours reviewed demonstrated nuclear 
localisation of β-catenin, which could be attributable to inconsistent fixation times in formalin 
resulting in variable antigen preservation or truly heterogeneous expression.  Further work 
needs to be done to confirm the cellular localisation of β-catenin in PTEN-null prostate tumours, 
along with complimentary IHC of other downstream post-transcriptional targets, such as c-myc, 
cyclinD1, MMP-7, Foxa1, and COX-2.  Analysis of these tumours by qRT-PCR and/or western 
blotting should be interpreted carefully because of the regional variation in antigen expression 
possibly reflecting heterogeneous recombination.  To better understand the mechanism that 
underpins PTEN-loss-mediated Wnt signalling, a technique such as laser-capture 
microdissection to isolate areas of nuclear (activated) β-catenin localisation for comparison 
with areas of membranous (wild-type) localisation in PBCre4+Ptenflox tumours would be 
helpful. 
Deletion of PTEN activates the PI3K/Akt/mTOR pathway, which in turn inhibits GSK3β through 
phosphorylation at Ser9 by p-Akt (Mulholland et al., 2006).  As such it is widely accepted that 
inactivated GSK3β results in a disabled ubiquitination complex and aberrant translocation of β-
catenin to the nucleus occurs (Kypta and Waxman, 2012).  This is schematically demonstrated in 
figure 54.  Studies in PCa cell lines support this notion (Persad et al., 2001, Sharma et al., 2002) 
but the belief is not universally held.  It has been reported in another study that utilised PC3 
PCa cells, that the axin-bound pool of GSK3β was distinct and protected from the pool activated 
by Akt (Ng et al., 2009).  Also ‘knock-in’ mice in which the Akt inactivating-phosphorylation sites 
on both GSK3α (Ser21) and GSK3β (Ser9) were mutated, did not display elevated Wnt signalling 
(McManus et al., 2005).  In a mouse model of bladder cancer PTEN loss alone was insufficient to 
activate Wnt signalling (Ahmad et al., 2011), suggesting that perhaps it is a tissue-specific 
phenomenon only seen in prostate.    However some human bladder cancers have been found 
to express high levels of nuclear β-catenin in conjunction with absent Pten and over-expressed 
Akt, implying there are important interactions between these pathways in human 
tumourigenesis (Ahmad et al., 2011).  Thus it is important to explore GSK3β staining with IHC to 
investigate whether its Akt-dependent deactivation is apparent upon PTEN deletion and 
important in PCa development.  In any event, β-catenin reportedly possesses an Akt 
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phosphorylation site at Ser552 to allow its activation by Akt directly, independent of GSK3β 
(Verheyen and Gottardi, 2010).   
 
Figure 54: A schematic representation of PTEN-loss-dependent activation of the Wnt 
pathway.  Activation of Wnt signalling and nuclear translocation of β-catenin remains 
contentious and may be tissue-specific.  Several points of synergy with p-Akt have been 
suggested.  Broken green lines represent hypothesised cooperation, whereas black lines 
represent known activation, and red lines depict inhibition. 
 
The importance of PTEN-loss-dependent activation of MAPK signalling on PCa development has 
not previously been described, however purported mechanisms to account for this interaction 
in other tissues are complex (Castellano and Downward, 2011).  Firstly this synergy has been 
demonstrated in human red blood cell progenitors, stimulated by erythropoietin (Schmidt et al., 
2004), which highlights the importance of PI3K/Akt/mTOR in connecting to and regulating Ras 
signalling.  Secondly these findings were corroborated in a zebrafish model, wherein the 
PI3K/Akt/mTOR pathway was found to regulate Ras signalling during both hematopoiesis and 
angiogenesis (Liu et al., 2008).  Together these data support the notion that crosstalk between 
the PI3K/Akt/mTOR and MAPK pathways exists.  The MAPK pathway through Ras is 
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PI3K/Akt/mTOR-dependent, and aberrant PI3K/Akt/mTOR signalling drives Raf/Mek/Erk 
activation through Raf by an uncharacterised mechanism (Wandzioch et al., 2004). 
4.4.3 Combinatorial activating mutations of β-catenin and/or Kras with/without Pten 
deletion cooperate to accelerate prostate tumourigenesis 
The survival of compound mutant mice is notably poorer than single mutants or wild-type mice, 
irrespective of their genotype.  Triple mutant mice appear to have the poorest outcome due to 
overwhelming tumour burden; however numbers in each double and triple cohort were too 
small to draw definitive conclusions on survival.  Histological analysis revealed the development 
of invasive adenocarcinoma as the primary cause of reduced longevity, illustrating that Wnt, 
PI3K/Akt/mTOR, and Ras/MAPK signalling do synergise in the prostate to promote 
tumourigenesis and disease progression. 
High grade tumours seen in compound mutant mice were comparable to the human Gleason 
pattern 4.  They were large solid tumours, microscopically displaying sheets of cells with 
widespread invasion of the surrounding stroma, often in cribriform pattern with marked 
pleomorphism.  High nuclear:cytoplasmic ratio with irregular nuclear borders and prominent 
nucleoli with cellular overlapping was seen.  Areas of necrosis were identifiable in addition to 
frequent mitoses and apoptotic bodies.  Mice bearing activating mutations of β-catenin were 
associated with keratinising squamous metaplasia, whereas those with Pten-loss were seen to 
have markedly thickened, and fibrous stroma.  Unfortunately no mice succumbed to metastatic 
disease as hypothesised; instead lymph nodes were prolifically infiltrated by lymphocytes. 
Beta-catenin/PTEN double mutant mice (PBCre4+Catnb+/lox(ex3)Ptenflox) clearly demonstrate 
upregulated PI3K/Akt/mTOR and Wnt signalling, which synergise to accelerate prostate 
tumourigenesis.  The low expression of p-mTOR seen in figure 51 (A8-D8) may represent less 
than complete activation, or that its level of expression is constitutionally low, or that the 
antibody used to target the p-mTOR antigen was weak, requiring longer or more concentrated 
incubation with the primary antibody or greater signal amplification.  If the first notion is true, 
Akt may be preferentially phosphorylated and activated at Thr308, in a PI3K/PDK1-dependent 
manner, at the expense of phosphorylation at Ser473 (and hence the mTOR avenue).  
Subsequent activation of p70S6k by PDK1 is sufficient to phosphorylate RpS6k independent of 
mTOR (Alessi et al., 1998, Pullen et al., 1998, Kozma and Thomas, 2002, Castellano and 
Downward, 2011).  MAPK signalling through Erk1/2 has also been shown to positively control 
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the activation of p70S6k (Babchia et al., 2010, Sunayama et al., 2010).  These mice also 
demonstrate upregulated MAPK signalling, which reflects cooperation between these 
pathways.  Hypotheses for how activated β-catenin and Pten-loss alone may activate MAPK 
signalling have been outlined above in their respective sections in this discussion. It can be seen 
that the abundant expression of p-Mek1/2 and p-Erk1/2 here suggests that synergistic 
interaction triggers MAPK signalling in the absence of an activating mutation in Kras. 
β-catenin/Kras mutants (PBCre4+Catnb+/lox(ex3)K-ras+/V12) overexpress both Wnt and MAPK 
signalling, which demonstrates synergy in accelerating the onset of PCa.  Interestingly intact 
PTEN is insufficient to abrogate Wnt signalling in the presence of dominant, stabilised β-catenin 
mutation.  CD44 does not appear to be expressed as avidly as when activating mutations of β-
catenin or Kras are combined with Pten loss.  Preserved Pten expression is concomitant with 
mild upregulation of p-Akt Thr308, but absent Ser473, reduced mTOR expression, and 
overexpressed p-RpS6k.  Upregulation of mutant Kras is sufficient to aberrantly activate the 
p110α subunit of PI3K, which in turn activates PDK1 resulting in Akt phosphorylation at Thr308 
(Castellano and Downward, 2011).  PDK1 and Erk1/2 can activate p70S6k and ultimately its 
substrate p-RpS6k (Babchia et al., 2010, Sunayama et al., 2010).  Furthermore nuclear Pten is 
capable of inhibiting mTOR activation independent of interference with Akt (Liu et al., 2005).  
Taken together, these data support the synergistic Wnt and MAPK-dependent PI3K/Akt 
signalling that serves to activate Akt independent of mTOR.  The mechanism of this synergistic 
interaction is illustrated in figure 55. 
Tumours from PTEN/Kras mice (PBCre4+PtenfloxK-ras+/V12) display co-activation of all three 
signalling pathways.  However the expression profile seen in these mice to some extent 
opposes the notion that (at least on an IHC level) in the presence of PTEN deletion, Wnt 
signalling is dependent on nuclear β-catenin.  Here it can be seen that on a compound 
background of activated Kras and PTEN loss, activation of downstream Wnt effectors may occur 
independent of β-catenin activation.  This could be implied by the absence of nuclear 
localisation of β-catenin in the presence of CD44 over-expression.  With this in mind, perhaps 
the appearance of cytoplasmic β-catenin staining, due to its accumulation (as seen here in 
figure 51, C1), which does not conform to the classical description of membranous staining (as 
seen in wild-type), may indicate that nuclear translocation is occurring at a level too low to 
detect with IHC. 
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Figure 55: A schematic representation of the mechanism by which PI3K/Akt signalling is 
activated by dominant, stabilised Kras in β-catenin/Kras double mutants 
(PBCre4+Catnb+/lox(ex3)K-ras+/V12).  It is felt that Ras/MAPK signalling cooperates with the 
PI3K/Akt pathway independent of mTOR in the presence of intact PTEN.  Broken green lines 
represent hypothesised cooperation, whereas black lines represent known activation, and red 
lines depict inhibition. 
 
Alternatively enhanced CD44 expression in PTEN/Kras mice could be the result of an expanded 
pool of PrSCs.  In addition to its role in Wnt signalling, CD44 is known to be a transmembrane 
glycoprotein involved in cell-cell adhesion, inflammation, and cell migration (Zoller, 2011, Guo 
et al., 2012) that avidly stains basal cells in benign human prostate (Palapattu et al., 2009).  
Studies have shown that CD44+ prostate epithelial cells in combination with other cell surface 
antigens and/or integrins select for stem/progenitor cells (see tables 4 and 5 in general 
introduction; human and murine PrSC markers respectively).  Moreover it is has been shown 
that the number of prostatic stem/progenitor cells are increased in Pten-null mice (Wang et al., 
2006) leading to tumour initiation.  Therefore it is conceivable that because formation of a 
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compound PTEN/Kras mutant increases the severity of PCa, one mechanism by which this could 
occur would be to expand the pool of SC/CSCs, and increase CD44 expression.  This question 
will be addressed by future work on culturing PrSCs from the prostates of these mouse models 
in vitro. 
In PTEN/Kras double mutants, there also appears to be occasional residual nuclear Pten 
expression (see figure 51 (C5)).   One theory for this could be that accelerated tumourigenesis, 
and thus poorer survival, has a negative impact on the time available for DNA recombination to 
occur, resulting in reduced PTEN deletion.  This may in part be supported by the fact that in 
PTEN single mutants (see figure 56), Pten expression negatively correlates with disease 
progression from PIN to invasive carcinoma.  
 
 
Figure 56: Pten expression negatively correlates with disease progression in the PTEN single 
mutant model.  The above PIN lesion displays residual Pten expression, which is absent from 
invasive adenocarcinoma (Tumour) but still retained by the surrounding stroma.  Images were 
taken at 40x magnification, and scale bars represent 100µm. 
 
Triple mutant mice demonstrated more severe, lethal high-grade PCa.  Lesions were locally-
advanced and non-metastatic.  The IHC expression profile exhibited by these mice has led to the 
belief that with increasing DNA damage i.e. when all 3 pathways are activated, there is selection 
of dominant pathways with/without deselection of other pathways in clonal expansion.  This 
concept may be further supported by the finding that triple mutant mice displayed abundant 
foci of squamous metaplasia throughout the prostate tumour and the urethra, suggesting that 
the Wnt pathway was most dominant in this model. 
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In human cancers, the impact of a given mutation will depend on the position and relative 
importance of the affected protein within the signalling pathway.  Although genetic 
heterogeneity between tumours is known to be widespread, it has long been appreciated that 
phenotypic heterogeneity may not be as extensive, with the same cellular pathways often 
repeatedly affected (Burrell et al., 2013).  The selection of dominant signalling cascades is often 
dictated by environmental pressures, such as progression to metastatic disease, or following 
treatment, whereby heterogeneity is wiped out; so-called clonal sweep (Greaves and Maley, 
2012).  The dominant signalling cascades that result thus dictate the clonal landscape resulting 
in a more homogeneous cell population.  These processes are far-removed from the tighter 
spatial regulation in the mouse models observed in this thesis, but it provides an insight into the 
selection/deselection of certain signalling transduction pathways in triple mutant mice resulting 
in rapid tumourigenesis. 
4.4.4 AR correlates positively with prostate cancer aggressiveness 
Synergistic activation of two or more pathways results in a PCa similar to the human disease.  
Previous work has demonstrated that Wnt (Truica et al., 2000), PI3K/Akt/mTOR (Carver et al., 
2011), and Ras/MAPK (Carey et al., 2007) signalling are all capable of regulating AR.  It has been 
shown here that in vivo cooperation between these pathways when mutated in combination 
demonstrate synergistic overexpression of AR compared with single mutants, which in turn 
express a significantly higher level of AR expression than wild-type prostate.    
The development of CRPC is not commonly associated with the loss of AR expression.  Instead, 
evidence points to the accumulation of molecular changes that reduce the threshold of AR 
ligand required for proliferation and survival (Isaacs and Isaacs, 2004).  To this effect, a 2- to 5-
fold increase in AR mRNA is both necessary and sufficient for progression to CRPC in mouse 
models, and subsequently, cells can become supersensitive to androgens rather than being 
independent of them (Chen et al., 2004a).  This discovery led to the introduction of novel anti-
androgen therapies in the fight against the human disease, namely abiraterone, and 
enzalutamide (Karantanos and Thompson, 2013).  As a whole this evidence raises the possiblity 
that overexpression of AR in all single and combinatorial PCa models used in this thesis may be 
sufficient to promote androgen-independent prostate growth, a poorly modelled area in vivo.  
Validation by castration studies could contribute important information to the landscape of 
CRPC development and provide platforms for therapeutic testing. 
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4.4.5 p63 correlates negatively with prostate cancer aggressiveness 
Expression of p63 was shown to diminish with disease progression in tumours of all genotype 
when compared with their respective PIN lesions.  This mimics human prostate cancer whereby 
progression to a luminal phenotype is pathognomonic.  Given that p63+ basal cells are more 
proliferative, and that secretory cells originate from p63+ basal cells, the reduction of p63 is felt 
to reflect the withdrawal of differentiated malignant cells from the stem cell/progenitor 
compartment.  The presence of p63+ cells does not prevent tumours being classified as 
malignant, as basal cell markers can be retained by murine cancer cells (Ittmann et al., 2013).  
Linear stem cell theory dictates that luminal cells arise from basal cells, therefore differentiated 
cancer cells in mice could feasibly retain p63 expression.  The progressive loss of p63 in parallel 
with tumour progression may reflect elevated MAPK signalling (Pearson et al., 2009).  MAPK is 
postulated to be a negative regulator of p63 since Src and MEK were activated in the luminal 
cells of p63–/– prostate (Kurita et al., 2004).    Therefore, it is likely that loss of basal cells disturbs 
the interaction between stromal cells and epithelial cells, and causes activation of Src, and 
hence Ras/MAPK signalling, in luminal cells. 
Activated β-catenin and PI3K/Akt/mTOR signalling are also reportedly regulators of p63, and so 
might explain why tumours arising in β-catenin/PTEN double mutants 
(PBCre4+Catnb+/lox(ex3)Ptenflox) and PTEN/Kras mice (PBCre4+PtenfloxK-ras+/V12) express 
higher levels of p63 than others, but significantly less than wild-type prostate.  βeta-catenin is 
known to induce high levels of p63, which in turn drives differentiation towards a squamous cell 
fate, and so foci of keratinising squamous metaplasia in β-catenin/PTEN mice 
(PBCre4+Catnb+/lox(ex3)Ptenflox) could thus account for increased p63 expression.  In 
addition, PI3K/Akt/mTOR signalling has been shown to regulate p63 in keratinocytes; treatment 
of immortalised keratinocytes with EGF resulted in activation of both the MAPK and PI3K 
pathways.  Subsequent pharmacological inhibition of PI3K/Akt/mTOR but not MAPK signalling 
nullified the increase in ΔNp63 expression (Barbieri et al., 2003).  This could also account for the 
increased incidence of p63+ cells in β-catenin/PTEN and PTEN/Kras tumours. 
4.4.6 Ki67 correlates positively with prostate cancer aggressiveness 
The Gleason grading system for human PCa makes no reference to the proliferation rate of 
cells, but the addition of Ki67 status could provide additional prognostic information at 
147 | P a g e  
 
diagnosis.  In humans studies Ki67 accurately predicts overall survival for patients undergoing 
watchful waiting (non-curative management) (Berney et al., 2009); time to radical treatment for 
men on active surveillance (deferred curative management) (Kristiansen, 2012);  time to 
biochemical relapse in men treated with radical prostatectomy (Laitinen et al., 2008, Gunia et 
al., 2008, Miyake et al., 2010); and disease progression in patients undergoing external beam 
radiotherapy (Khor et al., 2009).  In these mouse models, compound dysregulation of Wnt, 
PI3K/Akt/mTOR, and/or MAPK signalling results in the synergistic increase in Ki67 expression 
that clearly correlates with grade and stage progression.  The triple mutant tumours displayed 
the greatest degree of proliferation due to deregulated cell cycle kinetics.  It will be interesting 
to find out whether these findings are corroborated in a human prostate cancer tissue 
microarray. 
4.4.7 Probasin-Cre demonstrates unwanted mosaic genetic deletion when inherited 
maternally 
Cohorts for both 100day and endpoint in all genetic combinations were incomplete at the end 
of the period of study in this thesis due to the previously unappreciated phenomenon that 
maternal transmission of probasin-Cre leads to loss of transgene efficacy, and mosaic genetic 
deletion in target males.  Ongoing efforts at the time of writing have since rectified this, and re-
established a mouse colony with correctly functioning probasin-Cre.  Future work aims to fully 
recruit to all incomplete cohorts to ensure that characterisation of each genetic combination is 
robust, and capable of withstanding statistical analysis for publication. 
 
4.5 CHAPTER SUMMARY 
Utilisation of conditional mouse models through Cre-loxP technology allows activation of the 
Wnt, PI3K/Akt/mTOR, and Ras/MAPK pathways to initiate prostate tumourigenesis.  These 
signalling transduction pathways are not closed loops functioning in isolation; it has been 
shown here that both dominant stabilisation of β-catenin, and PTEN loss trigger activation of 
their own pathways and the ectopic activation of neighbouring pathways clearly demonstrating 
synergy.  Furthermore combinatorial, synergistic pathway activation drives rapid disease 
progression from PIN to high-grade locally invasive adenocarcinoma.  These models accurately 
mimic features of the human disease and provide a platform for the pre-clinical testing of novel 
therapeutic agents aimed at curing high-grade prostate cancer.  
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Chapter 5:   Establishing a 3D primary tissue culture assay to explore 
self-renewal in murine adult prostate epithelial stem cells (PrSCs) 
 
5.1 INTRODUCTION 
Adult epithelial stem cells are of interest due to their ability to facilitate organ homeostasis and 
for their potential role in tumourigenesis.  Throughout the life span of an adult organ, stem cells 
operate to replace lost or damaged tissue to ensure proper function (Blanpain et al., 2007), 
such as in the blood, skin, and intestine.  Owing to their longevity and inherent self-renewal 
capacity, adult stem cells are potential cells of origin for certain cancers (Barker, 2009).  
Prospective isolation of these cells and investigation into their properties will allow better 
understanding of their basic biological processes when designing and/or testing novel 
therapeutic agents. 
The rodent prostate is a suitable model system to investigate the properties of adult epithelial 
stem cells due to the proven ability of the rodent gland to undergo seemingly unlimited cycles 
of involution after castration and subsequent organ replenishment upon androgen 
reintroduction (English et al., 1985, English et al., 1987).  Perhaps the most important reason to 
study prostate stem cells (PrSCs) is that they too are androgen independent (or castration 
resistant, Montpetit et al., 1988), and therefore similar to the subpopulation of prostate cancer 
cells capable of initiating CRPC, the lethal phase of the disease (Antonarakis and Eisenberger, 
2011).  Identifying critical self-renewal pathways in PrSCs may provide new therapeutic targets 
against the SC that would be of use as adjuncts to current therapies, which for the most are 
only effective against differentiated tumour cells. 
5.1.1 Cancer stem cell theory 
Cancer stem cells (CSCs) are SCs that are capable of populating all cell types within a malignant 
neoplasm, but the precise derivation of CSCs remains elusive.  Theoretically, a CSC could evolve 
from any one of the following mechansims: (a) an oncogenic mutation within a developing 
stem- or progenitor cell, (b) an oncogenic mutation within an adult stem- or progenitor cell, or 
(c) de-differentiation of a mutated tumour cell that acquires stem-like properties. 
Strictly speaking the CSC model postulates for hierarchical organisation of tumours with cancer 
stem cells at the top of the lineage hierarchy, capable of indefinite self-renewal, unlike their 
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progeny, which undergo terminal differentiation and loss of tumourigenicity (Isaacs and Coffey, 
1989).  Note that prostate CSCs may not display features of the cell of origin in this model 
(Wang and Shen, 2011).  In contrast, the stochastic (clonal) model proposes that the majority of 
cancer cells within a tumour are tumourigenic and possess varying genetic or epigenetic 
properties (Marotta and Polyak, 2009, Rosen and Jordan, 2009, Shackleton et al., 2009).  Clones 
with distinct growth advantages and/or therapy resistance that are capable of withstanding 
these selection pressures survive, and drive tumour progression.  Thus, in the clonal evolution 
model, it is essential to eliminate differentiated cancer cells in bulk to achieve therapeutic 
efficacy, whereas in the CSC model, tumour eradication ought to require dual therapy against 
both the CSC and the tumour bulk.  In theory, these two models do not need to be mutually 
exclusive (Wang and Shen, 2011).  Cancers that follow the CSC model may simultaneously 
undergo clonal evolution if more than one type of CSC coexists, or CSCs are under 
environmental selection (Marotta and Polyak, 2009).  Similar to other solid tumours, it is 
presently unclear whether prostate cancers are organised hierarchically and follow the CSC 
model exclusively, which suggests that cancer-initiating mutations could occur in different cells 
of origin within the prostate epithelium.  Indeed this notion has recently been supported by 
claims that prostate cancer can initiate from both the basal and luminal cell lineages (Choi et al., 
2012), and furthermore these separate entities display distinct molecular signatures that are 
predictive of human patient outcomes (Wang et al., 2013).  During prostate cancer progression, 
clonal progeny of the resulting TICs are constantly under selection, from such factors as 
environmental and treatment pressures.  Some of these clones may gain additional growth and 
survival advantages and become the driving force of tumour malignancy, ultimately acquiring 
the properties of CSCs. 
5.1.2 The origin of human cancer stem cells 
Cancer stem cells often share antigenic profiles with normal tissue stem/progenitor cells 
(Ginestier et al., 2007, Malanchi et al., 2008), and as CSCs may originate from oncogenic 
transformation of a normal tissue SC, many studies have focused on the identification of normal 
PrSCs as a starting point for subsequent studies to determine whether genetic alterations of 
these SCs may confer tumour-initiating properties (Wang and Shen, 2011).  Distinctive 
methodologies have been established to identify and investigate prostate epithelial cells with 
stem-like capabilities in both humans and mice.  As discussed in the introduction, many of these 
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purported SC populations are non-overlapping.  The identification of candidate SCs has led to 
the consideration of whether these populations in the mouse, or their analogous populations in 
humans, can serve as cells of origin for prostate cancer.   
5.1.3 In vitro and in vivo experiments have provided evidence for PrSC/CSCs 
To date, no one assay is capable of displaying all characteristics of SC/CSCs, and therefore three 
main assays have been employed to satisfy this brief in both humans and mice.  These include, 
(a) 2D culture for proliferation and differentiation in vitro, (b) 3D culture to display self-renewal 
in vitro, and (c) for reconstitution of the primary tissue in allografts, be it normal or malignant 
(termed xenografts if human cells are transplanted into mice).   
To facilitate study of human prostate CSCs methods usually include, fresh frozen, primary 
tumour cells (usually from RRP samples) or established cell lines for 2D culture in vitro (also 
known as colony-forming assays), or cell line xenografts using immunodeficient mice.  One 
group has employed magnetic bead cell sorting to isolate CD44+α2β1-integrinhiCD133+ cells 
from primary human cancers, and showed that this subpopulation displayed high proliferative 
potential in 2D culture, as well as the ability to differentiate to a luminal phenotype in culture 
following treatment with dihydrotestosterone (Collins et al., 2005).  A subsequent collaborative 
paper involving the same group reported how CD44+α2β1-integrinhiCD133+ cells can initiate 
prostate cancer, which displays a luminal phenotype, following xenotransplantation (Lawrence 
et al., 2013).  This technique however is complex, and is limited by low yield of graft success 
(27% when transplanted with mouse UGS mesenchyme, 0% when cultured alone), occasional 
absence of PCa cells in the graft, and because immunodeficient mice are used, grafts are often 
infiltrated with  host immune cells with unknown impact on the graft (Lawrence et al., 2013).  
Attempts to develop 3D tissue culture assays to enrich for human SCs have failed as it appears 
that these cells are unable to form spheres, instead preferring to proliferate in 2D monolayer 
(Garraway et al., 2010, Guo et al., 2012).   
Other studies claim to have isolated CSCs from long-established human PCa cell lines, using 
similar combinations of cell-surface markers.  For example, CD44+α2β1-integrinhiCD133+ cells 
were isolated from the DU145 cell line (Wei et al., 2007), CD133hi cells were identified from the 
human telomerase reverse transcriptase-immortalised primary tumour-derived prostate 
epithelial cell lines (Miki et al., 2007), and CD44+CD24- cells were isolated from the LNCaP cell 
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line (Hurt et al., 2008), and CD44+CD133+ cells in the PC3 and DU145 cell lines (Dubrovska et al., 
2009).  The CSC properties of these cell populations were demonstrated by colony formation 
assays and tumour reconstitution following subcutaneous injection, whereas other studies 
demonstrated tumour formation using allografts under the renal capsule (Gu et al., 2007). 
Cell lines were long preferred to primary PCa cells because the latter are notoriously difficult to 
culture (Peehl, 2005).  However in the former, extensive passaging is likely to alter the genetic 
properties of cell lines compared to the precursor human primary tumours from which they 
were established (Wang and Shen, 2011).  Assays employed to demonstrate prostate CSC 
properties may be fundamentally flawed.  In particular, 2D colony formation assays in culture 
may selectively favour cells that are better adapted to the culture conditions, and may not 
accurately model micro-environmental conditions in vivo (Quintana et al., 2008).  Similar 
concerns apply to in vivo assays, as many studies have employed flank or sub-renal capsule 
injection of CSCs to assess tumour-initiation ability, and thus are not conducted within a 
prostate microenvironment.  A recent publication showed how basal cells, both in vivo and in 
vitro, can exhibit substantial plasticity when removed from their endogenous tissue 
microenvironment (Wang et al., 2013).  Moreover their work supports the notion that genetic 
lineage tracing in vivo, and not transplantation-based assays, represents a gold standard for 
identification of SCs/CSCs (Snippert and Clevers, 2011). 
The specificity of the cell-surface markers utilised in CSC studies is also questionable and their 
biological function is often unknown.  Although CD44 and CD133 have been implicated as CSC 
markers in a variety of tissues, such as brain/CNS (Uchida et al., 2000, Singh et al., 2004), breast 
(Al-Hajj et al., 2003), and prostate (Richardson et al., 2004), proving their specificity to the CSC is 
difficult.  To highlight one example, CD133 is broadly expressed in luminal cells of colon, lung 
and pancreas, and appears to display little specificity for colon cancer-initiating cells (Shmelkov 
et al., 2008).  Furthermore another study noted that CD133+ cells from the DU145 cell line were 
no more clonogenic than CD133- cells, while CD133 was not expressed in other prostate cell 
lines including DuCaP, LAPC-4, 22Rv1, LNCaP, and PC-3 (Pfeiffer and Schalken, 2010).  Finally, 
mouse CD133 was shown to be widely expressed by prostate luminal cells, whereas human 
CD133 is less broadly expressed in benign tissue, but is upregulated in regions of inflammation 
within tumours, suggesting a lack of correlation with CSCs (Missol-Kolka et al., 2011).  Thus, the 
utility of current putative CSC markers for identification of prostate CSCs remains unclear. 
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5.1.4 Why use mouse models to study the function of PrSC/CSCs? 
Difficulties associated with human prostate CSC culture can be circumvented by the use of 
mouse prostate in similar tissue culture experiments.   Mouse models are advantageous as they 
can largely evade host cross-species transplantation reactions, and candidate CSCs can be 
analysed from genetically defined tumours in vivo. 
Mouse prostate cancer models have not as yet been extensively exploited to identify candidate 
CSCs by way of tumour-reconstitution/allograft assays.  However, the Lin-Sca-1+CD49fhi 
subpopulation from constitutive Pten-null mice displayed tumour-initiating properties in both 
3D culture and following reconstitution of malignant glands in renal grafts in vivo (Mulholland et 
al., 2009).  A similar approach was later used to isolate Lin-Sca-1+ cells from tumours in a 
conditional Pten deletion model.  This paper went on to report how cancer-associated 
fibroblasts enhanced the pro-tumourigenic effects of candidate CSCs in renal grafts over and 
above normal fibroblasts (Liao et al., 2010). 
Given that one theory for CSC provenance postulates for oncogenic transformation of a PrSC, 
many studies using mouse tissue have focused on this to determine whether genetic alterations 
in PrSCs may confer tumour-initiating properties.  As previously mentioned, the reporting of 
non-overlapping candidate SC populations between groups has understandably raised 
controversy as to their precise biological roles and whether they truly serve as cells of origin for 
PCa. 
5.1.5 FACS enables prospective identification of purported PrSCs/CSCs 
FACS has been integral to the identification and isolation of candidate PrSCs, to allow assays 
challenging their function to be undertaken.  The prostate reconstitution/allograft assay 
involves culturing PrSCs with embryonic urogenital sinus mesenchyme (EUSM), and this method 
has shown Sca-1+ cells to be more efficient at regenerating prostatic tissues than Sca-1- cells 
(Burger et al., 2005, Xin et al., 2005).  Other studies have successfully displayed features of stem 
cells in vivo and in vitro that expressed cell surface markers CD49f and Trop2 (Lawson et al., 
2007, Goldstein et al., 2008).  Furthermore, 1 in 10 Lin-Sca-1+CD133+CD44+CD117+ cells have 
been reported to be capable of prostate reconstitution in the renal allograft assay (Leong et al., 
2008). 
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Several studies have also utilised FACS to isolate candidate human prostate epithelial stem cells.  
Cells expressing high levels of α2β1-integrin were more proliferative in 2D and xenograft culture 
than the total basal population (Collins et al., 2001).  Further enrichment of prospective these 
candidate PrSCs can be carried out using the marker CD133 (Richardson et al., 2004).  Similarly, 
the Trop2 marker can be used in combination with CD49f to enrich for sphere-forming cells 
from the human prostate consistent with the findings seen in mice (Goldstein et al., 2008). 
5.1.6 Trop2 is a candidate PrSC marker 
Tumour-associated calcium signal transducer 2 (Trop2) has been recognised as a candidate 
stem cell marker from prostate-specific microarray analysis, because it was 20-fold enriched in 
the murine prostate after castration (Wang, 2007), and 12-fold enriched in prostate sphere cells 
compared with the total epithelium (Goldstein et al., 2008).  Trop2 has no known function or 
ligand (Fornaro et al., 1995, Tsujikawa, 1999), and is a type I transmembrane protein akin to 
EpCAM, a family of transmembrane glycoproteins that mediate calcium-independent epithelial 
cell-cell adhesion.  Trop2 expression has been reported in normal and/or malignant tissue from 
kidney, lung, ovary, testis (El Sewedy et al., 1998), colon and rectum (Ohmachi, 2006), pancreas 
(Fong, 2008), and breast (Huang, 2005).   
This chapter reports the successful identification and isolation of a subpopulation of prostate 
epithelial basal cells from histologically normal tissue, which displays the ability to self-renew in 
vitro, consistent with a stem-like phenotype.  The steps taken to optimise this 3D sphere-
forming assay are also described here. 
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5.2 CHAPTER AIMS 
The aims of this chapter are: 
1. To evaluate a panel of postulated CSC markers as readouts of disease progression from 
normal prostate to invasive tumour in autochthonous mouse models of prostate cancer 
2. To identify potential markers at immunohistochemistry that could be used to identify 
stem cells at FACS 
3. To optimise a tissue culture assay to allow maintenance and expansion of primitive 
prostate cells that display stem cell characteristics in vitro 
4. To demonstrate the ability of prostate epithelial stem cells identified prospectively at 
FACS in normal murine prostate to act as stem cells in 3D culture 
5. To determine whether alteration of the genetic background of murine prostate 
epithelium to create a pro-oncogenic environment, alters the pool of stem cells 
 
5.3 RESULTS 
5.3.1 Validation of proposed stem cell markers in autochthonous mouse models of human 
prostate cancer 
Cancer stem cells may arise from normal stem/progenitor cells that have undergone malignant 
transformation (Jordan et al., 2006).  As such, markers of normal prostate stem/progenitor cells 
may also be markers of prostate CSCs/initiating cells.  Given that PrSCs are felt to reside in the 
basal layer, one might also expect a number of luminal cells in normal prostate to express SC 
markers if luminal cells are believed to not arise from a separate luminal progenitor (see figure 
13, in General Introduction). 
The expression of postulated CSC markers was examined by IHC in formalin-fixed, paraffin-
embedded sections of both normal mouse prostate and prostate tumours.  The cellular 
antigens tested for are included in table 16, along with proportion of positive staining. 
Putative CSC markers CXCR4 (Miki et al., 2007), EpCam (Guo et al., 2012), Integrin-β1 (Collins et 
al., 2001), Lrig1 (Powell et al., 2012), Sca-1 (Burger et al., 2005, Xin et al., 2005), and CD133 
(Collins et al., 2005) were not expressed in either normal prostate or prostate tumours at 
immunohistochemistry (photographs not shown), and so will not be discussed further. 
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CSC marker 
Intensity 
in normal 
prostate 
Proportion 
of normal 
prostate 
Localisation 
in normal 
prostate 
Intensity 
in tumour 
Proportion 
of tumour 
Localisation 
in tumour 
CD44 - - - ++ +++ C and M 
CXCR4 - - - - - - 
EpCam - - - - - - 
FRMD4a + + Nuc +++ +++ C and M 
 Integrin-β1 - - - - - - 
Lrig1 - - - - - - 
Notch1 ++ +++ C +++ +++ C and Nuc 
Notch4 + +++ C ++ +++ C 
Trop2 ++ ++ Nuc +++ +++ C and M 
Sca1 - - - - - - 
CD133 - - - - - - 
 
Table 16: Putative markers of prostate SC/CSCs tested by immunohistochemistry.  Staining 
intensities and proportion were scored and the pattern of expression noted.  Intensity scores: - 
absent expression; + low intensity; ++ moderate intensity; +++ high intensity.  Proportion 
scores: - absent expression; + 1-5% expression; ++ up to 50% expression; +++ 51-100% 
expression.  Localisation: C, cytoplasmic; M, membranous; Nuc, nuclear.  N=3 for all stains. 
 
5.3.1.1   CD44 
CD44 is a cell surface glycoprotein involved in cell–cell interactions, cell adhesion and migration.  
In addition to these cellular functions, CD44 is extensively used as a surface marker for isolating 
CSCs from breast, prostate, pancreas, ovarian, and colorectal cancers (Jaggupilli and Elkord, 
2012).   However, the usefulness of CD44 as CSC marker remains uncertain (Slomiany et al., 
2009).  CD44 has been assigned roles in cancer initiation (Leung et al., 2010), and metastasis 
(Visvader and Lindeman, 2008), but its association has been opposed in breast (Lopez et al., 
2005) and prostate cancer (Gao et al., 1997) because its high expression failed to differentiate 
areas of normal tissue from cancer (Naor et al., 2002).  CD44 is found to be ubiquitously 
expressed in most normal and cancer cells, which has limited its widespread use as a lone CSC 
marker.  However in combination with other surface markers, it serves to purify populations 
that have displayed SC traits in vitro and in vivo (see tables 4 and 5 for summaries of human and 
mouse PrSC markers respectively – General Introduction). 
As shown in figure 57, CD44 was not expressed in normal prostate but was heterogeneously 
overexpressed in tumours, where it stained strongly in a cytoplasmic/membranous fashion.   
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Figure 57: Expression of CD44 in normal prostate and prostate tumour.  Error bars 100µm. 
 
5.3.1.2   FRMD4a 
FRMD4a is a human epidermal SC marker upregulated in squamous cell carcinoma (Jensen and 
Watt, 2006), and in this regard it has been implicated in cell polarity (Ikenouchi and Umeda, 
2010) and metastasis (Goldie et al., 2012). 
Infrequent luminal cells in normal prostate demonstrated nuclear avidity for FRMD4a while 
tumours ubiquitously exhibit strong cytoplasmic staining (see figure 58).  This does not satisfy 
the description of a SC/CSC marker.   
 
Figure 58: Expression of FRMD4a in normal prostate and prostate tumour.  Error bars 100µm. 
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5.3.1.3    Notch1 
NOTCH1 encodes for a member of the notch family of single pass transmembrane receptors.  
The Notch pathway is a short-range communication system that regulates cell fate (Leong and 
Gao, 2008), and inappropriate Notch activation stimulates proliferation, restricts 
differentiation, and/or prevents apoptosis (Pannuti et al., 2010).  Mammals have four paralogs 
that essentially vary in the number of EGF repeats in the extracellular domain (Pannuti et al., 
2010).  Mouse models have unearthed a direct role for Notch signalling in the regulation of 
various stem/progenitor cells, including the hematopoietic system, skin, hair, inner ear, skeletal 
muscle, and intestine (Chiba, 2006).  In normal mouse prostate, Notch1 mRNA expression was 
upregulated following castration and down-regulated following hormone replacement (Wang et 
al., 2004), providing evidence for its role as a normal SC marker.  Recently its importance in 
mediating chemoresistance in PCa has also identified it as a potential CSC marker (Liu et al., 
2014), but more data are required from both animal and human studies to prove its value in 
either role. 
In normal prostate Notch1 expression can be seen to stain both luminal and basal prostate 
epithelial cells, whereas it is expressed ubiquitously in tumour cells and surrounding stroma.  It 
appears to localise to the cytoplasm in normal prostate, and is over-expressed in both the 
cytoplasmic and nuclear compartments in tumour.  When associated with tumour, stroma 
exhibits cytoplasmic localisation.  This does not fit the SC/CSC phenotype, as demonstrated in 
figure 59. 
 
Figure 59: Expression of Notch1 in normal prostate and prostate tumour.  Error bars 100µm. 
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5.3.1.4   Notch4 
There is good evidence for the role of Notch in CSC regulation in breast cancer, which has 
provided the basis to question whether the same function can be extrapolated to prostate 
(Pannuti et al., 2010).  In breast ductal carcinoma in situ (DCIS), the ability to culture SCs into 
spheroids (called “mammospheres”) is dramatically decreased by co-culture with a Notch-4 
monoclonal antibody (Farnie et al., 2007).  This intimates cooperation between epidermal 
growth factor receptor and Notch4 in DCIS SC maintenance. 
Notch4 stains only luminal epithelial cells in normal prostate with low intensity, and it is widely 
expressed in all tumour cells with higher intensity.  Both display cytoplasmic staining, which is 
overall reduced compared with Notch1.  Stromal cells do not stain for Notch4.  These findings 
are not in-keeping with a stem cell phenotype, and can be seen in figure 60. 
 
Figure 60: Expression of Notch4 in normal prostate and prostate tumour.  Error bars 100µm. 
 
5.3.1.5   Trop2 
Trop2 was found to be enriched after castration and in the basal prostate epithelium (Goldstein 
et al., 2008).  Both its location within the mouse prostate and demonstration of its function in 
vitro and in vivo satisfy the stem cell brief in the mouse. 
A minority of normal prostate luminal cells and a significant proportion of basal cells display 
nuclear staining with Trop2 antibody.  Conversely, prostate tumours exhibit cytoplasmic and 
membranous staining in the vast majority of cells in a heterogeneous fashion.  A subset of cells 
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is seen to stain with greater intensity than the bulk of tumour cells.  Given that Trop2 is a 
transmembrane glycoprotein member of the EpCam family, these findings support those of 
others that Trop-2 is a regulator of cell-cell adhesion in PCa (Trerotola et al., 2012).  
Interestingly Trop2 is also expressed in the stroma.  The expression pattern seen here satisfies 
cancer stem cell theory, whereby there is upregulation of Trop2 expression on malignant 
transformation. 
 
Figure 61: The expression pattern of Trop2 in normal prostate and prostate tumour is 
consistent with cancer stem cell theory.  Trop2 is seen to stain a significant proportion of 
triangular basal cells (inset – red arrowheads), and a small minority of luminal cells (inset – 
black arrowheads), in normal prostate.  There is massive upregulation of Trop2 expression seen 
in tumour in-keeping with a CSC phenotype that has undergone malignant transformation from 
a normal SC.  Error bars 100µm. 
 
5.3.2 Optimisation of PrSC 3D tissue culture assay 
Single unsorted prostate epithelial cells from 100-day old mice were plated in Matrigel at 
varying densities in 12-well plates to determine the optimal density for (a) accurate counting of 
prostate organoids, and (b) bulk passage of cells (see figs (a) and (b) below). 
Plated cell densities ranged from 1000 cells/well to 10E6cells/well and the average numbers of 
prostate organoids grown out and counted are shown for each. 
When accurately quantifying the organoid-forming efficiency (or the sphere-forming unit) a 
plated density of 10E4cells/well was deemed to be optimal (see (a) and (c) below).  
Furthermore in order to maintain sphere-forming cells (PrSCs) through numerous rounds of 
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passage, plating cells at a density of 10E5 was employed as it appeared to consistently maximise 
the yield of organoids (see (b) and (d) below).  Beyond this density there is toxicity to sphere-
forming cells thereby inhibiting organoid-formation (see (d-f) below). 
 
 
 
 
Figure 62: Assay optimisation to determine optimal plating density.  Experiments to ensure 
the optimal plating densities for (a) accurately counting prostate spheres, and (b) to maximise 
yield of sphere cells, where performed.  Counting of spheres was best done at 10E4/well (c), as 
it can be seen that increasing seeding density to 25E4/well could introduce bias when counting 
spheres (d).   At higher densities, sphere growth is impaired (e & f).  Error bars 200µm.  
Photographs taken on inverted brightfield microscope. 
(a) (b) 
(c) (d) 
(e) (f) (e) 
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The live cellular yield from each 100-day old wild-type prostate ranged from 1.25x10E6 to 
2x10E6 (mean 1.6x10E6, median 1.4x10E6 cells) when stained with trypan blue (n=5).   
It was noted that the ratio of live:dead cells counted by trypan blue exclusion varied according 
to genotype, as depicted in the box and scatter plots below.  This suggests that genomic 
instability negatively correlates with cell fate.  Possible explanations for this finding include: 1. 
combinatorial pro-oncogenic mutations result in abnormal cell signalling, which in turn trigger 
activation of pro-apoptotic pathways, and/or 2. the increased number of dead cells seen may 
be a consequence of necrosis. 
 
 
Figure 63: The proportion of dead cells correlates with the degree DNA mutation.  The ratio of 
live:dead cells were counted by trypan blue exclusion of single prostate epithelial cells.  It can 
be seen from the box plots that the proportion of dead cells counted from mutant prostates is 
higher than wild-type, and this is greatest in combinatorial mutants compared with single 
mutants or wild-type; n=3 for all genotypes. 
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Unsorted prostate epithelial cells from 100 day-old wild-type mice are incapable of self-
renewal.  To determine the self-renewal capacity of unsorted cells, prostate epithelial cells were 
digested into single cell suspension and passaged to finality in triplicate.  It can be seen that 
unsorted cells possess restricted self-renewal capacity; being capable of a maximum 2 rounds of 
passage only (n=4), with a median 128 spheres formed in the 1st generation (1/72 cells).  In the 
2nd generation, this diminished to median 32 spheres per well (p=0.083), hence a ratio of 1/167 
1st generation sphere cells were capable of self-renewal.  No 2nd generation sphere cells were 
capable of forming spheres in the 3rd generation, thus demonstrating attenuated ‘stemness’. 
 
Cohort 1st Generation 2nd Generation 3rd Generation 
1 140 63 - 
2 136 - - 
3 120 60 - 
4 64 3 - 
Median 128 31.5 - 
 
Table 17: Unsorted prostate epithelial cells are incapable of self-renewal in vitro.  None of 
these cells was able to passage to generation 3, and the median number of spheres formed in 
the 2nd generation was significantly less than the 1st. 
 
To enable the function of normal PrSCs to be evaluated, techniques to enable their prospective 
isolation in vitro were explored. 
5.3.3 Prostate epithelial stem cells possess the antigenic profile Lin-CD49f+Sca1+Trop2Hi 
To enable the isolation and cultivation of PrSCs, a single cell suspension of prostate epithelial 
cells was sorted by FACS, cultured to permit sphere formation, then passaged and re-plated to 
allow direct comparison of their self-renewal capacity with unsorted prostate epithelial cells.  
The flow-diagram in figure 64 illustrates this process. 
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Figure 64: Normal mouse prostates were digested and sorted to extract PrSCs for 3D primary 
culture.  The above flow diagram depicts the abbreviated version of the methods of culture and 
passage.  For a more detailed explanation, please refer to section 3.5 in methods and materials. 
 
In order to quantify the stemness of wild-type PrSCs in vitro, the number and proportion of 
stem cells formed at each generation after passage were established, along with PrSC organoid 
size.  When assessing prostate organoid size, a cut-off of 40μm was set because these small 
structures seemed to cease growing at or around day 5 and so were not counted as PrSC 
organoids. 
A typical FACS plot would yield the following proportions for each subpopulation (as a 
percentage of total cell number), and each experimental FACS plot is shown thereafter: 
 Trop2Hi:   median 7.6%  (IQR 5.7 – 11.4) 
 Not CD49f/Sca1+:  median 27.5%   (IQR 22.8 – 32) 
 Not Trop2Hi:   median 5.7%  (IQR 4.6 – 7.1) 
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Experiment 
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Experiment 
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Experiment 
4 
Figure 65: FACS plots from each experiment used to utimately select out the Trop2Hi subpopulation in five gated phases 
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The FACS plots from each of 4 experiments are shown in figure 65 in 5 gated phases.  Following 
digestion into single cell suspension (gate 1), all cells are shown in the forward scatter vs side 
scatter plot, in which cell debris (labelled P1) and cell clumps were excluded.  In gate 2, live cells 
only were selected using DAPI exclusion (seen here as dark green), before all Lin- cells were 
gated for (seen as dark green in gate 3).  In gate 4 all cells expressing high levels of CD49f–PE-
Cy5 and Sca-1–PE–Cy7 were chosen (blue population), and finally of these shown in gate 5, cells 
expressing high levels of Trop2-APC were defined (light green).  The large green population in 
gate 4 represents the “not CD49f/Sca1+” population, and the light blue population in gate 5 
represents the “not Trop2Hi” population. 
 
Figure 66: The proportions of live PrSCs counted prior to re-plating demonstrate variability in 
each generation, and with each experiment.  The number of live Trop2Hi PrSCs cells was 
compared with the previous generation’s count (a), and with the original number of PrSCs at 
the beginning of each experiment (b).  Prefix G, denotes the generation after plating and 
passage, whereas D, denotes the number of days elapsed since cells were plated, i.e. G1D7 is 
the 7th day of the 1st generation.  Prostate spheres were always passaged on day 7. It is worth 
noting that experiments were terminated at day 7 of G4, and so spheres were fixed in formalin 
for IHC, rather than re-dissociating back to single cells for counting. 
 
After FACS in each culture experiment, the remaining number of live Trop2Hi PrSCs was 
determined by Trypan blue exclusion before plating.  It can be seen that while there was 
variability amongst experiments, comparison of the proportion of live cells to the previous 
generation (figure 66a) shows that from the end of the 1st generation (G1D7) the Trop2Hi cell 
population is expanded in vitro as illustrated by the median plot (black broken line).  Perhaps 
the reason for the initial dip in cell number at G1 is that progenitor cells lose their self-renewal 
capacity and undergo apoptosis, while the stress of passage stimulates PrSCs to replicate.  
When compared to the number of cells at the beginning of each experiment (figure 66b), the 
(a) (b) 
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median cell number at the termination of all but experiment 4 is decreased.  This suggests that 
Trop2Hi cells can be maintained in vitro despite repeated rounds of passage.  In reality cells are 
inevitably lost each time the cells are re-dissociated back to single cells and passaged.  
Furthermore in figure 66(b), the median Trop2HiPrSC number is lower at the end of generation 3 
than at the starting point of each experiment.  Despite this it can be seen from the graph that 
the median number of PrSCs begins to increase and thus perhaps at this point, progenitors are 
exhausted and PrSCs are becoming more purified. 
5.3.4 PrSC organoids demonstrate self-renewal in vitro 
Murine prostate epithelial cells expressing the antigenic profile Lin-Sca-1+CD49f+Trop2Hi 
(Trop2Hi) were capable of self-renewal in vitro (n=4), whereas both Lin-Sca-1-CD49f- (not 
CD49f/Sca-1+) and Lin-Sca-1+CD49f+Trop2Lo (not Trop2Hi) were incapable of sustained self-
renewal. 
 
Figure 67: PrSCs are increasingly purified through at least three rounds of passage whereas 
other prostate epithelial cells are not.  Columns depict median, while error bars represent SD; 
significance was tested using the non-parametric Mann-Whitney test, p<0.05 (95% confidence 
interval), n=4.  Analysis was performed in SPSS 20 (Armonk, NY: IBM Corp). 
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Figure 67 plots the median number of prostate spheres formed per generation (n=4) in each of 
the 4 prostate cell populations.  It was shown earlier (see table 17) that unsorted prostate cells 
lose the ability to form spheres beyond G2.  In a similar manner, cells that are not Trop2Hi lack 
the ability to undergo self-renewal.  The ability of cells that do not express CD49f+Sca1+ to self-
renew declines significantly from G2 to G3 (p=0.050).  Trop2 enriches for sphere-forming cells 
from the mouse prostate that display self-renewal in vitro.  Second, 3rd, and 4th generation 
Trop2Hi cells form significantly more spheres than 1st generation cells (p=0.021, 0.021, and 0.034 
respectively), but apparent increases in the sphere-forming efficiency from 2nd to 3rd, and 3rd to 
4th are not statistically significant (p=0.386, and 0.355 respectively).  
 
Table 18: PrSCs become more efficient at forming spheres than other prostate epithelial cells 
through multiple rounds of passage.  The proportion of Trop2Hi cells capable of forming 
spheres rises from 1/69 to 1/16 from G1 to G4 respectively wheras the ability of other 
populations diminishes.  SFU = number of spheres/number of cells plated x 100% 
 
The Trop2Hi subpopulation can be purified through at least 4 rounds of passage, and thereby 
increasing the proportion of Trop2Hi cells capable of forming spheres from approximately 1/69 
in the 1st generation (G1) to around 1/16 in the 4th generation (G4).  In contrast, cells that are 
not Trop2Hi are incapable of self-renewal, whereas both unsorted cells, and not CD49f+Sca1+ 
cells, are capable of limited self-renewal in vitro as illustrated by their diminishing sphere-
forming ability in table 18.  
SFU (%) G1 G2 G3 G4
Unsorted cells 1.28 0.32 0.00 -
Trop2Hi 1.46 4.14 4.83 6.39
Not CD49f+Sca1+ 0.26 1.25 0.19 0.00
Not Trop2Hi 1.46 0.00 - -
Ratio of sphere forming 
cells
G1 G2 G3 G4
Unsorted cells 1/78 1/313 - -
Trop2Hi 1/69 1/24 1/21 1/16
Not CD49f+Sca1+ 1/392 1/80 1/526 -
Not Trop2Hi 1/68 - - -
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Figure 68: PrSCs consistently form large spherical structures in vitro, whereas other prostate 
epithelial cells do not.  The appearance of prostaspheres at each time point on an inverted 
brightfield microscope are shown (a); scale bars depict 50µm.  The size of prostate spheres 
formed in each generation at days 1, 4, and 7 after plating are shown for each group (b).  Only 
spheres greater the 40µm in size were counted.  Columns depict median, while error bars 
represent SD; significance was tested using the non-parametric Mann-Whitney U test, p<0.05 
(95% confidence interval), n=4.  Analysis was performed in SPSS 20 (Armonk, NY: IBM Corp). 
 
By day 4 of G2, Trop2Hi spheres are significantly larger than those that do not express 
CD49f+Sca1+ (p=0.034).  Moreover in G3, Trop2Hi spheres grow faster and larger than not 
CD49f/Sca1+ cells (p=0.034).  As such no sphere that lacked Trop2Hi expression met the size 
criteria for counting in G2 (see figure 68(b)), and neither did the vast majority of those not 
expressing CD49f/Sca1+ in G3.  Spheres from unsorted cells are not included in figure 68. 
(a) 
(b) 
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Figure 69: Prostaspheres display a basal phenotype.  Formalin-fixed, paraffin-embedded 
prostaspheres were sectioned for IHC analysis.  They demonstrate signs of early squamous 
differentiation and keratin deposition centrally.  Error bars depict 50µm. 
 
Prostate spheres can either be solid in appearance, or display an organised bi-laminar structure 
with a central lumen and secretions within it.  When stained with H&E, secretions appear 
consistent with keratin suggesting squamous differentiation centrally.  However they 
predominantly consist of a primitive basal phenotype, as highlighted by p63 and CK5 staining, 
thus their constituent cells remain largely undifferentiated.  Furthermore they appear to lack 
CK8 and CK18, markers of terminally differentiated luminal cells.  Interestingly, cells located 
centrally display weak AR+ expression (luminal cell marker), perhaps indicating that they may be 
in the early stages of differentiation here.  Proliferating cells reside in the periphery, as 
indicated by avid Ki67 expression. 
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5.3.5 Assay optimisation 
This technique posed several quality control issues during its inception.  These are outlined 
below along with the approaches for addressing and solving these problems. 
Problem: How to determine the optimal number of prostates to use in order to extract 
sufficient numbers of PrSCs for each experiment 
Solution: Perform number reduction experiments to discover the minimum number of 
prostates acceptable 
 
Optimisation of an assay to analyse the biological properties of PrSCs may eventually be useful 
as a baseline comparator for CSCs isolated from transgenic mouse models of human PCa.  One 
hypothesis to be explored in future experiments is that CSCs are more difficult to prospectively 
identify and culture than PrSCs from wild-type mice if earlier findings hold true (see unsorted 
cell live:dead ratios), whereby genomic instability (i.e. increasing the number of pro-oncogenic 
mutations) reduces cell survival.  Ultimately this will impact upon the yield of SC/CSCs, thus the 
minimum number of prostates that allows a complete experiment needed to be determined, all 
the while remaining mindful of the guidance outlined by the National Centre for the 
Replacement, Refinement and Reduction of Animals in Research (NC3Rs).  Thus the minimum 
number of prostates acceptable was defined as, ‘the number of glands sufficient to allow 
development of at least 4 generations of prostate spheres in vitro’. 
Given that firstly the PrSC population is hypothesised to comprise ≤1% of murine prostate 
epithelium, and because secondly wild-type murine prostates are small, sorting of a single 
prostate was not attempted. 
The following table outlines the results from experiments performed to determine the 
minimum number of prostates required for 3D PrSC culture: 
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Number of 
prostates 
Number of 
experiments 
performed 
Sphere 
generation 
attained 
Adequacy 
for PrSC 
culture 
10 1 4 Inadequate 
4 4   -* Inadequate 
3 4 4 Adequate 
2 4 3 Inadequate 
 
Table 19: Digestion of three prostates per experiment is shown to be optimal 
 
While 10 prostates provided ample material for tissue culture, it would not be feasible to 
continue this usage due to unacceptably high expenditure in animal fees, and it would also be 
insensitive to NC3Rs guidance.  Conversely using only 2 prostates per culture experiment was 
found to be insufficient because obtaining 4th generation prostate spheres were not feasible.  
When attempts were made with 4 prostates, experiments suffered due to poor digestion; this 
can be seen in table 19 (*).  However using 4 prostates per experiment was felt to be 
unacceptably high both for reasons already stated, in addition to the fact that even the most 
efficient breeding will form triple mutants at a rate of 1 in 16.  Ultimately 3 prostates were 
deemed to be an appropriate number to use whilst enabling a full experiment to be completed. 
 
Problem: How to make the technique more manageable and maximise the cellular yield 
obtained for each experiment 
Solution: Perform experiments with different digestion times 
 
If performed in a single day, the technique from dissection to plating can be thought of in the 
following steps: 
1. Dissection and mechanical dissociation  1 hour 
2. 1st stage of enzymatic digestion  2 hours 
3. Formation of single cell suspension 0.5 hours 
4. Enrichment of PrSCs   4 hours 
5. Counting and plating cells  2 hours 
Total       9.5 hours 
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The arduousness of this technique should not be understated, and to make this more 
manageable without compromising the cellular yield, the following questions were explored: 
1. Could prostate epithelial cells be safely digested overnight? 
2. Does the duration of digestion affect cell viability? 
3. Does the duration of digestion affect cell yield? 
 
To answer these questions, wild-type mouse prostates were digested in identical conditions for 
2 hours and overnight (n=4).  Representative FACS plots from these experiments are shown in 
figure 70 for comparison, along with median values for key readouts in table 20: 
 
 
Table 20: Overnight enzymatic digestion does not adversely affect epithelial cell viability and 
maximises cellular yield 
 
It appears that prostate epithelial cells can withstand overnight digestion; in fact the median 
proportion of total live cells was greater in the overnight group than the 2 hour group, 56.5% vs 
39.8% (p=0.018 Mann-Whitney test).  Furthermore the overnight digestion appears not to 
affect the total percentage yield of PrSCs when compared with 2 hour digestion; the median 
proportion of Trop2Hi cells in the overnight group was 13.7% whereas it was 8.8% in the 2 hour 
group (p=0.237, Mann-Whitney test). However given that the proportion of live cells when 
digested overnight is greater, the total number of Trop2Hi (PrSCs) in real terms is truly larger.  
These facts combined mean that using overnight digestion is feasible, and increases cellular 
yield. 
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Two hour digestion 
 
 
Overnight digestion  
 
____________________________________________________________________________________________________________________Figure 
70: Representative FACS plots highlighting the effect of the duration of digestion on cellular yield 
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Occasionally it would be evident at FACS that poor digestion had occurred, despite efforts 
throughout to keep the volume of media and enzymatic concentrations constant.  Three 
examples of tissue that underwent inadequate digestion are shown in figure 71.  In all 3 
examples shown, there are significant proportions of debris demonstrated (P1 on FACS plots), 
resulting in fewer live cells, and ultimately few Trop2Hi cells (PrSCs).  This point is further 
highlighted in table 21, along with a subsequent breakdown of the different fractions obtained 
from FACS. 
Example 
Debris 
[P1] 
(% of total) 
Live cells 
(% of 
parent 
population) 
Live cells 
(% of 
total) 
Lin- fraction 
(% of total) 
Trop2Hi 
cells 
(% of total) 
Trop2Hi cells 
(Hand 
counted) 
1 63.2 88.6 21.6 15.8 0.1 5,000 
2 54.7 78.9 21.3 9.6 0.2 17,500 
3 34.0 70.8 30.3 29.9 0.5 35,000 
 
Table 21: Digestion of prostates into single cell suspension is critical to a successful 
experiment 
 
If and when tissue chunks remained following overnight digestion, this was remedied by 
performing a further hour-long round of digestion with fresh collagenase and dispase on a 
shaking platform at low speed prior to the trypsin stage, rather than forcing tissue chunks 
through a needle and syringe under pressure.  If upon performing FACS the proportion of debris 
was > 1/3 and/or the proportion of total live cells was <1/3, then samples were discarded as 
these features appeared to represent inadequate digestion that was difficult to overcome, and 
sorted cells were unlikely to contain a satisfactory proportion of PrSCs. 
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____________________________________________________________________________________________________________________ 
Figure 71: Three examples of inadequate digestion leading to poor cellular yield. 
Poor digestion  
Example 3 
 
Poor digestion  
Example 2 
 
Poor digestion  
Example 1 
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5.4 CHAPTER CONCLUSION 
5.4.1 Primitive prostate epithelial cells that possess the antigenic profile Lin-
CD49f+Sca1+Trop2Hi display stem cell characteristics in vitro 
Using the assay described here, PrSCs that display self-renewal can be isolated prospectively 
from wild-type murine prostate, and can be expanded and purified in 3D culture, whilst largely 
circumventing differentiation.  These findings verify those published by others (Goldstein et al., 
2008, Lukacs et al., 2010). 
Self-renewal is defined as the ability of stem cells to maintain their undifferentiated state, and 
this attribute was investigated to determine whether Trop2Hi murine prostate cells could 
demonstrate the potential to act as PrSCs in vitro.   Three main readouts were reported to 
quantify stemness in each of the 3 subpopulations.  Firstly, the number of spheres grown out at 
each generation, secondly sphere-forming units (number of spheres as a ratio of cells plated), 
and thirdly sphere size at the end of each generation.  It has been shown that Trop2Hi cells form 
significantly more prostate spheres than each of the other subgroups by the end of G2.  This 
equates to sphere-forming units of approximately 1/69 in G1, with efficiency improved to 1/16 
in G4, further highlighting that cells exhibiting Trop2Hi can be maintained and purified in vitro.  
Additionally Trop2Hi cells formed significantly larger prostate spheres in vitro.  Midway through 
G3, Trop2Hi spheres grow significantly larger and faster than those not expressing CD49f/Sca1+.  
Taken together, Trop2Hi cells display an important distinguishing feature of PrSCs, namely, the 
ability to self-renew in vitro. 
5.4.2 PrSC organoids are shown to be spherical and largely undifferentiated by IHC 
Overall, the IHC expression profile of p63+ CK5+ AR- CK8- CK18- suggests that PrSCs originate 
from the basal layer within prostate epithelium.  Prostaspheres do however display early signs 
of squamous differentiation at their core by the presence of weak AR+ staining (luminal 
differentiation), and keratin (squamous differentiation), which has been reported in 3D culture 
assays from other tissues e.g. epithelial SCs from tongue papillae (Hisha et al., 2013).  This is 
likely to be a consequence of upregulated Wnt signalling in Trop2Hi cells (Stoyanova et al., 
2012), because it is known that dominant stabilised β-catenin induces high levels of p63 to drive 
cells into a transdifferentiated squamous cell fate (Francis et al., 2013).  Basal cells that express 
unopposed p63 outside their niche, and thus AR:ER homeostatic environment, are likely to 
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create dysregulated ERα, which is linked to keratinising squamous metaplasia formation, and in 
turn encourages basal cells to proliferate (Risbridger et al., 2007).   
Non-adherent or free-floating 3D culture assays for the investigation of neuronal stem cells 
have been in use for over 20 years.  However, they were noted to suffer from differentiation 
when plated on an adherent surface.  Differentiation was avoided in this assay by the use of the 
semisolid mimic of the extracellular matrix (ECM)-rich basement membrane, Matrigel.  By 
artificially re-creating the ECM, cell signalling truly representative of the stem cell 
microenvironment is promoted, thus maintaining basal cells, that express high levels of ECM-
binding integrins, in an undifferentiated state (Pontier and Muller, 2009). 
5.4.3 Trop2 is co-expressed in both human and mouse prostate 
The amount of Trop2Hi cells from normal murine prostate represents 7.6% (IQR 5.7 – 11.4) of 
total prostate cells, consistent with other reports in mice (Goldstein et al., 2008).  We know that 
the PrSC subpopulation in humans equates to 1 – 15% (defined by confocal microscopy and 
FACS respectively) of total basal cells.  Using the technique described in this chapter, the 
proportion of Trop2Hi PrSCs as a proportion of basal cells (CD49f/Sca1+) is approximately 45%.  
Clearly it is difficult to make direct comparisons between the size of PrSC populations in mice 
with and humans firstly because of the difference in anatomy, and secondly due to the lack of a 
PrSC marker that is consistently retained in both species.  The basal layer in mice is 
discontinuous whereas in humans it constant, and thus PrSCs in humans should intuitively 
represent a smaller proportion of basal cells than in mice.  One method that may facilitate 
direct comparison between the 2 species would be to perform FACS on normal prostate from 
both human and mouse, and to select the high expression of an agreed PrSC marker that is 
proven in both species as a proportion of the the p63-expressing basal cells. 
One such marker that is conserved between species is tumour-associated calcium signal 
transducer 2 (Trop2).  Trop2 was recognised as a candidate stem cell marker from prostate-
specific microarray analysis when found to be 20-fold enriched in the murine prostate after 
castration (Wang, 2007), and 12-fold enriched in prostate sphere cells compared with the total 
epithelium (Goldstein et al., 2008).   
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Another marker that enriches for the in vitro sphere-forming ability of normal prostate from 
both human and mouse PrSCs is CD166Hi (Jiao et al., 2012).  Also known as activated leukocyte 
cell adhesion molecule (ALCAM), it is highly upregulated in human and murine CRPC samples.   
Compared to CD166Lo cells, one of the distinguishing features of CD166Hi cells is their higher 
expression of Trop2. 
5.4.4 Trop2 poses a therapeutic target for the treatment of prostate cancer 
Identifying pathways that are critical to PrSC survival and self-renewal may provide new 
therapeutic targets for the treatment of PCa.  Although Trop2 serves as a putative PrSC marker 
and is upregulated in various epithelial cancers, its functional role in self-renewal, 
transformation, and signal transduction has remained unclear until recently.  Trop2 consists of 
two biologically distinct domains, and is activated by regulated intramembrane proteolysis.  It is 
ultimately cleaved within the transmembrane domain, leading to expulsion of the extracellular 
domain (ECD) and translocation of the intracellular domain (ICD) to the nucleus (Stoyanova et 
al., 2012).  Nuclear ICD is found in human prostate cancer but not in benign tissue, implicating 
Trop2 cleavage in cancer development.  The ICD promotes self-renewal, initiates prostatic 
intraepithelial neoplasia (PIN), and is involved in a β-catenin-dependent signalling cascade.  
Overexpression of Trop2 leads to up-regulation of the β-catenin downstream targets cyclin D1 
and c-myc, demonstrating that Trop2 signals via β-catenin (Stoyanova et al., 2012).  Moreover, 
nuclear β-catenin co-localises with the nuclear ICD of Trop2 in human prostate cancer.  
Furthermore, loss of β-catenin abolishes Trop2-driven self-renewal and transformation activity.  
If Trop2 cleavage is impaired by blockage of important cleavage sites, its self-renewal and 
transformation capacity is abrogated, demonstrating that RIP is essential for Trop2 activity. 
5.4.5 Novel primary tissue culture techniques are valuable but subject to criticism  
While Trop2Hi cells are hypothesised to consist predominantly of PrSCs, within this 
subpopulation there may be contamination from progenitors such as transit-amplifying cells; 
these also possess self-renewal capability, albeit to a lesser extent.  The definition of what 
constitutes Trop2Hi is undeniably subjective.  In order to therefore minimise bias, the two pairs 
of experiments (n=2 x 2) were consistent in selecting the Trop2Hi subgroups relative to one 
another.  The process of passage aims to mitigate progenitor cell contamination of the PrSC 
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population by exhausting their attenuated self-renewal capacity, however it is not known how 
many passages are required for this to occur completely. 
Other limitations of 3D primary tissue culture assays were considered throughout this work.  It 
currently remains unknown whether all Trop2Hi cells are capable of forming prostate spheres.  
For neurospheres it has been reported that aggregation of cells into spheres occurred even at 
low plating densities (Mori et al., 2006, Singec et al., 2006).  By employing time lapse 
photography it has been shown that sphere aggregation is enhanced by the spontaneous 
locomotion of neurospheres (Singec et al., 2006), and by experimenter-induced aggregation 
during plate movement (Coles-Takabe et al., 2008).  In contrast several studies (albeit from the 
same group) report that prostate spheres demonstrate clear clonality (Lawson et al., 2007, Xin 
et al., 2007, Lukacs et al., 2008), as authenticated by co-culturing prostate cells with fluorescent 
lineage tracing markers (GFP+ and dsRED+), and no spheres containing both cells were 
observed.  Presumably Matrigel culture also favours clonal outgrowth because cells are 
immobilised and cannot merge together.  Following on from the findings in this thesis, work has 
already begun to modify this method to plate very low seeding densities in 384 well plates by 
incorporating new technology.  The claim that Trop2Hi prostate spheres are truly clonal can be 
further substantiated by passaging spheres formed at lower density in order to perform linear 
regression analysis.  The plating of single cells would be extremely challenging using this current 
technique but is theoretically possible using FACS. 
A sticking point for many stem cell assays is that stem cells possess the innate ability to shuttle 
between quiescent and activated states (Li and Clevers, 2010) and that even more committed 
progenitors can revert back to a more primitive state (Davies and Fuller, 2008).  This feature 
likely prevents their depletion in vivo and minimises the possibility of mutagenesis during 
replication.  It could be argued that this assay, as a readout of PrSC function, only selects for 
more physiologically active cells, whereas stem cells are felt to be predominantly quiescent and 
remain in phase G0 of the cell cycle.  Bearing this in mind, the process of passage may represent 
the stress stimulus required to reintroduce PrSCs back into the active phase of the cell cycle. 
It is not the intention to claim that this in vitro 3D sphere forming assay gives an accurate 
readout of in vivo PrSC activity, rather it reflects the ability of Trop2Hi cells to exhibit self-
renewal, an important stem cell trait.  To complete the whole picture as to their biological 
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attributes, future experiments will aim to further satisfy the assertion that Trop2Hi cells are 
PrSCs.  A 2D colony-forming assay to explore proliferation and differentiation (in the presence 
of dihydrotestosterone) is being trialled, whereby Trop2Hi cells will be co-cultured with feeder 
(STO) cells.  Secondly an allograft assay for the in vivo regeneration of prostate tubule has been 
the subject of recent grant proposals to Prostate Cancer UK, and The Urology Foundation.  
Transplantation of purified PrSCs back into their endogenous niches can complement in vitro 
assays in evaluating their in vivo potential.  Although envisioned to be challenging, serial 
passage studies could help determine the self-renewal capacities of these cells in vivo, arguably 
the best indicator of the presence of PrSCs.  Xenograft assays of CD133+ human prostate cells 
transplanted under the renal capsule of immunocompromised mice only successfully formed 
grafts in 27% when co-cultured with mesenchymal tissue and never successful when cultured 
alone (Lawrence et al., 2013).  It is anticipated therefore that adopting this technique will be 
both timely and expensive. 
5.4.6 Optimisation of this 3D primary tissue culture assay provides a baseline standard with 
which to compare the function of SC/CSCs in mouse models of tumourigenesis 
By performing similar experiments on Cre-LoxP transgenic mouse models of prostate cancer, 
future experiments will aim to discover how mutations of Pten, K-ras and β-catenin alone and in 
combination within the prostate epithelium impacts on the pool of CSCs.  In particular, the 
influence of these pathways upon the putative CSC population will be interrogated to address 
the hypothesis that deregulation of these pathways drives both tumour growth and progression 
by directly expanding the CSC population. 
5.4.7 The technical demands of this 3D primary cell culture assay may prevent its 
widespread adoption 
The inception of any assay poses many technical considerations and this was no different.  It 
was deemed that 3 prostates per experiment would be most suitable when looking to perform 
the same experiments on the prostates of transgenic pro-tumourigenic mice in future.  Taking 
into account the finding (stated earlier in the chapter) that cells with genomic instability are less 
likely to survive the digestion process, more mice would ideally be needed.  However when 
aiming to use double and triple mutant mice, the likelihood of obtaining more than 3 
genotypically identical mice of similar age is low.  It is also currently being investigated whether 
fresh prostate tissue can be frozen and later thawed successfully without affecting cell viability.  
It is understood that the enzymatic digestion of primary tissue can affect cell surface antigen 
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survival thereby influencing marker expression (Pastrana et al., 2011).  Despite this, results here 
show that marker expression was preserved using overnight digestion, and indeed cellular yield 
was improved. 
5.5 CHAPTER SUMMARY 
The successful isolation and cultivation of prostate epithelial cells with stem-like attributes will 
allow their unique biological properties to be explored further.  These experiments provide a 
baseline standard with which to compare the function of prostate cancer stem cells from mouse 
models of tumourigenesis in due course. 
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Chapter 6:   General Discussion 
The generation of mouse models that accurately mimic the molecular interactions in human 
prostate cancer are valuable for studying PCa initiation and disease progression.  They also 
provide platforms for in vivo testing of novel therapeutic agents.  With this in mind, this thesis 
aimed to evaluate the roles of the Wnt, PI3K/Akt/mTOR, and Ras/MAPK pathways, all important 
signal transduction pathways in human PCa, in prostate tumourigenesis.  Furthermore, the 
identification of biomarkers to stratify PCa risk or select for personalised therapeutic strategies 
is an ultimate aim. 
The rodent prostate provides an ideal model system to explore the properties of PrSCs, due to 
the persistence of androgen-independent cells upon castration, and these cells may contribute 
to treatment failure and the development of CRPC.  The use of primary tissue culture allows the 
prospective isolation and purification of prostate epithelial cells that can demonstrate stem-like 
properties in vitro and in vivo.  By developing an understanding of PrSC biology and the 
mechanisms that govern self-renewal, it is hoped that new therapeutic agents targeted at killing 
the PrSC can prevent CRPC, the fatal form of disease. 
Beta-catenin (PBCre4+Catnb+/lox(ex3)) and PTEN (PBCre4+Ptenflox) single mutant mice 
demonstrated activation of their own and other cell signalling pathways, highlighting the 
importance of synergy between them in prostate tumourigenesis.  Previous studies have shown 
that Kras single mutant (PBCre4+Kras+/V12) mice develop non-lethal PIN lesions, and do not 
progress to adenocarcinoma (Pearson et al., 2009, Mulholland et al., 2012); therefore these 
mice were not studied further in this thesis. 
Work in this thesis demonstrates that dominant stabilisation of β-catenin promotes progression 
from HGPIN with keratinising squamous metaplasia at 100 days, to lethal prostate tumours 
consistent with adenocarcinoma.  As expected, these tumours demonstrate activated Wnt 
signalling, as shown by the upregulation of nuclear β-catenin, and CD44.  They also reveal 
simultaneous activation of the PI3K/Akt/mTOR, and Ras/MAPK signalling pathways.  
Mechanisms for β-catenin-dependent upregulation of PI3K/Akt/mTOR and Ras/MAPK signalling 
are not well understood, and the manner by which this may occur has been speculated in this 
study following a review of the literature. 
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Activation of PI3K/Akt/mTOR signalling in β-catenin mutants may result from the upregulation 
of Wnt effectors c-myc and cyclinD1, both of which are capable of triggering the cell cycle and 
metabolic reprogramming.  This postulated mechanism is expanded upon in figure 52, however 
it may ultimately result in elevated PI3K/AKT/mTOR signalling at, or downstream of, Akt.  This 
hypothesis will be addressed with further IHC for other Wnt effectors such as c-myc, cyclinD1, 
MMP-7, Foxa1, and COX-2, along with qRT-PCR and western blotting for the respective 
molecules in both pathways. 
Previous studies in colorectal cancer have linked Wnt pathway activation to increased 
Ras/MAPK signalling in vitro and in vivo, with evidence of synergy at the β-catenin/Tcf4-
mediated gene expression level (Park et al., 2006), and multiple levels including β-catenin-
independent direct signalling resulting from increased Wnt 3a ligand levels and β-catenin/Tcf-4-
dependent post-gene transcriptional events (Yun et al., 2005).  This has been corroborated by 
findings in this thesis, wherein the MAPK proteins Mek and Erk were over-expressed in the 
presence of dominant stabilisation of β-catenin.  These findings however contrast with those of 
others (Pearson et al., 2009), whereby MAPK signalling was detected at normal levels in the 
prostate tumours of β-catenin single mutant mice. 
Pten-deficient prostate tumours were characterised by the upregulation of PI3K/Akt/mTOR 
signalling, and the unexpected synchronous activation of Wnt, and MAPK signalling. 
Prostate tumours in which PTEN was deleted (PBCre4+Ptenflox) demonstrated evidence of 
upregulated nuclear β-catenin and CD44 expression.  This suggests activated Wnt signalling but 
expression of these proteins was inconsistent and possible reasons why have been discussed.  
Further work to clarify whether synergy occurs at the level of GSK3β, or β-catenin, is ongoing at 
the time of writing.  In addition to analysing more PTEN-null prostate tumour samples, future 
experiments should include IHC for GSK3β if a suitable primary antibody is commercially 
available, along with IHC of downstream post-transcriptional targets to verify upregulated Wnt 
signalling.  They include c-myc, cyclinD1, MMP-7, Foxa1, and COX-2.  As antigen expression may 
be heterogeneous in these tumours (as already identified), a technique such as laser-capture 
microdissection may allow qRT-PCR and/or western blotting to compare areas of nuclear 
(activated) β-catenin localisation or activated Wnt signalling, with areas of membranous (wild-
type) β-catenin localisation or inactive Wnt signalling in PTEN-null (PBCre4+Ptenflox) tumours. 
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These tumours also demonstrated Pten-loss-dependent activation of MAPK signalling, which 
has not previously been reported.  Again given that numbers were low, it is hoped that this 
notion will be strengthened when current cohorts of PBCre4+Ptenflox mice age.  Mechanisms to 
explain this synergy have not been explored in this work, but evidence for crosstalk is supported 
by other animal models, claiming that the MAPK pathway through Ras is PI3K/Akt/mTOR-
dependent and that aberrant PI3K/Akt/mTOR signalling drives Raf/Mek/Erk activation.  Despite 
these findings, the manner by which these interactions occur is complex and remains 
uncharacterised in the scientific literature. 
Simultaneous cooperating mutations in the Wnt, PI3K/Akt/mTOR, and Ras/MAPK pathways 
were seen to significantly reduce survival due to PCa.  Upon constitutive activation of all three 
pathways, mice failed to survive beyond three months due to high grade, locally-advanced non-
metastatic tumours.  Mice bearing double mutations demonstrate reduced survival, but for 
reasons outlines earlier, more mice will need to be investigated to address whether or not 
these findings are statistically significant.  In spite of this obvious limitation, this thesis provides 
sufficient evidence to conclude that Wnt, PI3K/Akt/mTOR, and Ras/MAPK signalling synergise in 
the prostate to promote tumourigenesis and disease progression. 
This thesis demonstrates that the molecular profile of PCa progression in these mouse models 
parallels the human disease.  There is upregulation of AR, and Ki67, along with down-regulation 
and eventual loss of p63 concomitant with tumour grade. 
The in vivo cooperation between the Wnt, PI3K/Akt/mTOR, and Ras/MAPK pathways, when 
mutated in combination, demonstrates synergistic overexpression of AR compared with single 
mutants, which in turn express a significantly higher level of AR expression than wild-type 
prostate.   The development of CRPC is not commonly associated with the loss of AR expression, 
and so these models may also in time be shown as a sound platform through which to 
investigate CRPC, given that only a modest increase in AR mRNA is both necessary and sufficient 
for progression to CRPC in mouse models (Chen et al., 2004a). 
Data in this thesis provide evidence for the inclusion of Ki67 when diagnosing PCa due to its 
clear correlation with DNA damage, and disease stage and grade.  However its adoption as a 
diagnostic adjunct has suffered from badly designed studies that have hampered its widespread 
clinical adoption. 
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Loss of p63 expression is a hallmark of human PCa, which is associated with luminal cell 
differentiation.  Total loss of p63 expression was seen in high grade tumours in these mouse 
models, with very low levels in low grade tumours and PIN, reflecting the human disease. 
When transmitted paternally, the PBCre4 transgene reliably demonstrated genetic 
manipulation of target alleles in murine prostate epithelium.  The data published in this thesis 
supports the work of others (Wu et al., 2001, Birbach, 2013), wherein paternally inherited loxP-
flanked alleles are inefficiently recombined by maternal PBCre4.  The introduction of mosaic 
genetic deletion led to contamination of the mouse colony with dilution and eventual loss of 
the PBCre4 transgene.  As such, experiments deemed essential to this thesis were unfortunately 
delayed, and as a result prevented full population of survival cohorts, and similarly prevented 
FACS of mutant prostates to evaluated SC/CSC biology as outlined in the thesis aims and 
objectives (see chapter 2). 
Tumours in combinatorial mutants appeared morphologically similar to Gleason pattern 4, 
when compared with lower-grade tumours from single mutant mice, which appeared largely 
akin to Gleason pattern 3.  However, there were limitations identified during histological 
characterisation that limit the widespread use of Gleason grading in mouse models; for some 
lower-grade lesions, the Gleason pattern was seen to be evolving, rather than the cytological 
morphology.  A lesion was deemed to be PIN in the absence of invasion, but when stromal 
invasion was evident, irrespective of the degree of invasion, one was obliged to grade the 
invasive element rather than the bulk of in situ tumour.  As explained earlier in the general 
introduction, murine prostate lobes are encased in thin stroma that is not comparable to the 
dense fibromuscular stroma of the human.  All cases were reviewed by Dr David Griffiths, a 
consultant histopathologist, and in several cases single cells were seen to be invading the 
surrounding scanty stromal tissue in the absence of high grade in situ tumour.  The presence of 
high grade in situ tumour with single cells invading stroma is pathognomonic of Gleason pattern 
5.  Only descriptions of invasive pattern 3 or 4 (low- or high grade) were used in this thesis, but 
herein lies the difficulty in extrapolating Gleason pattern 5 to mouse models of prostate cancer. 
Deregulation of the Wnt, PI3K/Akt/mTOR and Ras/MAPK pathways have all been identified as 
playing important roles in human prostate cancer, but the interplay between them has been 
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largely unmodelled.  This thesis is the first to explore crosstalk between these three influential 
signal transduction pathways simultaneously in mouse models of prostate tumourigenesis. 
Appreciating the molecular consequences of critical mutations in human PCa will prove valuable 
for tailoring treatment depending on a tumour’s genetic background.  This principle forms the 
basis of personalised medicine; a priority for the management of solid cancers such as breast, 
bowel, lung, prostate, ovary and melanoma through many worldwide strategies.  The Medical 
Research Council/National Institute of Health Research-funded Stratified Medicine Initiative is 
one example of such a programme in the UK.  To this end, and following on from experiments in 
this thesis, a human PCa tissue microarray (TMA) has been created from a tissue repository at 
the Wales Cancer Bank to determine whether or not the consequences of mutations in the Wnt, 
PI3K/Akt/mTOR and Ras/MAPK pathways seen in these mouse models are relevant to the 
human disease.   The oncogenomics of archived PCa samples will be explored using either 
standard pyrosequencing or next generation DNA sequencing, and pathway expression profiles 
will be determined using IHC as in this study.  Findings can then be analysed against disease-
specific clinical outcomes to define any correlation, in the hope of identifying further 
biomarkers for PCa that may help to identify men with aggressive disease, or stratify risk.  It is 
currently not known whether or not activating mutations of CTNNB1, KRAS, and/or PTEN occur 
in combination in human PCa, but future work will aim to address this research question. 
Drugs used in combination with ADT are increasingly being investigated in an effort to 
circumvent the adaptive capacity of PCa cells, and the failure of current regimen to overcome 
CRPC.  Different approaches include targeting the same pathway at different levels (vertical 
combinations) or aiming for different pathways synchronously (horizontal combinations).  If 
studies following on from this thesis similarly identify that the Wnt, PI3K/Akt/mTOR and 
Ras/MAPK are synchronously deregulated in human PCa, future experiments could be aimed at 
targeting PCa in vivo using the horizontal approach.  The data contained in this thesis emphasise 
that multiple signalling pathways synergise within the same prostate tumour, and for this 
reason, current strategies for the treatment of PCa may be fundamentally flawed. 
The primary tissue culture assay verified in this thesis allows a population of cells with stem-like 
characteristics that can be isolated using the antigenic profile Lin-CD49f+Sca1+Trop2Hi, to be 
maintained and expanded through multiple rounds of passage in vitro.  In contrast, other 
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subpopulations defined by FACS, namely not CD49f/Sca1+, and Trop2Lo cells, demonstrated 
notably attenuated self-renewal.  Furthermore, Trop2Hi PrSCs were seen to possess a basal 
expression profile at IHC (i.e. p63+ CK5+ AR- CK8- CK18-), suggesting they remain largely 
undifferentiated following multiple rounds of passage.  Further proof that Trop2Hi cells remain 
undifferentiated following passage will be addressed by re-staining single cells post-passage for 
the same antigenic profile and re-sorting them using FACS.  It is anticipated that cells will tightly 
cluster in the Trop2Hi region if they retain stem-like characteristics, similar to the appearance of 
immortalised cell lines that are truly clonal. 
Despite these promising results, further data to verify the notion that Lin-CD49f+Sca1+Trop2Hi 
prostate epithelial cells are PrSCs are required.  Ideally, evidence demonstrating the ability of 
these cells to differentiate and repopulate all cell types of the normal prostate, along with the 
ability to self-renew in vivo, would be confirmatory. 
If CSCs originate from malignant transformation of a normal PrSC, then it stands to reason that 
they may share antigenic profiles (Ginestier et al., 2007, Malanchi et al., 2008).  To this end, this 
thesis aimed to determine whether alteration of the genetic background of a prostate tumour, 
by utilising the mouse models of PCa outlined in chapter 4, altered the size of the pool of PrSCs, 
or enhanced their ability to display self-renewal in vitro.  Unfortunately due to time constraints, 
and eventual loss of the PBCre4 transgene, experiments thought to be achievable at the outset 
were not performed.  However, the initial data reported in this study have formed the basis of 
successful grant awards from Prostate Cancer UK, and The Urology Foundation, which will 
enable future work to continue. 
Primary 3D tissue culture proved to be technically challenging due to time constraints, the size 
of the murine prostate and thus the low yield of PrSCs, and the expense of failed experiments.  
In spite of this, efforts were made to increase efficiency where possible.  For example, rather 
than performing the whole technique in one day, it was noted that survival was not adversely 
affected by overnight digestion, and furthermore cellular yield was actually improved.  It will be 
interesting to discover how genetically modified prostate epithelial cells stand up to the 
stresses of this assay, given that the cell viability of combinatorial mutant mice after digestion 
into single cells was significantly reduced prior to sorting (see figure 63).  Intuitively both the 
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length of time and the cost of each experiment improved alongside operator experience, and 
should continue to do so in future. 
To date, the main criticism of stem cell assays has been that many have failed to avoid 
differentiation.  It is felt that this phenomenon may be alleviated by culturing SCs in 3D using 
Matrigel, as utilised in this thesis, because this method more accurately mimics the tumour 
microenvironment in support of clonal outgrowth (Sato et al., 2011, Pastrana et al., 2011).  
Further experiments using time lapse photography may allow visualisation of developing 
prostate spheres in order to determine whether they occur due to cellular aggregation, or 
whether they are truly clonal, capable of growth from single cells.  There is evidence to support 
both notions, but this question may be answered by linear regression analysis when PrSCs are 
plated at lower densities, and as single cells.  The resultant prostate spheres can then be 
quantified using automatic plate readers with parameters set to detect only spheres of agreed 
dimensions, rather than counting by hand. 
Thesis Summary 
Mouse models continue to play a pivotal role in the study of the molecular events that surround 
PCa initiation, as well as providing pre-clinical platforms for testing novel therapeutic agents 
tailored to a tumour’s genetic background.  Models such as those developed in this thesis, 
which reflect features of the human disease, may prove valuable if the same profile of 
mutations and their molecular consequences are validated in human PCa.  The discovery of 
biomarkers aimed at identifying aggressive disease and stratifying PCa risk may be achievable 
following these experiments. 
In opposition to the conventional stochastic model of tumour development, there is evidence 
to support the CSC theory in PCa.  Indeed given that CSCs are hypothesised to survive in a 
castrate environment they may be resistant to ADT, which remains the cornerstone of 
treatment for advanced PCa, and responsible for treatment failure and ultimately CRPC.  As 
such, efforts to culture PrSCs/CSCs and learn of their self-renewal properties may aid 
development of more sophisticated treatments for advanced PCa.  This thesis goes some way to 
appreciating the function of normal PrSCs as a baseline comparator of CSCs from mouse models 
of prostate tumourigenesis that display deregulation of the Wnt, PI3K/Akt/mTOR, and/or 
Ras/MAPK pathways in due course. 
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